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Abstract
The aim of this project was to determine the temporal and spatial pattern 
of expression of GDNF family receptors in the developing embryo, with particular 
emphasis on expression in the peripheral nervous system, and to investigate how 
expression of receptor mRNAs is regulated in developing neurons. It was hoped 
that the data obtained would prove useful in further characterizing the role that 
the GDNF family of neurotrophic factors play in embryonic development. Semi- 
quantitative PCR revealed that GFRa-1, GFRa-2, GFRa-4 and ret mRNAs aie 
widely distributed with both complementaiy and overlapping, though distinct, 
patterns of expression m the chicken embryo during development.
Different populations of PNS neurons display different levels of 
responsiveness to GDNF and NTN and then sensitivity to these factors change 
throughout development. Examination of receptor expression by quantitative RT- 
PCR revealed that neurons that are more sensitive to GDNF express higher levels 
of GFRa-1 mRNA than GFRa-2 mRNA, and neurons that are more sensitive to 
NTN express higher levels of GFRa-2 mRNA compared to GFRa-1 mRNA. 
However, developmental changes in responsiveness of a population of neurons to 
these factors are not consistently paralleled by changes in the relative levels of 
GFRa transcripts. Furthermore, all neuronal populations express relatively high 
levels of ret mRNA. These results indicate the responsiveness of PNS neurons to 
GDNF and NTN is in pait governed by the relative levels of expression of then 
GPI-linked receptors.
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To determine how the expression of the GDNF family receptors is 
regulated, embryonic neurons were cultured under different experimental 
conditions. 1 found that GFRa-1, GFRa-2, GFRa-4 and ret mRNAs are not 
significantly regulated by GDNF and/or NTN. However, depolarizing levels of 
KCl cause marked changes in the expression of GFRa mRNAs. The effects of 
KCl are inhibited by L-type Ca2+ channel antagonists, suggesting that they were 
mediated by elevation of intracellular free Ca2+. KCl treatment increases the 
response of neurons to GDNF and decreases their response to NTN. There is no 
marked effect of depolarization on ret mRNA expression.
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Chapter 1
Introduction
1.1. Development of the Vertebrate Nervous System
The diversity of cells in the nervous system and their intricate and precise 
interconnections present a developmental problem that has no parallel in other 
tissues. Tens of thousands of cell types must be generated at the right time and 
place, must extend their axons and dendrites, and must choose among millions of 
partners to make appropriate synaptic connections. Unraveling the mechanisms by 
which those events occur in an orderly and timely fashion is the ultimate puzzle in 
developmental biology.
In vertebrates, the development of the nervous system is initiated at the 
gastrula stage, when the embryo consists of three layers, namely, ectoderm, 
mesoderm, and endoderm. Triggered by chemical signals from the mesoderm, a 
region of the ectoderm, the neuroectoderm, begins to thicken and indent, forming 
a neural groove on the surface of the embryo along what will become its rostral- 
caudal (head-to-tad) axis. The lips of the neural groove start to swell, then meet 
and fuse to form a neural tube (Figure 1.1). The neural tube will give rise to the 
brain and the spinal cord, i.e., the central nervous system (CNS).
Along the line where the neural tube pinches off from the future epidermis, a 
number of cells break loose from the neuroectoderm and migrate through the 
mesoderm. These neural crest cells form almost all of the peripheral nervous 
system (PNS), including autonomic sympathetic and parasympathetic neurons,
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most sensory neurons, and support cells of the PNS, such as the Schwann cells 
and satellite cells.
Neural foldNeural plate
Neural crest
Epidermis
Neural tube
Figure 1.1. Formation of the neural tube and neural crest. The ectodermal cells 
are represented either as precursors of the neural crest (black) or as precursors of 
the epidermis (colour). The ectoderm folds in at the most dorsal point, forming a 
outer epidermis and an inner neural tube. The neural crest cells pinch off from the 
tube and migrate to their final destinations.
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1.2. Ganglia of the peripheral nervous system
The peripheral nervous system is composed of sensory and autonomic 
ganglia and peripheral nerves. Sensory ganglia ate anatomically segregated into 
cranial (including the trigeminal, nodose, vestibulo-acoustic and geniculate 
ganglia) and dorsal root ganglia. The autonomic nervous system has three 
principal divisions: the sympathetic (including the prevertebral sympathetic ganglia 
and the paravertebral sympathetic chain), the parasympathetic (including the 
cranial parasympathetic ganglia and terminal parasympathetic ganglia) and the 
enteric nervous system (ENS).
Neurons of the peripheral nervous system offer many advantages for 
studying the different phases of neural development. They and their progenitor cell 
populations are well defined, have less extensive synaptic contacts than their CNS 
counterparts and are accessible to both in vitro and in ova experimental 
manipulation from the earliest stages of their development.
1.3. Embryonic origin of the peripheral nervous system ganglia
Vertebrate cranial sensory ganglia are derived from two distinct embryonic 
sources, the neural crest and the neurogenic placodes (Noden, 1978; D’Amico- 
Martel and Noden, 1983; Le Douarin, 1986). The neurogenic placodes are 
epithelial thickenings appearing in the cephalic ectoderm of the early vertebrate 
embryo. In the chicken embryo, the neurons of the ventrolateral part of the 
trigeminal ganglion, and the vestibulo-acoustic, geniculate, petrosal and nodose 
ganglia are derived from neurogenic placodes. The neuronal cells of the
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dorsomedial trigeminal ganglion, the trigeminal mesenchephalic nucleus (TMN), 
the jugular ganglion and the dorsal root ganglia are derived from different regions 
of the neural crest (D'Amico-Martel and Noden, 1983; Vogel, 1992). The 
Schwann cells and satellite cells associated with aU sensory ganglia arise 
exclusively from the neural crest (D’Amico-Martel and Noden, 1983; Vogel, 
1992).
Neural crest cells give rise to the neurons and glial cells of the sympathetic 
and parasympathetic ganglia (D'Amico-Martel and Noden, 1983; Bronner-Fraser, 
1988; Le Douaiin, 1980). Both neuronal and gUal cells of the ENS are also 
derived from the neural crest. Enteric progenitors originate from the vagal, sacral, 
and truncal region of the neural crest (Le Douarin et al., 1973, 1974; Bronner- 
Fraser, 1988; Serbedzija et al., 1991; Epstein et al., 1994). Cell lineage studies 
have shown that premigratory crest cells are not generally committed to a single 
fate prior to migration (Bronner-Fraser, 1988). Their differentiation is influenced 
by the microenvironment of both the migratory pathway and the destination site.
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1.4. Apoptosis
The construction of a functional nervous system is the culmination of both 
neurogenerative and neurodegenerative processes. In the vertebrate nervous 
system, approximately half of the neurons produced by neurogenesis die during 
embryonic and early postnatal development (Oppenheim, 1991). This 
developmentaUy programmed neuronal death generally occurs by apoptosis 
(Oppenheim, 1991; Sanders and Wride, 1995), an intrinsic mechanism of cellular 
suicide that is employed by most, if not all, cells that die during the course of 
development (Kerr et al., 1972). Common morphological features of apoptotic 
cells include cytoplasmic shrinkage, and chromatin condensation.
There are two major causes of neuronal cell death during development. 
One results from an inadequate supply of neurotrophic factors and the other 
results from factors that bind to death receptors. Of these, death resulting from 
inadequate trophic support has been the most intensively studied. Recently death- 
inducing receptors have been found in neurons. For example, several reports have 
shown that the p75 neurotrophin receptor, a member of the TNF/Fas family, 
transduces ligand-dependent apoptotic signals in chicken retina and TMN neurons 
(Frade et al., 1996; Davey and Davies, 1998). The intracellular events leading to 
apoptosis following activation of the p75 receptor have not yet been elucidated. 
Death-signaling receptors such as CD95 (a Fas receptor), p55 tumour necrosis 
factor (TNF) receptor, death receptor-3 (DR3), DR4 and DR5 have been studied 
in more detail in non-neuronal systems. In these cases, the apoptotic events that 
follow receptor activation have been fairly well documented (Yuan, 1997).
Depending on the specific apoptotic trigger and cell type, any one of many 
different intracellular signaling pathways can be activated during the induction 
phase of the apoptotic process. However, these pathways converge on one or two
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control points in the execution or commitment phase of the apoptotic programme 
(Green and Kroemer, 1998). Investigation of the molecular mechanisms leading 
from the initial trigger to the culmination of the ceUulai' apoptotic response have 
revealed that the components of the cell death machinery in. species as distantly 
related as humans, Drosophila melanogaster and Caenorhabditis elegans are 
remarkably well conserved. Genetic analysis of C. elegans has identified three 
genes that are pivotal to programmed death of somatic cells in the nematode. 
These are ced-3, ced-4 and ced-9 (EUis and Horvitz, 1986; Hengartner and 
Horvitz, 1994). ced-3 encodes a cysteine pro tease of the caspase family (Yan et 
al., 1993; Xue et al., 1996) whose activation is promoted by the product of ced-4. 
Together these proteins are responsible for the 131 somatic cell deaths that occur 
during normal nematode development, ced-9 works upstream of ced-3 and ced-4 
and antagonizes their function in surviving cells (Hengartner et al., 1992). It is 
thought that ced-9 physically interacts with ced-4 thus preventing activation of 
ced-3 (Chinnaiyan et al., 1997; Spector et al., 1997; Irmler et al., 1997; Wu et al., 
1997a, b). This death pathway has acquired higher levels of complexity in 
mammals. The caspase family of cysteine proteases, currently 13 in number, are 
the mammalian counterpart of ced-3 (Bergeron and Yuan, 1998), the Bcl-2 family 
of genes, currently 15 in number, are the ced-9 homologues (Bergeron and Yuan, 
1998) and Apaf-1 is the homologue of ced-4 (Zou et al., 1997). Caspases are 
critical mediators of downstream apoptotic events. They are involved in a 
proteolytic cascade and induce disassembly as a result of cleavage of numerous 
cellular substrates (Nicholson and Thornberry, 1997; Cohen 1997).
Caspases are constitutively present in the cells and must therefore be inhibited for 
the cell to survive. It appears that the Bcl-2 family of proteins act upstream of 
caspases and regulate their activity. The Bcl-2 family contains both pro-apoptotic 
(Bcl-xs, Bax, Bak, Bad, Bik, Bid, Bim, Hrk, Bik) and antiapoptotic (Bcl-2, Bcl-
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XL, Bfl-1 Bcl-w, A-1, Mcl-l) members (for review see Kelekar and Thompson, 
1998). A common feature of the family members is their ability to homodtmerize 
and heterodimerize thi'ough theh conserved regions, BHl, BH2, BH3, and BH4. 
Many family members lack one or more of these domains. It has recently emerged 
that many of the pro-apoptotic members contain only the BH3 domain (Kelekar 
and Thompson, 1998). The level of expression of pro-apoptotic and anti-apoptotic 
proteins and theh interactions seem to regulate ceU death (Rao and White, 1997). 
Furthermore, post-translational phosphorylation of some Bcl-2 family members is 
also involved in controlling apoptosis to prevent caspase activation (Gajewski and 
Thompson, 1996). It has been shown that Apaf-1 binds pro-caspase-9 in the 
presence of cytochrome c and ATP. This event leads to the activation of caspase- 
9, which in turn cleaves and activates caspase-3. Caspases once active can cleave 
each other, resulting in a proteolytic cascade that leads to cell death (Zou et al, 
1997; Li et al., 1997). It is thought that antiapoptotic Bcl-2 family members may 
interact with Apaf-1 (and possible, as yet undiscovered, related proteins) to 
prevent caspase activation (Chinnaiyan et al, 1997). Members of the Bcl-2 family 
are also thought to influence cell survival by regulating the release of cytochiome 
c from mitochondria which in turn can activate pro-caspase-9 directly in the 
cytosol
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1.5. Role of neurotrophic factors in neuronal development
1.5.1. Neurotrophic theory
Neurons are generated in excess in the developing nervous system. 
Superfluous and inappropriately connected neurons are eliminated in a phase of 
cell death which begins shortly after neurons innervate their target fields 
(Oppenheim, 1981). It is now widely accepted that the tai'get field plays an 
important role in regulating the number of neurons that survive by its production 
of a limited quantity of neurotrophic factors which the innervating neurons require 
for theii* survival. Neurons that are able to procure an adequate supply of this 
factor survive, whereas neurons that cannot, die. Evidence for this 'neurotrophic 
hypothesis' has come principally from work on nerve growth factor (NGF), the 
first neurotrophic factor to be identified and characterized (Levi-Montalcini and 
Angeletti 1968; Thoenen and Barde 1980; Davies, 1988a,b; Baide 1989).
The most important direct evidence is the finding that certain populations 
of developing neurons aie dependent on NGF for survival in vitro and in vivo. 
Administration of anti-NGF antibodies during the phase of tar get field innervation 
eliminate these neurons, whereas exogenous NGF rescues neurons that would 
otherwise die (Johnson et al., 1980; Hamburger and Yip, 1984). Considerable 
indirect support for the theory comes from studies of the synthesis, expression and 
transport of NGF. Synthesis of NGF in the target tissues of NGF dependent 
neurons coincides with the beginning of target field innervation (Davies et al, 
1987; Korsching and Thoenen, 1988) and the level of NGF expression is found to 
be proportional to the final innervation density (Harper and Davies, 1990). NGF is 
conveyed from target tissues to the cell bodies of the innervating neurons by rapid, 
retrograde axonal transport (Hendry et al, 1974; Korsching and Thoenen, 1983).
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The purification of BDNF (Barde et al., 1982) extended the generality of 
the neurotrophic theory to a second neurotrophic factor. BDNF promotes the 
survival of subsets of embryonic neurons in vitro and prevents loss of these 
neurons in vivo when administered to embryos during the phase of naturally 
occurring neuronal death (Holer and Barde, 1988). Likewise, these same neurons 
are lost in mice that have tar geted null mutations in the BDNF gene (Ernfors et al, 
1994; Jones et al., 1994) or the BDNF receptor tyrosine kinase (trkB) gene (Klein 
et al., 1993).
The discovery that NGF and BDNF are structurally related proteins led to 
the identification of additional members of this family of proteins: neurotrophin-3 
(NT-3), NT-4/5, NT-6 and NT-7. In addition to these neurotrophins, several other 
families of neurotrophic factors have been identified. These include neuropoietic 
cytokines, TGF-P and GDNF. Each of these families of neurotrophic factors will 
be discussed in detail m the following sections.
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1.5.2. The family of neurotrophins and their receptors
The term neurotrophin refers to a family of proteins that have common 
structural and functional features. To date, six neurotrophins have been 
characterized. These are: nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5 or NT-4), 
neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7). These factors have been 
shown to influence the proliferation, survival, differentiation, growth, synaptic 
function and regeneration of a wide variety of neurons in both the peripheral and 
central nervous system. It has been suggested that NGF evolved as the result of a 
duplication event of a gene that might have been BDNF- or NT-3- hke. It is also 
interesting to note that NGF acts as a neuron survival factor preferentially on 
those parts of the PNS that are generated late in ontogeny, and possibly phylogeny 
(e.g. sympathetic chain) (Barde, 1994). Neurotrophins interact with two 
structurally distinct classes of receptors on the cell surface. These are tyrosine 
kinase receptors of the Trk family and a transmembrane receptor called p75. Trk 
receptors mediate most actions of neurotrophins with a well-defined specificity. In 
general, NGF binds and activates Trk A, BDNF and NT-4 bind and activate TrkB 
and NT-3 binds and activates TrkC. However, there is some overlap in receptor 
specificity between members of the neurotrophin family. All neurotrophins are 
capable of binding to p75, albeit with lower affinity.
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Nerve growth factor
NGF was &st discovered by Levi-Montalcini in 1951 (Levi-Montalcini, 
1987). High concentrations of NGF were observed in the mouse submandibular 
salivary glands which facilitated its purification and cloning of the NGF gene in 
several species (Scott et al., 1983; Ulhich et al., 1983; Meier et al., 1986; Ebendal 
et al., 1986). NGF as purified from the submandibular salivary gland, consists of 
three subunits: a , (3 and y and has a molecular weight of 130 kDa (Varon et al., 
1968). The biological activity is conferred by the NGF p subunit, hence the active 
form of NGF is often referred as P-NGF. Mature P-NGF is synthesized from 
prepro-P-NGF (26 kDa) and exists in its active form at physiological 
concentrations as a homodimer (Berger and Shooter, 1977; Scott et al., 1983; 
Edwards et al., 1988). Analysis of the three-dimensional structure of mature NGF 
has revealed that it contains a motif of three intrachain disulphide bridges, known 
as the "cysteine knot" and three antiparallel P strands (McDonald et al., 1991).
Extensive tissue culture studies have established that NGF promotes the 
survival of sympathetic neurons and subpopulations of neural crest-derived 
sensory neurons within neurons of the peripheral nervous system, but has no 
demonstrable effect on placode-derived cranial sensory neurons, enteric neurons, 
parasympathetic neurons or spinal motor neurons (Chun and Patterson, 1977; 
Hamburger, 1981; Davies and Lindsay 1985; Gorin and Johnson, 1980; Davies, 
1994a). In these and other studies NGF was found to be a target derived growth 
factor.
In situ hybridization studies have shown that NGF is distributed at high 
levels within regions of the CNS that aie innervated by the cholinergic neurons of 
the basal forebrain (hippocampus, olfactory bulb and neocortex) and regions 
containing the cell bodies of these neurons (septum, nucleus of the diagonal band
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of Broca, nucleus basalis of Meynert). The highest level of NGF mRNA occurs 
within the hippocampus and cortex (Korsching et al, 1985). Comparatively low, 
but significant NGF levels have also been found in various other brain regions 
(Whittemore et al., 1986).
Confirmation of the specificity of NGF for certain peripheral nervous 
system neurons has been obtained fiom analysis of mice with targeted disruption 
of the NGF gene (Crowley et al., 1994). Mice that are homozygous for a null 
mutation in the NGF gene are born with virtually no sympathetic neurons and a 
loss of >70% of the normal complement of dorsal root and trigeminal ganglia 
neurons (Crowley et al., 1994). Interestingly, there is no marked loss of basal 
forebrain cholinergic neurons or other CNS neuronal populations (Crowley et al., 
1994). NGF deficient mice die soon after biith (Crowley et al, 1994).
Brain-derived neurotrophic factor
Brain-derived neurotrophic factor (BDNF), initially isolated firom pig 
brain, was the second member of the neurotrophin family to be characterized. 
BDNF is a basic protein (pl~10.1) with a molecular weight of 12.3 kDa (Barde et 
al., 1982). The mature BDNF protein is 119 amino acids in length, one amino acid 
more than NGF, and like NGF exists as a stable homodimer linked by 3 disulphide 
bridges (Radziejewski et al, 1992). BDNF displays approximately 50% sequence 
identity to NGF, including conservation of aU six of the structurally important 
cysteine residues (Leibrock et al., 1989).
BDNF expression is largely restricted to the CNS. BDNF mRNA and 
protein levels have been detected in the hippocampus, amygdala, thalamus, 
projection areas of the olfactory system, inner and outer pyramidal layers of the
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neocortex, claustrum, septum, cerebellum, and the superior coUiculus (Leibrock et 
al,. 1989; Hofer et al, 1990; Wetmore et a l ., 1990; Phillips et al, 1990; Dugich- 
Djordjevic et al ., 1995a; Gall et al, 1992; Huntley et al, 1992), suggesting that 
BDNF has a more widespread distribution than NGF. Outside the CNS, BDNF 
mRNA has been observed in the target tissues of populations of BDNF responsive 
neurons and, perhaps surprisingly, in a subset of the neurons of dorsal root, 
trigeminal, geniculate, and sympathetic ganglia, suggesting a possible autocrine or 
paracrine mechanism fashion (Robinson et al, 1996; Schecterson and Bothwell,
1992).
BDNF has been shown to support the survival of both neural crest- 
(trigeminal mesencephalic nucleus, jugular and dorsal root ganglion) and placode- 
(ventrolateral trigeminal ganglion, geniculate, petrosal, vestibular, and nodose 
ganglion) derived sensory neurons. In addition BDNF supports the survival of 
dopaminergic neurons within the substantia nigra, basal forebrain cholinergic 
neurons, hippocampal neurons, cerebellar granule cells, and retinal ganglion cells 
(Davies et al, 1986; Barde et al, 1987; Hofer and Barde, 1988; Alderson et al, 
1990; Hyman et al, 1991; Knüssel et al, 1991; Oppenheim et al, 1992; for 
review see Korsching, 1993).
Homozygous mutant mice lacking the BDNF gene display substantially 
reduced numbers of cranial and spinal sensory neurons. In particular, significant 
numbers of sensory neurons are lost in the trigeminal, geniculate and vestibulai* 
ganglia and in the nodose-petrosal complex (Ernfors et al, 1994a; Jones et al, 
1994). In contrast to previous studies showing that motor neurons aie supported 
by BDNF in vivo (Yan et al, 1992; Oppenheim et al, 1992; Sendtner et al, 
1992a, Vejsada et al, 1998) and in vitro (Henderson et al, 1993), motor neuron 
development is largely unperturbed by targeted disruption of the BDNF gene 
(Ernfors et al, 1994a; Jones et al, 1994). Although the CNS of BDNF deficient
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mice shows no gross stuctural abnormalities, the expression of neuropeptide Y 
and calcium binding proteins is altered in many neurons, suggesting that these 
neurons may not function normally (Ernfors et al, 1994a; Jones et al, 1994).
Neurotrophin-3
Neurotrophin-3 (NT-3), the third member of the neurotrophin family to be 
identified, was cloned on the basis of sequence homology between BDNF and 
NGF (Hohn et al, 1990; Maisonpierre et al, 1990; Jones and Reichardt, 1990; 
Rosenthal et al, 1990). The predicted size of the mature NT-3 polypeptide is 119 
amino acids. NT-3 is a basic protein (pi ~ 9.3) with a moleculai' mass of 13.6 kDa 
(Hohn et al, 1990; Maisonpierre et al., 1990). Mature rat NT-3 peptide displays 
57% and 58% amino acid identity with rat NGF and BDNF respectively, and 
contains all six cysteine residues involved in forming the cysteine knot motif. Like 
NGF and BDNF, NT-3 exists as a homo-dimer at physiologically relevant 
concentrations (Radziejewski et al, 1992).
Despite the high structural homology with NGF and BDNF, NT-3 has 
distinct biological activity and a different spatiotemporal pattern of expression. In 
contrast to NGF and BDNF, the level of NT-3 mRNA is high during fetal 
developmental and reduced in the adult. NT-3 mRNA has a widespread tissue 
distribution. In the brain, levels of NT-3 mRNA are greatest in the cerebellum, 
medulla oblongata and hippocampus. In the periphery, NT-3 mRNA is mostly 
found in the heart, kidney, liver, skin, muscle, lung, spleen, and intestine, 
suggesting that it may act as a target-derived trophic factor for sympathetic and 
sensory neurons (Maisonpierre et al, 1990; Hohn et al, 1990; Rosenthal et al, 
1990).
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The neurotrophic activities of NT-3 have been analyzed using cell culture 
and in vivo approaches. Neurons responsive to NT-3 include subpopulations of 
the dorsal root ganglia (Maisonpierre et al., 1990), nodose ganglia (Rosenthal et 
al., 1990), trigeminal ganglia (Buchman and Davies, 1993), cochlear ganglia 
(Farinas et al., 1994), as well as proprioceptive neurons of the trigeminal 
mesencephalic nucleus (Hohn et al., 1990) and developing muscle sensory neurons 
(Hory-Lee et al., 1993). Moreover, NT-3 has been shown to induce survival, 
differentiation and/or proliferation of neuronal precursor populations (Kalcheim et 
al., 1992; Pinco et al., 1993; DiCicco-Bloom et al., 1993; Verdi and Anderson, 
1994; Chalazonitis et al., 1994; Henion et al, 1995; Karavanov et al, 1995; 
Memberg and Hall, 1995). NT-3 also enhances the proliferation and survival of 
oligodendrocyte precursor cells in vivo and in vitro as well as promoting their 
clonal expansion when applied with platelet-derived growth factor (Barres et al, 
1993; Barres et al, 1994; McTigue et al, 1998).
Neurotrophin-3 deficient mice display substantial neuronal cell loss in all 
peripheral sensory ganglia including the trigeminal ganglion, nodose ganglion, 
trigeminal mesencephalic nucleus and superior cervical ganglion (Ernfors et al., 
1994b; Farinas et al, 1994; Tessarolo et al, 1994). Significantly, spinal 
proprioceptive afferents and their peripheral sense organs (muscle spindles and 
Golgi tendon organs) are completely absent in homozygous mutant mice. No 
gross abnormalities aie seen in Pacinian corpuscles, cutaneous afferents containing 
substance P and calcitonin gene-related peptide, and deep nerve fibers in the joint 
capsule and tendon (Ernfors et al, 1994b). In contrast with the severe effects that 
NT-3 gene has on PNS neurons, neurons of the CNS do not appear to be 
seriously perturbed by the mutation (Ernfors et al, 1994b). Although these 
findings may not agree with many previous in vitro studies on the effects of NT-3, 
they are consistent with in vivo work showing that NT-3 does not effectively
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promote the survival of motor neurons after transection (Sendtnert et al., 1992a; 
Koliatsos et al., 1993).
Neurotrophiii-4/5
Neurotrophin-4/5 (NT-4/5) is the fourth member of the neurotrophin 
family to be discovered. It was originally cloned from Xenopus and designated 
neurotrophin-4 (HaUbook et al., 1991). Subsequently, human and rat clones were 
identified, initially named NT-5, that share 65% amino acid identity Xenopus 
NT-4 (Berkemeier et al., 1991). It is currently widely believed that Xenopus NT-4 
and mammalian NT-5 are the same protein and are referred as NT-4/5 (Ip et al., 
1992a). Mature NT-4/5 is a basic protein containing 123 amino acids, including all 
six conserved cysteine residues common to the entire family. The overall amino 
acid homology of the mammalian NT-4/5 with other neurotroplhns is 50% with 
NGF, 54% with BDNF and 52% with NT-3 (Ip et al., 1992a).
NT-4/5 is widely distributed in both embryonic and adult tissues. These 
include the testis, muscles, lungs, prostate, thymus, heait, placenta, and brain (Ip 
et al., 1992a; Berkemeier et al., 1991; Timmusk et al., 1993). NT-4/5 shows 
strong developmentaUy regulated expression in the above tissues suggesting a 
target-derived role for neurons innervating them. In the CNS, NT-4/5 mRNA is 
detected in hypothalamus, pons, meduUa, cerebeUum, cerebral cortex, olfactory 
bulb and hippocampus (Timmusk et al., 1993). OveraU, the amount of NT-4/5 
mRNA expressed in the whole adult rat brain is considerably less (-10 times) than 
that of NGF, BDNF and NT-3 mRNAs (Ip et al., 1992a).
Several studies have demonstrated that different populations of neurons 
from the peripheral and central nervous system respond to NT-4/5 during
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development and in adulthood. In general, these overlap with BDNF responsive 
neurons. In the PNS, NT-4/5 promotes the survival of early trigeminal, jugular, 
and nodose ganglia (Ibânez et al, 1993; Davies et al, 1993a), and neurons of the 
dorsal root and paravertebral sympathetic ganglia (HaUbook et al, 1991; 
Berkemeier et al., 1991). AdditionaUy, neurons of the vestibular and sphal gangUa 
in the inner ear can be rescued from the detrimental effects of different 
neurotoxins, by administration of NT-4/5 both in vitro and in vivo (Zheng et al, 
1995a, b). In the CNS, NT-4/5 has been shown to prevent the death of developing 
and adult spinal motor neurons (Henderson et al, 1993; Friedman et al, 1995; 
Funakoshi et al, 1995) and facial motor neurons (KoUatsos et al, 1994).
NT-4/5 deficient mice exhibit loss of sensory neurons in the nodose- 
petrosal and geniculate gangUa (Conover et al, 1995; Liu et al, 1995). In 
contrast, motor neurons of the facial nucleus and sympathetic neurons are 
unaffected (Conover et al, 1995; Liu et al, 1995), suggesting that other factors 
could sustain these neurons in the absence of NT-4/5, and/or NT-4/5's primary 
role is not survival for these neuronal populations.
Neurotrophin-6
Neurotrophin-6 (NT-6) was cloned from a genomic Ubrary of the teleost 
platyfrsh Xiphophorus maculatus by low stringency hybridization to overlapping 
sequences of NGF (Gotz et al., 1994). Like the rest of the neurotrophins, NT-6 is 
synthesized as a precursor polypeptide that upon proteolytic cleavage gives rise to 
a 143-residues mature basic protein that contains aU sk  cysteines conserved in the 
family. However, NT-6 contains an additional feature not shared by NGF, BDNF, 
NT-3 and NT-4/5: an insertion of 22 amino acids between the second and third
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cysteine residues of the mature molecule which contains the heparin domain (Gotz 
et al, 1994).
NT-6 mRNA is expressed in both developing and adult brain. It is also 
found in adult ghl, liver and eye, with weak expression in skin, spleen, heart and 
skeletal muscle (Gotz et al, 1994). Like NGF, NT-6 supports the survival of 
embryonic chick DRG and sympathetic neurons. However, lower levels of 
survival are seen with saturating concentrations of NT-6 compared to those 
observed with NGF. Cultured nodose and cüiary neurons do not survive with NT- 
6, suggesting that the spectrum of NT-6 activity is similar to that of NGF (Gotz et 
al, 1994).
Neurotrophin-7
Neurotrophm-7 (NT-7) is the most recent member of the neurotrophin 
family to be isolated. It was originally cloned from a genomic library of the teleost 
common carp Cyprinus carpio using the polymerase chain reaction (PCR) (Lai et 
al, 1998). Subsequently, zebrafish NT-7 was cloned (Nilsson et al, 1998). NT-7 
shares about 66% amino acid identity to Xiphophorus NGF and NT-6. NT-7 
possesses structural characteristics common to all known neurotrophins, such as 
the presence of six conserved cysteine residues and the flanking conserved 
sequences. In addition there is an insertion of 15 amino acids at the position 
corresponding to that observed for NT-6 (Lai et al, 1998; Nilsson et al, 1998).
Northern blotting analysis revealed that NT-7 mRNA is predominantly 
expressed in adult skin, heart and intestine, with weak expression in brain and 
testis (Lai et al, 1998). The neurotrophic activity of NT-7 was demonstrated by
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its ability to promote neurite outgrowth and neuronal survival of chick dorsal root 
ganglia (Lai et al, 1998).
Neurotrophin receptors
NGF BDNF NT-4/5 NT-3■ V Y/V
TrkA TrkB TrkC
Figure 1.2. Neurotrophin receptors; binding patterns.
See text for details.
Two classes of neurotrophin receptors have been identified, members of 
the Trk family of receptor tyrosine kinases and the common neurotrophin receptor 
p75. Most of the biological activities of the neurotrophins are mediated by the Trk 
family (Chao, 1992). NGF interacts with the TrkA receptor (Hempstead et al., 
1991; Kaplan et al., 1991; Klein et al., 1991a); BDNF and NT-4/5 bind with high 
affinity to TrkB (Berkemeh et al., 1991; Glass et al., 1991; Klein et al., 1991b, 
1992; Soppet et al., 1991; Squinto et al., 1991; Ip et al., 1992a) and NT-3 
associates strongly with TrkC (Lamballe et al., 1991). Both NT-4/5 and NT-3
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appear to be somewhat promiscuous. NT-4/5 can bind and activate TrkA 
(Berkemeir et al., 1991; Ip et al., 1992a) while NT-3 can also signal through TrkA 
and TrkB (Lamballe et al., 1991; Soppet et al., 1991; Squinto et al, 1991) (Figure 
1.2). However, the activation of TrkA by NT-3/NT-4/5 and TrkB by NT-3 is less 
efficient than activation of Trks by theii* preferred ligand. For example, NT-4/5 
signaling via TrkA can support late mouse trigeminal (E l2 onwaids) and 
sympathetic (E15) neurons only when applied at high- 10 times above 
physiological- concentrations (Huber et al, personal communication). Whether 
NT-6 binds to any of these receptors is not known at the present time. NT-7 can 
bind TrkA but with considerable lower affinity than that of NGF (Lai et al, 1998).
Pairwise comparison of TrkA, TrkB and TrkC reveals 66-68% amino-acid 
sequence identity (Lamballe et al, 1991). The region that appears to be most 
conserved among Trks is the cytoplasmic domain. In common with other tyrosine 
kinase receptors, the catalytic domain is interrupted by a short insert sequence. 
However, certain amino acid substitutions in highly conserved kinase motifs and a 
short carboxy-terminal taü distinguish Trks from other subfamilies of tyrosine 
kinase cell surface receptors (Barbacid, 1994). The extracellular domain of the 
Trk receptors exhibit two distinct subsets of cell adhesion-related motifs 
(Schneider and Schweiger, 1991): two immunoglobulin-like (Ig) domains and an 
array of three tandem leucine-rich motifs (LRM) flanked by two distinct cysteine 
clusters (see Figure 1.3).
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LRM deletion
Kinase
insertions
TrkA TrkB TrkC
Figure 1.3. Neurotrophin receptors: isoforms.
Abbreviations: Cc, cysteine cluster; LRM, leucine-rich motifs; Ig,
immunoglobulin-like domains; TM, transmembrane domain; JM, TK, tyrosine 
kinase domain. See text for details.
Several Trk receptor isoforms have been identified. The two TrkA kinase 
isoforms differ by the presence of six ammo acid residues located in the 
extracellular domain near the transmembrane region (Barker et al., 1993;
50
Horigome et al., 1993). Both isoforms appear to have similar biological 
properties, but they have different pattern of expression. Whereas the TrkA 
isoform carrying the six amino acid insert is primarily expressed in neuronal cells, 
the other isoform has been found in other cell types (Baiker et al., 1993; 
Horigome et al., 1992). With regard to TrkB, two variants with truncated 
intracellular domains (Klein et al, 1990a; Middlemas et al, 1991) and several 
isoforms with deletions in the leucine-rich motifs (Ninkina et al, 1997) have been 
identified. The truncated isoforms are the most abundant form m a variety of non­
neuronal tissues, but they aie also expressed in neurons (Valenzuela et al, 1993; 
Armanini et al, 1995; Ninkina et al, 1996). Truncated TrkB isoforms within the 
nervous system increase their abundance relative to the full length receptor as 
embryonic development progresses (Allendoerfer et al, 1994). Several functions 
of the truncated forms have been proposed including inhibitors of signaling of the 
full length TrkB receptor by the formation of functionally inactive receptor 
heterodimers (Eide et al, 1996; Ninkina et al, 1996), positive regulators of 
BDNF action by presenting BDNF to full length receptors (Klein et al, 1990a; 
Middlemas et al, 1991; Beck et al., 1993) and signal transducers of a presently 
unknown signaling pathway (Baxter et al, 1997).
Three TrkC isoforms containing inserts of varying length within the kinase 
domain, and four transcripts with no tyrosine kinase domain have been described 
(Tsoulfas et al, 1993; Valenzuela et al, 1993). All forms are widely expressed in 
the nervous system, with the truncated forms predominating in non-neuronal 
tissues. Insert-containing forms of TrkC retain the ability to autophosporylate in 
response to NT-3, but cannot mediate proliferation in fibroblasts or neuronal 
differentiation in PC 12 cells (Tsoulfas et al, 1993; Valenzuela et al., 1993). This 
suggests that the inserts alter the range of intracellular proteins that activated
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TrkC can interact with and thus change the ultimate signaling capabilities of this 
receptor.
Trk kinase receptors become activated by a two-step process that involves 
their ligand-mediated dimerization followed by autophosphorylation on at least 
five tyrosine residues within thiee distinct domains of the intracellular portion of 
the receptor (Kaplan and Stephens, 1994). These phosphorylation events are 
required for the activation of the catalytic region of the Trk receptor as well as the 
recruitment of signaling protein substrates. At least four proteins, namely the 
SH2-containing adaptor protein (She) (Pelicci et al., 1992; Obermeier et al., 1993; 
Stephens et al., 1994) and its neural-specific isoform N-Shc (Nakamura et al, 
1996), the phospholipase C-yl (PLC-yl) (Ohmichi et al, 1991; Bella et al, 1991), 
SH2-containing tyrosine phospatase-1 (SHP-1) (Vambutas et al, 1995) and the 
Sue 1-associated neurotrophic factor target (SNT) (Rabin et al., 1993) directly 
associate with activated Trks. These proteins couple Trks to several intracellular 
signaling pathways. In brief. She activates the phosphatidylinositol 3-kinase (PI3- 
kinase) and Ras-MAP kinase pathways which are implicated in neuronal 
differentiation and survival. Activation of PLC-yl results in elevated activity of 
protein kinase C and induced calcium uptake (although there are some conflicting 
reports) (Guiton et al, 1994). Elevated calcium levels have been associated with 
survival, injury and plasticity (reviewed by Jiang and Guroff, 1997). The SNT and 
SHP-1 pathways aie stül unknown, but SNT might be involved in cell cycle 
control. An important point that has arisen from the neurotrophin signaling studies 
is that neuronal survival and differentiation are the result of co-operative 
processes, le. the activation and interaction of many different signaling pathways 
(for reviews see, Barbacid, 1994; Greene and Kaplan, 1995; Kaplan and Miller, 
1997; Gunn-Moore and Tavaré, 1998).
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Northern analysis and in situ hybridization studies have shown widespread 
expression of each of the Trk receptors throughout the CNS and periphery. In the 
CNS almost all neurons appear to express TrkB or TrkC (or both) (Klein et al., 
1989, 1990a, b; Merlio et al., 1992; TessaroUo et al., 1993; Lamballe et al., 1994), 
whereas TrkA expression is highly restricted to cholinergic neurons of the basal 
forebrain or striatum (Vasquez and Ebendal, 1991; Holtzman et al., 1992; Merlio 
et al., 1992; Steininger et al., 1993). In the PNS, Trk receptors have been detected 
on aU classes of neurons with the notable exception of pai asympathetic neurons of 
the ciliary ganglion. TrkA transcripts have been found in DRG, sympathetic and 
other neural crest-derived ganglia (Martin-Zanca et al., 1990; TessaroUo et al., 
1993; Schropel et al., 1995), whereas TrkB and TrkC are expressed to some 
degree in aU ganglia (Klein et al., 1989; Ninkina et al., 1996; CarroU et al., 1992; 
TessaroUo et al., 1993; LambaUe et al., 1994). Outside the nervous system, trkA 
mRNA expression has been observed in certain ceUs of the immune system 
(Ehrhard et al., 1993a, b). TrkB mRNA has been detected in lung, muscle and 
ovaries, whereas TrkC mRNA is expressed in several facial structures and tissues 
of the body cavity (TessaroUo et al., 1993; LambaUe et al., 1994).
In order to analyze the physiological relevance of the neurotrophin 
receptors during development, mutant mice lacking either functional TrkA, TrkB 
or TrkC genes have been generated by homologous recombination (Klein et al., 
1993, 1994; Smeyne et al, 1994). In general, the phenotype of mice carrying a 
nuU mutation in each neurotrophin receptor gene is simUar to that observed for its 
Ugand (Crowley et al, 1994; Jones et al, 1994; Ernfors et al, 1994a, b). Mice 
lacking functional TrkA display severe sensory defects chai'acterized by a 
complete loss of nociceptive activity. Neuroanatomical examination reveals 
extensive neuronal ceU loss in trigeminal, dorsal root and sympathetic gangUa. 
Interestingly, cholinergic basal forebrain neurons shown to express TrkA are not
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affected by the mutation (Smeyne et al., 1994). TrkB deficient mice display 
extensive neuronal cell loss in nodose-petrosal, dorsal root, and trigeminal ganglia. 
Finally, mice lacking the TrkC kinase receptors are severely defective in 
proprioception. This sensory defect is due to the complete absence of la muscle 
afferent projections to spinal motor neurons and reduced number of large 
myelinated axons in the dorsal root and posterior columns of the spinal cord. In 
addition, they show a 20% loss of DRG neurons (Klein et al, 1994).
The low-affinity neurotrophin receptor p75 binds aU the members of the 
neurotrophin family (Rodrigues-Tebar et al, 1990, 1992), p75 is a 75 kDa protein 
with a richly glycosylated extracellulai’ domain containing four cysteine-rich 
homologous segments and a short cytoplasmic domain that is not related to 
receptors with kinase activities (Johnson et al, 1986; Chao et al., 1986; Radeke et 
al, 1987). More than 10 other molecules with similar structure have been 
identified and are collectively referred to as tumor necrosis factor (TNF) receptor 
family members. In addition, p75 shares homology with some of these receptors 
within a short sequence of the cytoplasmic domain, referred to as the death 
domain (Feinstein et al, 1995), a region that has been associated with apoptosis 
(Brakebusch et al., 1992; for review see Baker and Reddy, 1996).
p75 is widely expressed in both developing and adult animals by both 
neurons and non-neuronal cells (Yan and Johnson, 1989; Ernfors et al, 1988; 
Buck et al, 1987). Contrary to the expectation that p75 plays an important role in 
the development of many tissues, mice homozygous for the mutation display no 
obvious defects in any major organ including the peripheral ganglia, suggesting no 
more than a modulatory function for p75 (Lee et al., 1992, 1994a). In line with 
this, higher concentrations of NGF aie required to ensure the survival of p75 
deficient neurons, compared to neurons obtained from wM-type animals (Davies 
et al, 1993b; Lee et al, 1994b). Further, it has been shown that p75 plays a role
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in ligand discrimination by Trk receptors (Clary and Reichardt, 1994; Lee et al., 
1994b Benedetti et al., 1993; Ryden et al., 1995). Recent findings indicate that in 
addition to modulating Trk function, p75 signals on its own. Specifically, in neural 
cell lines and ghal cells neurotrophin binding to p75 stimulates the generation of 
ceramide (Dobrowsky et al., 1994, 1995; Casaccia-Bonnefîl et al., 1996), 
activation of nucleai' factor (NF)-kB and translocation of this protein to the 
nucleus (Carter et al., 1996), and enhancement of jun kinase (JNK) activity 
(Casaccia-Bonnefil et al., 1996). Both ceramide accumulation and JNK activation 
are correlated with apoptotic stimuli m a number of systems, and several 
observations suggest that p75 may play a role in regulating apoptosis (Barrett and 
Bartlett, 1994; Frade et al., 1996; Casaccia-Bonnefil et al, 1996). Further, it has 
been shown that competitive signaling between Trks and p75 can determine cell 
survival (Yoon et al, 1998; Maliartchouk and Saragovi, 1997; Davey and Davies, 
1998), a finding supported by evidence for the existence of receptor ahosterism 
(Wolf et al, 1995; Ross et al, 1996, 1998). The apoptotic role of p75 has been 
confirmed in two transgenic systems. First, mice lacking a functional BDNF gene 
display an increased number of sympathetic neurons compared to normal 
littermates, suggesting that BDNF, which does not activate Trk receptors in these 
neurons, acts through p75 to cause apoptosis (Bamji et al., 1998). Second, mice 
over-expressing the intracellular domain of p75 show profound reductions in the 
number of sympathetic, peripheral sensory, and neocortical neurons, as well as 
increased neuronal death following axotomy (Majdam et al, 1997).
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1.5.3. The family of neuropoietlc cytokine and their receptors
Neuropoietic cytokines, or neurokines, constitute a family of cytokines 
which exhibit pleiotrophy and redundancy in biological activities. The family 
includes: ciliaiy neurotrophic factor (CNTF), growth-promoting activity (GPA), 
leukemia neurotrophic factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), 
cardiotrophin 1 (CT-1), and interleukin-11 (IL-11). Cytokines have been found to 
regulate a number of properties in cells of the developing and mature nervous 
system including, proliferation, survival, differentiation, regeneration and 
neurotransmitter phenotype. Analysis of the genes encoding these proteins reveals 
a shared exon organization suggesting evolutionary descent from a common 
ancestral gene (Bruce et al., 1992). Furthermore, although the cytokines share 
very little sequence identity (<30%), they adopt a very similar tertiaiy structure 
(Bazan, 1991). Family members signal through very similar multi-subunit 
receptors that contain a common transducing component. This later fact could 
partially explain the functional redundancy of the cytokines.
Ciliary neurotrophic factor
Ciliaiy neurotrophic factor (CNTF) was first identified in 1976 as a trophic 
activity found in heart conditioned medium that was able to support the survival of 
chick ciliary ganglion neurons in vitro (Helfand et al, 1976). Subsequent studies 
have led to the purification (Barbin et al, 1984; Manthorpe et al, 1986) and 
cloning of rat (Stockh et al, 1989), rabbit (Lin et al, 1989, 1990) and human 
(Masikowski et al, 1991) CNTF. Biochemical analysis of CNTF has revealed that
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it is a 200 amino acid long protein with a molecular weight of 22.8 kDa and pi of 
5.78 (Stockli et al., 1989; Lin et al., 1989). One unusual feature of CNTF is that it 
lacks a consensus sequence for glycosylation and a secretory signal peptide, 
suggesting that it is a cytosolic protein (Stockli et al., 1989; Lin et al., 1989).
CNTF is widely expressed in the adult rat nervous system, but not 
elsewhere. High levels of CNTF mRNA can be found in sciatic and optic nerves, 
olfactory bulb and spinal cord. Lower levels of CNTF mRNA aie expressed in the 
brain stem, cerebellum, septum, hippocampus, striatum and midbrain (Stockli et 
al., 1991; Dobrea et al., 1992; Ip et al., 1993a). In these tissues, CNTF is mainly 
produced by glial cells.
It is now well established that in addition to cüiaiy neurons, a wide vaiiety 
of peripheral and central neurons respond to CNTF. In vitro, CNTF enhances the 
survival of sensory neurons (Barbin et al., 1984), motor neurons (Sendtner et al., 
1990; Arakawaet al., 1990; Oppenheimet al., 1991), cerebellar neurons (Larkfors 
et al., 1994) and hippocampal neurons (Ip et al., 1991). Further, CNTF inhibits 
proliferation and enhances cholinergic properties of neuronal precursors from the 
sympathetic ganglion (Ernsberger et al., 1989a) and stimulates cholinergic 
differentiation of mature sympathetic neurons (Saadat et al., 1989). CNTF has a 
number of neurotrophic action in vivo. For example, CNTF can protect embryonic 
spinal motoneurons from naturally occurring cell death (Oppenheim et al., 1991). 
In addition, CNTF can rescue neonatal rat facial motor neurons (Sendtner et al., 
1990), adult rat anterior thalamic neurons (Clatterbuck et al., 1993), medial septal 
neurons (Hagg et al., 1992) and neurons of the substantia nigra (Hagg and Varon,
1993) from post-axotomy degeneration. CNTF also protects adult rat retinal 
photoreceptors from constant light damage (LaVaü et al., 1992).
In addition to these effects on neuronal ceUs, CNTF can act on the ghal 
cells of the nervous system. For example, CNTF promotes the in vitro
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differentiation of glial progenitors into astrocytes (Hughes et al., 1988; LMen et 
al., 1988), and the maturation and survival of cultured oligondendrocytes (Louis 
et al., 1993). Outside of the nervous system CNTF has been shown to maintain 
the pluripotentiality of cultured embryonic stem cells (Conover et al., 1993). 
Additionally, CNTF has myotrophic actions on skeletal muscle in vivo (Helgren et 
al., 1994).
Although CNTF has many trophic effects on both embryonic and neurons, 
the actual physiological role of CNTF in vivo remains unclear. This is for thiee 
reasons. First, CNTF mRNA is only expressed postnatally (Stockli et al., 1989). 
Second, CNTF is primarily synthesized by glial cells and not in neuronal target 
tissues such as skeletal muscle or skin (Stockli et al., 1989, 1991; Lilhen and Raff, 
1990). Third, CNTF lacks a hydrophobic secretory sequence and is not released 
from transfected eukaryotic ceUs, implying that it is a cytosolic molecule 
(Friedman et al., 1992; Rende et al., 1992; Sendtner et al., 1992b; Reiness and 
Nishi, unpublished data).
It has been suggested that CNTF might act as a lesion factor under 
pathological conditions. In the PNS, CNTF protein has been detected in the 
extracellular fluid following nerve injury (Sendtner et al., 1992b). This is coupled 
to a sharp decrease in the levels of cytoplasmic CNTF in Schwann cells (Friedman 
et al., 1992) perhaps due to its release (by an unknown mechanism) in response to 
injury. In the CNS, mechanical lesions result in dramatic increase in CNTF mRNA 
and protein expression in tissue bordering the wound site (Ip et al., 1993b; Asada 
et al., 1995). Such an increase in CNTF production could be localized to reactive 
astrocytes in the resulting glial scar (Ip et al., 1993b; Rudge et al., 1994). The 
expression pattern of CNTF has led to the prediction that it does not play a critical 
role during normal development, but rather that it has a role in response to injury 
or in long-term maintenance. Consistent with this possibility, mice in which the
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CNTF gene has been disrupted develop normally with only mild motor neuron 
loss and atrophy later in adulthood (Masu et al., 1993).
Growth-promoting activity
Growth-promoting activity (GPA) was initially purified fi'om chicken 
sciatic nerve (Eckenstein et al., 1990) and later cloned from embryonic chicken 
eye (Leung et al., 1992). GPA shares about 48% amino acid identity with 
mammalian CNTF, suggesting that it is the avian homologue. However, marked 
differences in secretion and expression suggest otherwise. GPA is a 195 amino 
acid residues protein with a predicted molecular weight of 21.3 kDa and pi of 5.1. 
(Eckenstein et al., 1990). Although the crystal structure of GPA has yet to be 
resolved, computer analysis predicts that GPA contains alpha helices in the same 
amino acid residues as CNTF (Sendtner et al., 1994). GPA, like CNTF, lacks an 
N-terminal secretory signal sequence, yet unhke CNTF it is detected in a 
biological active form in both choroid smooth-muscle-conditioned medium (Nishi, 
unpublished data) and cell lines transfected with a GPA cDNA (Leung et al., 
1992). The ability to be secreted appeal's to be due to the presence of an internal 
signal sequence between amino acids 40 and 60 (Reiness et al., 1995).
GPA has been shown to promote the survival of a wide vaiiety of neuronal 
cell types within the PNS, including ciliary ganglion neurons, lumbar sympathetic 
neurons and, in contrast to CNTF, E8 DRG neurons (Eckenstein et al., 1990; Finn 
et al., 1998). Moreover, GPA like CNTF, induces choline acetyltransferase 
expression in neonatal rat sympathetic neurons (Fann and Patterson, 1994) and 
vasoactive intestinal peptide expression in embryonic chick sympathetic neurons 
(Heller et al., 1994). Analysis of GPA expression has demonstrated that, unlike
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CNTF, it is found in the developing chicken embryo. In particular, it is expressed 
in cells innervated by CG neurons (Finn and Nishi, 1996a) and in the embryonic 
sciatic nerve (Leung et al., 1992).
Leukemia inhibitory factor
Leukemia inhibitory factor (LIF) was originally purified, characterized, and 
cloned by virtue of its ability to induce differentiation and suppress proliferation of 
the murine myeloid leukaemic cell line Ml (Tomida et al, 1984; Gearing et al, 
1987; Hüton et al, 1988a, b; Metcalf et al., 1988). Subsequently, it has been 
shown that LIF is identical to hepatocyte-stimulating factor III, a glycoprotein 
capable of stimulating the synthesis of several acute phase plasma proteins 
(Baumann and Wong, 1989), the melanoma-derived lipoprotein lipase inhibitor 
(Mori et al., 1989) and cholinergic neuronal differentiation factor fiom heart cells 
(Yamanori et al., 1989).
Mature LIF protein comprises of 179 amino acid residues, and has a 
moleculai' weight o f -20 kDa and pi of -8.8 (Gearing et al, 1987). Analysis of the 
three-dimensional structure of LIF has revealed a folding pattern similar to the 
other neurokines- four alpha hehcal cores connected by more hneai' linker regions 
(Bazan, 1991; Robinson et al., 1994).
LIF mRNA can be detected, albeit at low levels, in most tissues during 
development (Bhatt et al, 1991). In the adult, LIF transcripts are found in the 
brain, heart, thymus, liver and intestine (Bhatt et al, 1991). In situ hybridization 
and immunohistochemical analysis of the adult rat brain have shown that LIF 
mRNA is predominantly expressed by hippocampal pyramidal cells, hilar 
interneurons and granule cells of the dentate gyrus. Neurons of the cerebral
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cortex, cerebellum, cholinergic basal forebrain nuclei and the striatum also express 
LIF mRNA (Lemke et al., 1996). Interestingly, LIF transcripts do not appear to 
be expressed by astrocytes in vivo (Lemke et al., 1996), although primary 
astrocyte cultures have been shown to express LIF mRNA (Murphy et al., 1995).
LIF exhibits pleiotrophic activities on a wide range of ceU types. In many 
instances the effects of LIF aie similar, if not identical, to those of CNTF. LIF 
regulates the transmitter phenotype and expression of many neuropeptides in 
cultured sympathetic and sensory neurons (Yamamori et al., 1989; Nawa et al., 
1991; Bazan, 1991; Fan and Katz, 1993). LIF also stimulates the differentiation of 
neural crest cells into sensory-like neurons and enhances the survival of several 
populations of embryonic and postnatal sensory neurons in culture (for review see 
Horton et al., 1996). In addition, LIF promotes the survival of spinal motor 
neurons both in vitro (Martinou et al., 1992; Henderson et al., 1993) and after 
deafferentation or axotomy in vivo (Wei et al., 1994; Vejsada et al., 1995). 
Furthermore, LIF increases the survival of astrocytes and retinal pigment epithehal 
cells (Gadient et al, 1998; Gupta et al, 1997) in addition to promoting the 
generation, maturation, and survival of oligodendrocytes in vitro (Mayer et al, 
1994; Vos et al, 1996). LIF also plays a role in the response to injury of both 
neural and peripheral tissues. In the CNS, mechanical lesions result in a dramatic 
increase (30-fold) in LIF mRNA close to, but not immediately adjacent to, the 
lesion site. Such an increase in LIF production is localized in astrocytes and a 
small number of microglial cells (Banner et al, 1997). In the periphery, LIF has 
been shown to stimulate skeletal muscle regeneration after injury by increasing the 
size, but not the number, of the muscle fibers. Furthermore in this lesion model, 
injured muscles appear to express LIF mRNA (Barnard et al., 1994).
Mice lacking the LIF gene have been generated to investigate its role in 
vivo. In contrast to its many effects in culture, LIF deficient mice appear to have
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no major developmental abnormalities. However, homozygous mutant adult 
females have a defect in uterine function which prevents implantation of the 
developing embryo. This is consistent with the observation that LIF mRNA is 
expressed in the uterus prior to and during implantation in the uterus (Steward et 
al., 1992; Bhatt et al, 1991; Song et al, 1998). In addition, absence of LIF 
appears to result in reduced expression of neuropeptides in peripheral neurons 
both in vitro and in vivo (Rao et al., 1993). Finally, careM analysis of the brain in 
LIF knockout mice has revealed a significant deficit in myelin basic protein 
expression in female, but not male, young and adult mice, suggesting an alteration 
in the normal oligondedrocyte population (Bugga et al, 1998).
Interleukin-6
Interleukin-6 (IL-6), originally named human B cell stimulatory factor-2 
(BSF-2), was characterized and isolated as a T cell-derived factor that caused the 
terminal maturation of activated B cells to immunoglobulin-producing cells 
(Hirano et al, 1985, 1987). Subsequent studies have led to the cloning of IL-6 
from several species (Hirano et al, 1986; Chiu et al, 1988; Northemann et al, 
1989). Mature IL-6 protein is 184 amino acids long with a predicted molecular 
weight of about 20 kDa (Hirano et al, 1986; Chiu et al, 1988). Human and 
mouse IL-6 have very httle sequence identity, with only 41% homology at the 
ammo acid level (Chiu et al, 1988).
In situ hybridization analysis of the adult rat brain have shown that IL-6 
mRNA is expressed in the pyramidal and granular neurons of the hippocampus, 
habenulae, dorsomedial and ventromedial hypothalamus, large pyramidal neurons 
of the piriform cortex, internal capsule, optic tract, scattered neurons of the cortex
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and granular cells of the cerebellum (Schobitz et al, 1992, 1993; Gadient and 
Otten, 1994).
IL-6 is perhaps the most extreme example of a pleiotropic cytokine with 
diverse functions throughout the body. Peripherally, IL-6 is known to stimulate 
the acute phase hepatocyte response (Gauldie et al, 1987) and the differentiation 
of B lymphocytes (Kopf et al, 1994; Lee, 1992). In addition, IL-6 plays a role in 
bone remodeling by osteoclasts (Poli et al, 1994) and stimulates protein 
breakdown in muscle (Goodman, 1994). In the central nervous system, IL-6 
supports the survival of cultured embryonic and postnatal midbrain 
catecholaminergic neurons (Kushima et al, 1992). IL-6 also supports the survival 
of spinal cord (Kushima and Hatanaka et al, 1992) and basal forebrain cholinergic 
neurons (Hama et al, 1989). In the PNS, IL-6 promotes the smwival of nodose 
and trigeminal ganglion neurons (Horton et al, 1996). IL-6 also modulates 
cholinergic differentiation and expression of neuropeptides such as substance P in 
cultured sympathetic neurons (Fann and Patterson, 1994), and induces 
differentiation of PC12 cells into a neuron-Hke phenotype (Satoh et al, 1988). 
Furthermore, IL-6 stimulates astrocyte proliferation (Campbell et al, 1993; 
Chiang et al, 1994; Fattori et al, 1995), and plays a role in the protection against 
neuronal damage (Akaneya et al, 1995; Hkohata et al, 1996; Ikeda et al, 1996) 
and modulation of pain (DeLeo et al., 1996; Geiss et al, 1997; Oka et al, 1995; 
Arruda et al., 1998).
IL-6 deficient mice are viable, fertile and do not present any evident 
phenotypic abnormality in the nervous system or peripheiy either during 
development or in adulthood. However, these mice display impaiied immune and 
acute phase responses to infection (Kopf et al, 1994). IL-6 deficient mice also 
display defective hepatocyte regeneration (Cressman et al, 1996) and specific 
bone phenotype (Poh et al, 1994).
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Oncostatin M
Onco statin M (OSM) was initially described as a growth regulatory 
molecule which could inhibit the growth of certain tumor cell lines and stimulate 
the growth of several normal fibroblast lines (Zarling et al,, 1986). Subsequently, 
OSM was cloned fi'om several species (Malik et al., 1989, 1995; Hara et al.,
1997). Mature OSM protein is 196 amino acids long and has a molecular weight 
of -28 kDa (Malik et al., 1989). The predicted crystal structure of oncostatin M 
reveals a four-hehcal bundle motif similar to other neurokines (Rose and Bruce, 
1991; Bazan, 1991). The expression of OSM is largely restricted to 
haematopoietic cells, including activated peripheral T-lymphocytes and 
lipopolysacchai'ide induced human monocytes (Bruce et al., 1992).
The effects of OSM in vitro, which have been largely determined using 
various cell lines, overlap with those of other neurokines (Bruce et al., 1992). In 
the developing nervous system, OSM promotes the survival of nodose, trigeminal 
and DRG ganglion neurons in culture (Horton et al., 1996; Ware et al., 1995). 
OSM also plays a role in regulating oligodendiocyte cell survival and 
differentiation (Vos et al., 1996).
Cardiotrophin-1
Cardiotrophin-1 (CT-1) is the latest member of the neurokine family to be 
isolated. It was initially identified based on its ability to induce cardiac myocyte 
hypertrophy in vitro (Pennica et al., 1995a). Mature CT-1 protein is 203 amino 
acids long with a molecular weight of 21.5 kDa. Like CNTF, CT-1 lacks a 
conventional amino-terrninal secretion signal sequence; CT-1 is, however, found
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in the medium of transfected mammalian cells. CT-1 mRNA is widely expressed in 
adult mouse tissues, including heart, kidney, skeletal muscle, liver, lung, testis, 
spinal cord, and brain (Pennica et al., 1995a).
The biological actions of CT-1 largely resemble those of other neurokines. 
For example, CT-1 inhibits the growth of the mouse Ml myeloid leukemia cell 
line, but unlike IL-6, CT-1 does not stimulate B cell expansion. CT-1 also inhibits 
the differentiation of mouse embryonic stem cells in a simOai* way to CNTF, LIF 
and OSM (Pennica et al., 1995b). In the nervous system, CT-1 promotes the 
survival of cultured rat hindbrain dopaminergic neurons, chicken ciliary neurons, 
mouse nodose neurons, late embryonic mouse trigeminal neurons and E l4.5 rat 
motoneurons (Pennica et al., 1995b; Horton et al., 1998; Arce et al., 1998). In 
addition, CT-1 induces a phenotypic switch in rat sympathetic neurons in vitro 
(Pennica et al., 1995b) and protects neonatal sciatic motoneurons against the 
effects of axotomy in vivo (Pennica et al, 1996). Although no gene disruption 
experiments have yet been carried out, chronic administration of CT-1 to mice 
results in increased growth of heart, liver, kidney and spleen, in addition to 
atrophy of the thymus, and increased platelet counts. These effects suggest that 
CT-1 has a broad spectrum of biological activities in vivo (Jin et al, 1996).
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Neurokine receptors
The biological action of the neuropoietic cytokines is mediated by 
multimeric cell surface receptors that share a common subunit, the glycoprotein 
gpl30 (see Figure 1.4).
IL-6 CNTF LIF OSM CT-1
IL6Ra CNTFRau I
e e e
gpl30 gpl30 gpl30 LIFRp gpl30 LIFRji gpl30 LIFRP mOSMR gpl30 gpl30 LIFRp
hOSMR
Figure 1.4. Neurokine receptors. 
See text for details.
For receptor activation, IL-6, CNTF and IL-11 first bind to their specific 
a-receptor subunits (Yamasaki et al., 1988; Davis et al., 1991; Hilton et al.,
1994). Subsequently, the a-receptor-ligand complex associates with gpl30, which 
then recruits either another gpl30 molecule, in the case of IL-6 and IL-11, or the 
LIF receptor P (LIFRp) subunit in the case of CNTF (Murakami et al., 1993; Yin
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et al, 1993; Davis et al., 1993a). For CT-1, LIF and human OSM (hOSM), 
receptor activation requires the heterodimerization between gpl30 and LIFRp 
without the involvement of an «-component. [There is some evidence for the 
presence of such a component, yet unknown, in the case of CT-1 (Pennica et al., 
1995b; Robledo et al, 1997)]. LIF and CT-1 first bind LIFRP with low affinity 
and then to gpl30, which increases the binding affinity but does not bind LIF or 
CT-1 by itself. In contrast, hOSM binds directly with low affinity to gpl30 and the 
bindmg affinity is increased by LIFRp, which does not bind hOSM by itself 
(Gearing et al, 1992; Liu et al, 1992; Pennica et al, 1995b). Recently, two 
additional OSM receptors have been described. The fiist, was isolated from 
human cells and composed of the hOSM receptor P (hOSMRp) and gpl30 
(Mosley et al, 1996). The second, was cloned from a mouse colon libraiy and 
composed of mouse OSMRp (mOSMRp) and gpl30. Human and mouse 
OSMRPs are believed to be orthologous (Lmdberg et al, 1998). Interestingly, 
mOSM, in contrast to hOSM, cannot signal thiough the LIFRp-gpl30 complex 
(Ichihaia et al, 1997; Lindberg et al, 1998).
Neurokine receptors (NRs) do not possess any intrinsic enzymatic 
activities. Their cytoplasmic domains contain no kinase or phosphatase domain 
and have regions of limited homology in the membrane-proximal part, often 
termed the boxl and box2 motifs (Murakami et al, 1991). Their extracellular 
domain displays characteristic structural motifs including four conserved cysteine 
residues in the amino-terminal part and the presence of a conseiwed WSXWS 
motif in the carboxy-terminal part (Bazan, 1990).
The key features of the transduction processes utilized by neurokines may 
be defined as follows. Upon ligand binding, dimerization of two gpl30 or one 
gpl30 and one LIFRp occurs. This event leads to rapid phosphorylation of 
tyrosine residues on the p-receptor components and other cellular proteins. Since
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NRs lack any intrinsic enzymatic activity, tyrosine phosphorylation is mediated by 
the JAK kinases (JAK). Four members of JAKs have been identified (Wilks et al., 
1991; Harpur et al., 1992; Kawamura et al., 1994; Firmbach-Kraft et al., 1990) 
and both gpl30 and LIFRP can bind JAKl, JAK2, and Tyk2 with some 
specificity, depending on the ceU type in which they are expressed (Stahl et al., 
1994, 1995). It is now generally believed that JAK kinases are pre-associated with 
gpl30 and LIFRp prior to receptor dimerization, and that dimerization of p 
components result in activation of these kinases (Stahl et al., 1994). The 
phosphorylated receptors recruit SH2-beaiing proteins thiough their tyrosine 
phosphorylated sites. These signal transducing proteins are then activated by the 
receptor-associated JAKs (for review see Stahl and Yancopoulos, 1994; 
Miyajima, 1997; Moutoussamy et al., 1998). It has been shown that substrates for 
JAK phosphorylation include: PLCy, PI3-kinase, PTPID, She, GRB2, Raf-1 and 
the MAP kinases ERKl and ERK2 (Boulton et al., 1994). Another target for 
tyrosine phosphorylation by activated JAK is the STAT (Signal Transducers and 
Activator of Transcripion) family of transcription factors.
There are seven STATs, of which STATl and STAT3 are the preferential 
signal transducers for neurokines (Stahl et al., 1995; Lai et al, 1995; Lütticken et 
al, 1994). STATs bind to activated NRs by viitue of their SH2-containmg 
domain. Following tyrosine phosphorylation by JAKs, STATs form either a 
homodimer or a heterodimer, before translocating to the nucleus where they bind 
DNA and regulate gene expression. STATs can also bind other transcription 
factors and thus modulate thek function (for review see, Moutoussamy et al, 
1998; Hoey and Schindler, 1998).
gp 130 and LIFRP aie widely distributed both in the periphery and 
nervous system. gpl30 mRNA has been detected in brain, heart, thymus, kidney, 
lung, hver and spleen. Additionally, gpl30 mRNA is expressed in ES cells,
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embryos and in all cell lines tested (Saito et al., 1992; Hibi et al., 1990; Taga et al., 
1989). At least two soluble valiants of gpl30, with the ability to bind both LIF 
and LIFRp, have been identified (Zhang et al, 1998; Diamant et al, 1997). 
Recent evidence suggest that soluble gpl30 is an antagonist of the effects of IL-6 
on various cell types especially in the presence of soluble IL-6Ra (sIL-6Ra) and 
plays a role in inflammation (MüUer-Newen et al., 1998; Zhou et al, 1998; 
Narazaki et al, 1993). Northern blotting and in situ hybridization analysis of 
LIFRp mRNA expression bas revealed that it is expressed in liver, placenta, 
ovaries, testes, brain (especially in regions relevant to the motor and sensory 
systems), kidney, skeletal muscle, uterus, pancreas, ES cells and in all cell lines 
examined (Owczavek et al, 1996; Yamakuni et al, 1996; Hilton and Nicola, 
1992). Like gpl30, LIFRp exists in both membrane-bound and soluble form 
(Layton et al, 1992; Zhang et al, 1998; Owczavek et al, 1996; Tomida, 1997). 
Although the role of sLIFRP in vivo is presently unclear, in vitro experiments 
have demonstrated that sLIFRp is able to block the activity of murine LIF (Layton 
et al, 1992; Tomida, 1995; Yamaguchi-Yamamoto et al., 1993).
The intracytoplasmic portion of IL-6Ra is very short (Yamasaki et al, 
1998) and is not required for signaling (Taga et al., 1989). IL-6Ra mRNA is 
found in many myeloma and normal cell lines (Kishimoto et al, 1992; Navarro et 
a l, 1991) as well as various regions of the brain (Yamasaki et al, 1998; Banning 
et al, 1998). In the nervous system, IL-6Ra appears to colocalize with its ligand 
IL-6 and is expressed by both neuronal (including PNS sympathetic and sensory 
neurons) and glial cells (Schobitz et al, 1992, 1993; Gadient and Otten, 1994,
1996). The IL-6Ra exists also in a soluble form (Lust et al., 1992) that is 
generated through either proteolytic shedding of the cognate receptor or 
differential mRNA splicing (Müllberg et al, 1993; Jones et al, 1998). Soluble IL- 
6Ra s(IL-6Ra) is functional, and in vitro appears to enhance the effect of IL-6
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(Lust et al., 1995; Taga et al., 1989). In vivo, sIL-6Ra has been implicated in 
diseases such as Alzheimer’s (Angelis et al., 1998; Hampel et al., 1998), 
extrameduUary hematopoiesis and plasmacytoma formation (Peters et al, 1997; 
Schirmacher et al., 1998). In addition sIL-6Ra has been shown to prolong plasma 
IL-6 half-life (Peters et al, 1996).
A unique feature of CNTFRa is that it lacks a transmembrane domain. 
Instead, CNTFRa is anchored to the plasma membrane via a glycosyl- 
phosphatidylinositol (GPI) linkage that can be cleaved by phosphatidylinositol- 
specific phospholipase C (PIPLC), an enzyme that cleaves the anchors of GPI 
linked proteins (Davis et al, 1991). CNTFRa expression is largely restricted to 
the nervous system where it is localized to neuronal populations that respond to 
CNTF, including sympathetic, sensory and parasympathetic ganglia (Ip et al, 
1993a). In the CNS, CNTFRa is a prominent marker for motor neurons and 
motor related brain areas, consistent with the role of CNTF in maintaining motor 
system function (Ip et al, 1993a). In addition, CNTFRa is widely expressed 
within other aieas of the CNS, suggesting additional potential targets for CNTF 
action (Ip et al., 1993a). In contrast to CNTF, CNTFRa is expressed during 
embryonic development. In particular, CNTFRa is expressed by neuronal 
precursors in the neuroepithelium of the CNS and by neural crest-derived 
progenitors in the PNS. Embryonic expression of CNTFRa implies the existence 
of a still unknown second ligand for this receptor (Ip et al, 1993a). In the 
periphery, CNTFRa is expressed in skeletal muscle (Ip et al., 1993a), an 
observation that and this is consistent with the myotrophic actions of CNTF 
(Helgren et al, 1994). CNTFRa can also exist as a soluble protein (Davis et al, 
1993b). Soluble CNTFRa (CNTFRa) has been detected in cerebrospinal fluid and 
in skeletal muscle after nerve injury. This later observation suggests that soluble
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CNTFRa may play a role in the physiological response to injury (Davis et al., 
1993b).
The in vivo role of the NRs has been further examined by the use of 
knockout mice. Targeted inactivation of the gpl30 gene results in a reduction in 
the total complement of haematopoietic cells and striking defects within the 
developing heart that lead to embryonic lethality (Yoshida et al., 1996).
LIFRp deficient mice die perinataUy (Ware et al., 1995) and display a significant 
reduction in the number of facial and spinal motor neurons (Li et al., 1995). In 
addition, they show decreased numbers and impaired differentiation of spinal 
brainstem and cord astrocytes (Ware et al., 1995; Koblar et al., 1998).
Ablation of the CNTFRa gene in mice results in a reduction in all motor neuron 
populations examined (DeChiara et al., 1995), as well as a reduction in,neuronal 
number in other PNS and CNS populations examined (DeChiara and 
Yancopoulos, unpublished data). CNTFRa knockout mice do not initiate the 
feeding process and die shortly after birth (DeChiara et al., 1995).
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1.5.4. The superfamily of TGF-P-related cytokines and their receptors
The transforming growth factor (TGF)-p superfamily is a large group of 
cytokines which are among the most versatile carriers of growth and 
differentiation signals. Members of this family participate in setting up the basic 
body plan during embryogenesis in mammals, frogs and flies; control formation of 
neural tube, limbs, cartilage, bone and sexual organs; suppress epithelial cell 
growth; promote wound repair; and influence important immune and endocrine 
functions. This superfamily, which currently includes around 40 members, has 
several groups. The main families are: TGF-ps, decapentaplegic-Ygl-rolaX&d 
(DVR), activins and glial ceU line-derived neurotrophic factor (GDNF). Some 
members cannot be classified into a specific subgroup, however, and new ones are 
still being identified. With the exception of GDNF family, all members of the 
TGF-p superfamüy signal through a receptor complex formed by two distantly 
related types of serine/thieonine kinase proteins.
Structure of the ligands
The various members of the TGF-p superfamily aie initially synthesized as 
larger precursor molecules with an amino-terminal signal sequence and a pro­
domain of varying size. This precursor protein is usually cleaved at a dibasic or 
RXXR site to release a mature carboxy-terminal segment (Massagué, 1990). 
Although the pro-domain is poorly conserved across different superfamily 
members, it is often well conserved for a particular family member isolated from 
several different organisms. The pro-domain appears to be required for normal
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synthesis and secretion of TGF-p family members (Gray and Mason, 1990; 
Hammonds et al., 1991; Thomsen and Melton, 1993). The pro-domain can also 
remain associated with the caiboxy-terminal signaling fragment to produce an 
inactive complex (Gentry and Nash, 1990). The mature TGF-p proteins are much 
more highly conserved and contain most of the sequence landmarks by which new 
family members are usually recognized. Seven cysteine residues within the mature 
region are neaily invariant in members of the superfamily. Crystallography studies 
have shown that six of these cysteines are closely grouped to make a rigid 
structure called a "cysteine knot". This knot locks the base of several p-sheet 
strands together and probably accounts for the strong resistance of many TGF-p 
superfamily members to heat, dénaturants, and extreme pH. The remaining 
cysteine residue m each monomer forms an additional disulfide bond that links two 
monomers into a dimer (Daopin et al., 1992; Schlunegger and Gmtter, 1992). 
Many hydrophobic contacts exist between two monomer subunits that could 
promote dimer formation even in the absence of a disulfide bond. Indeed this is 
the case for GDF-3 and GDF-9, proteins that lack the seventh cysteine 
(Schlunegger and Grütter, 1992; Daopin et al., 1992; Mcpherron and Lee, 1993).
The TGF-p family
The TGF-p family comprises at least five distinct protein species which are 
more closely related to each other than to any other members of the TGF-p 
superfamily (for review, see Krieglstein et al., 1995). These proteins are TGF-P 1, 
-p2, -p3, -p4, and- p5. TGF-p5 is an isoform which has been found in amphibians, 
and TGF-P4 is probably the chick homologue of mammalian TGF-p 1 (Burt and 
Baton, 1992). AU TGF-P isoforms are 25 kDa dimers, with 9 conserved cysteine
73
residues and a more than 70% sequence identity at the amino acid level (Roberts 
et al, 1990).
TGF-ps are widely distributed in developing and adult tissues representing 
all three primary embryonic germ layers. Tissues that express one or more TGF-p 
proteins include cartilage, bone, teeth, muscle, heart, blood vessels, lung, kidneys, 
gut, liver, eye, ear, skin and brain (Felton et al, 1991; Mülan et al, 1991; Schmid 
et al, 1991). In the developing and adult nervous system TGF-p 1 expression is 
restricted to meninges and choroid plexus. In contrast, TGF-P2 and TGF-ps are 
co-expressed in astroglial and Schwann ceUs as well as in many populations of 
central and peripheral neurons. TGFP-2 and TGFp-3 appear to be expressed at 
particularly high levels in neurons that project over long distances (for review, see 
Krieglstem et al., 1995).
Current knowledge on the functions of TGF-ps in the nervous system has 
been deduced from in vitro and in vivo lesioning studies. The available mouse 
mutants that are defective for either one of the isoforms (Shull et al, 1992; 
Kulkarni et al, 1993; Kaaitinen et al., 1995; Proetzel et al, 1995; Sanford et al,
1997) have faüed to reveal overt deficits in neural structure and function, possibly 
by virtue of compensatory effects of the remaining isoforms. TGF-Ps have been 
implicated in the regulation of neuronal survival of motoneurons (Martinou et al,
1998), sensory neurons (Chalazonitis et al, 1992) and midbrain dopaminergic 
neurons (Krieglstein and Unsicker, 1994; Poulsen et al, 1994). However, it is 
now emerging that the trophic effects of the TGF-Ps require the presence of other 
co-operative factors found in serum or produced by non-neuronal cells. Indeed it 
has been shown that highly enriched serum-free neuron cultures do not respond to 
TGF-Ps alone (Krieglstein and Unsicker, 1996; Krieglstein et al, 1998a). Many 
recent studies have emphasized the synergistic potential of the TGF-ps. For 
example, TGF-p3 can significantly increase the survival of cultured DRG neurons
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treated with NT-3 (Krieglstein and Unsicker, 1996). Similarly, TGF-p 1 greatly 
enhances the survival effects of NGF on DRG neurons (Chalazonitis et al., 1992). 
Moreover, addition of TGF-pl to cultures of spiral ganglion cells modulates 
bFGF receptor mRNA and increases FGF2-induced neuronal survival (Lefebvre et 
al., 1991). TGF-pl, -p2 or -p3 enhance cüiary neuron survival mediated by CNTF 
or FGF-2 and in combination with NT-3 or NGF promote it (Gouin et al., 1996; 
Krieglstein et al, 1998b) Recently, it has been reported that GDNF requires 
TGFPs for its trophic effects on chicken sensory, sympathetic and parasympathetic 
neurons (Krieglstein et al, 1998a).
TGF-ps also act on the non-neuronal cells of the nervous system. They are 
mitogens for Schwann cells (Ridley et al, 1989) and, together with FGF, 
synergistically regulate mitosis (Schubert, 1992). TGF-pl is chemotactic for 
cultured astrocytes (Morganti-Kossman et al, 1992) and TGF-Ps have, in most 
contexts, antiproliferative effects on them (for review, see Krieglstein et al,
1995).
The GDNF family 
Glial cell line-derived neurotrophic factor
The observation that the rat glial cell line, B49 released a factor which 
exhibited relative specificity for dopaminergic neurons in dissociated cultures of 
the rat embryonic midbrain lead to identification of GDNF a new member of the 
neurotrophic growth factor family (Engele et al, 1993; Lin et al, 1993a, b, 1994). 
GDNF is a glycosylated, disulfide-bonded homodimer that is distantly related (less 
than 25% amino acid identity) to members of the TGF-p superfamhy. The
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molecular weight of the GDNF homodimer is approximately 33-45 kDa while the 
monomer has a molecular weight of 16 kDa after glycosylation (Lin et al., 1993a, 
1994). Sequence data suggests that GDNF is synthesized as a precursor of 211 
amino acids that is cleaved and secreted as a mature protein of 134 amino acids 
(Bektesh et al., 1993; Lin et al., 1993a).
GDNF has a wide tissue distribution and is expressed both during 
development and adulthood. GDNF is expressed by both neuronal and non­
neuronal cells in the brain. The highest levels of GDNF mRNA are found in 
pyramidal and granular cells of the hippocampus. A tense signal is also observed in 
Purkinje cells of the cerebellum, in dopaminergic neurons of the substantia nigra 
and in subpopulations of striatal neurons. In addition, cholinergic neurons of the 
medial septal nucleus, the diagonal band of Broca, the ventral pallidum and 
habenula show high levels of GDNF mRNA. Moreover, motoneurons of the facial 
nucleus, SCG and DRG also express GDNF mRNA. In the spinal cord, neuronal 
expression is found in Clarke's column and the dorsal and ventral horn. Additional 
regions where GDNF mRNA is expressed in the head region include the carotid 
body, retina, vibrissae, inner ear, ear canal, developing teeth and epithelium in the 
nasal cavity (Nosrat et al, 1996; Pochon et al, 1997; Trupp et al, 1995; Schaar et 
al, 1993; Golden et al, 1998; Henderson et al, 1994). In the periphery, GDNF 
mRNA is present in numerous organs and tissues. These include kidney, testis, 
ovary, stomach, skin, muscle, adrenal, liver, spleen, intestine, lung, and blood 
(Suter-Crazzolara and Unsicker, 1994; Choi-Lundberg and Bohn, 1995; Trupp et 
al, 1995).
GDNF was initially characterized on the basis of its ability to promote the 
survival and morphological differentiation of cultured dopaminergic neurons (Lin 
et al, 1993a). Subsequently, using animal models of Parkinson's disease, GDNF 
injected into the substantia nigra or the striatum has been shown to protect
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lesioned dopaminergic neurons from the degenerative process induced by 1- 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Tomac et ai., 1995), 
transection of the medial forebrain bundle (Beck et al., 1995) and 6- 
hydroxydopamine (Bowenkamp et al., 1995). The neurotrophic actions of GDNF 
are not confined to dopaminergic neurons. Many studies have confirmed the 
neurotrophic effects of GDNF on motoneurons (Henderson et al., 1994; 
Oppenheimet al., 1995; Yan et al., 1995; Zurn et al., 1994, 1996; Houenou et al., 
1996; Li et al., 1995; Trok et al., 1996; Arce et al., 1998; Junger and Varon,
1997). For example, GDNF is more effective than neurotrophins in promoting the 
in vitro survival of both cranial and spinal motor neurons with higher potency and 
longer lasting support than neurotrophins (Henderson et al., 1994). In addition, 
GDNF induces choline acetyl-transferase (ChAT) activity and neurite outgrowth 
in motor neurons (Zurn et al., 1994, 1996). In motoneuron lesion paiadigms, 
GDNF prevents facial motoneuron death following axotomy in newborn rats (Yan 
et al., 1995), degeneration of adult spinal motoneurons after ventral root avulsion 
(Li et al., 1995), and the lesioned-induced decrease in ChAT immunoreactivity of 
adult facial motoneurons (Yan et al, 1995). Moreover, GDNF significantly 
improves the conduction velocity of motor axons of the tibial nerve in adult rats 
(Munson and McMahon, 1997). Other CNS neuronal populations that are 
supported by GDNF include noradrenergic neurons, cerebellar Purkinje cells, and 
basal forebrain cholinergic neurons (Arenas et al, 1995; Mount et al, 1995; 
Williams et al, 1996). In the peripheral neiwous system, GDNF promotes the 
survival of chicken embryonic sympathetic, parasympathetic and most sensory 
neurons (Buj-Bello et al, 1995; Ebendal, 1995; Trupp et al, 1995; Forgie et al.,
1999). GDNF does not support, with the exception of late submandibulai' (E17, 
E l8) and early nodose (E l2), the survival of mouse PNS neurons (Cacalano et al.,
1998).
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The physiological role of GDNF has been further analyzed by the use of 
transgenic models. Mice lacking the GDNF gene have deficits in dorsal root 
ganglion (23%), superior cervical ganglion (35%) and petrosal-nodose complex 
(23%), but not in hmdbram noradrenergic or midbrain dopaminergic neurons. 
Furthermore, these mice lack most of the enteric nerve plexus and display agenesis 
or severe dysgenesis of the kidneys (Moore et al., 1996; Pichel et al., 1996a, b; 
Sanchez et al., 1996; Granholm et al., 1997). In another transgenic model, mice in 
which muscle fibers overexpress GDNF, show increased numbers of motor axons 
innervating neuromuscular junctions (Nguyen et al., 1998).
Neurturin
Neurturin (NTN) is a neurotrophic factor that was purified and cloned 
based on its ability to support the survival of rat SCG neurons in vitro (Kotzbauer 
et al., 1996). It is synthesized as a precursor protein of 195 amino acids that upon 
cleavage yields a 100-residue mature protein. NTN contains all seven conserved 
cysteine residues found in the same relative position across the entire TGF-p 
superfamhy. Sequence comparison has revealed that mature NTN shares 42% 
simharity with mature GDNF and less than 20% with other members of the 
superfamhy. Biological active NTN is a homodimer with molecular mass of 25 
kDa on non-reducing electrophoresis gels (Kotzbauer et al., 1996).
NTN mRNA is found both within and outside the nervous system. In the 
CNS, NTN mRNA is present in the lateral and medial magnoceUular 
paraventricular nucleus and in the supraoptic nucleus of the hypothalamus, in 
anteromedial, anteroventral, ventrolateral and ventral anterior nuclei of the 
thalamus, in a number of areas of the hippocampal formation, including ah three
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fields of Ammon's horn (CAl-3) within the hippocampus proper and in the dentate 
gyrus, in the granule and Purkinje cell layers of the cerebellum, in the phiform 
cortex, in the striatum, in the neocortex and in the cingulate cortex (Golden et al.,
1998). Additional areas of NTN mRNA expression in head region include the 
developing inner ear, olfactory mucosa, the vibrissae, the epithelial portion of 
salivary glands and developing teeth (Widenfalk et al., 1997). In the periphery, 
NTN mRNA is present in the developing buds of the metanephiic kidney, smooth 
muscle layers of the developing ureter, lungs, heait, Sertoli cells, epithelium of the 
oviduct, blood and hver (Widenfalk et al., 1997; Kotzbauer et al., 1996).
The neurotrophic activities of NTN have been analyzed using cell culture 
and in vivo approaches. In the PNS, neurons responsive to NTN include 
embryonic chicken SCG, nodose, lumbar sympathetic, DRG, ciliary and DMTG 
(Kotzbauer et al., 1996; Forgie et al., 1999). Like GDNF, NTN supports the 
survival of only late submandibular and early nodose neurons in the mouse embryo 
(Cacalano et al., 1998). In the CNS, NTN promotes the in vitro survival of both 
developing and mature dopaminergic (DA) neurons and protects mature DA 
neurons from cell death induced by 6-OHDA, in vivo (Horger et al., 1998). 
Furthermore, NTN has been shown to support the survival of enteric neuron 
precursors and induce the proliferation of both these neurons and enteric glia 
(Heuckevoth et al., 1998).
Neurturin deficient mice are viable and fertile but have defects in the 
enteric nervous system, including reduced myenteric plexus innervation density 
and reduced gastrointestinal motility. Parasympathetic innervation of the lacrimal 
and submandibular salivary gland is dramatically reduced in NTN knockout mice, 
consistent with in vitro work showing that NTN is a neurotrophic factor for 
parasympathetic neurons. In addition, absence of NTN appears to result in the loss 
of cells from the trigeminal and dorsal root ganglia (Heuckeroth et al., 1999).
79
Persephîn
Persephin (PSP), the third member of the GDNF family to be identified, 
has recently been cloned based on homology to GDNF and NTN (Milbrandt et al,
1998). Persephin is synthesized as a precursor protein of 156 amino acids that 
upon cleavage at the RXXR site yields a 96 residues mature protein. PSP is 
approximately 40% identical to NTN and GDNF and displays the cysteine residue 
spacing characteristic of the TGF-|3 superfamily members as well as regions that 
are only common to GDNF family members. Biological active PSP is a 
homodimer, with the monomer having a molecular weight of 10-12 kDa 
(Milbrandt et al., 1998).
Initially, PSP mRNA expression was analyzed using RNA blotting and in 
situ hybridization. This approach detected no PSP mRNA, indicating low 
abundance for PSP transcripts (Milbrandt et al., 1998). Subsequently, semi- 
quantitative RT-PCR was employed and revealed ubiquitous PSP mRNA 
expression in both neuronal and non-neuronal tissue. PSP mRNA appears to be 
present at similar levels in most tissues examined, with slightly higher levels in 
embryonic tissues. Further, in the CNS, PSP mRNA has been detected in both 
neurons and ghal cells (Milbrandt et al., 1998; Jaszai et al., 1998).
Persephin, like GDNF and NTN, promotes the survival of ventral 
hindbrain dopaminergic neurons in culture and prevents their degeneration after 6- 
hydroxydopamine treatment in vivo. PSP supports the survival of motor neurons 
both in vivo following sciatic nerve axotomy and in vitro (Milbrandt et al., 1998). 
PSP, like GDNF, also promotes uteric bud branching (Milbrandt et al., 1998). 
However, in contrast to GDNF and NTN, PSP does not support the survival of 
any neurons of the PNS (Milbrandt et al., 1998; Forgie, unpublished observations; 
personal observations).
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Artemin
Artemin (ART) is the most recent member of the GDNF family to be 
isolated. It was identified fi-om a HTGS database using the BLAST 2.0 algorithm 
with mature NTN protein sequence as a query (Baloh et al., 1998a). Aitemin, like 
other family members contains a signal sequence for secretion and synthesized as a 
precursor protein that upon cleavage yields a 113 amino acids mature protein. 
Artemin shares 45% sequence identity to NTN and PSP and 36% to GDNF and 
possesses all seven conserved cysteine residues characteristic for the TGF-P 
superfamily (Baloh et al., 1998a).
Northern blotting has revealed that ART mRNA is expressed at veiy low 
levels in the adult and fetal brain. Interestingly, low-levels of ART transcripts are 
present in structures of the basal ganglia (subthalamic nucleus, putamen, 
substantia nigra) and in the thalamus, suggesting that it may influence subcortical 
motor systems. ART mRNA has been detected in many adult non-neuronal tissue, 
albeit at low levels. Areas where ART mRNA is expressed include the pituitary 
gland, placenta, and trachea. Among fetal tissues, kidney and lung show the 
highest levels of ART mRNA expression (Baloh et al, 1998a). Like GDNF and 
NTN, artemin supports the in vitro survival of several peripheral neuron 
populations (DRG, SCG, trigeminal, nodose) and dopaminergic neurons of the 
ventral midbrain (Baloh et al, 1998a).
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TGF-p superfamily receptors
Most members of the TGF-P superfamily signal through a conserved 
family of transmembrane serine/threonine kinase receptors, all of which have a 
characteristic structure that includes a short cysteine-rich extracellular domain, a 
single transmembrane domain and an intracellular ser/thr kinase domain (for 
review, see Massagué, 1998). Many of these receptors have now been identified in 
a wide variety of vertebrates and invertebrates including, humans, mouse, 
Xenopus, C.elegans and Drosophila. Functional characterization and compaiison 
of their primary amino acid sequence indicates that these receptors can be divided 
into two classes, the type I and the type II receptors. The type I receptor class is 
distinguished by a highly conserved sequence known as the "GS domain", which 
contains a repetitive glycine-serine motif and is located between the 
transmembrane and kinase domains. The type II receptor has a C-terminal 
extension which is rich in serine and thieonine but appears to have no role in type 
II receptor fonction (Wieser et al., 1993).
In addition to these signaling receptors, TGF-P subfamily members bind to 
two other transmembrane proteins, betaglycan (or type III receptor) and endoglin. 
Betaglycan binds all tfoee TGF-p isoforms with high affinity (Segarini et al., 1989; 
Cheifetz and Massagué, 1991) and facilitates TGF-p binding to the type II 
receptor (Wang et al., 1991; Lopez-Cashlas et al., 1993). Endoglin binds TGF-P 1 
and TGF-ps, but not TGF-p2 (Cheifetz et al, 1989). As with betaglycan, 
complexes between endoglin and TGF-P receptors have been observed 
(Yamashita et al, 1994). However, the role of endoglin in TGF-P binding to 
signaling receptors is unclear. Some evidence suggest that endoglin over­
expression diminishes TGF-p responses (Lastres et al, 1996).
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receptor
Ligands type II type I
receptor-regulated common
Smad Smad
Activin
TGFp
BMP2/4
Dpp
ActRII
ActRIIB
TpRII
BMPRII
ActRII
Punt
ActRIB
TpRI
BMPRI
BMPRIB
Tkv
Sax
Smad2
Smad3
Smad2
Smad2
Smad3
Smadl
Smad5
SmadS
Smad4
Smad4
Smad4
Medea
Table 1.1. Molecular components of TGF-p superfamily signal transduction.
TGF-Ps and related factors activate signaling by binding to and bringing 
together pairs of type I and II receptors (Table 1.1). Two general modes of 
binding ligands have been observed (for review, see Massagué, 1998). The first 
involves direct binding of ligand to the type II receptor and subsequent interaction 
of this complex with the type I receptor, which in effect becomes recruited into 
the complex. This binding mode is characteristic of TGF-p and activin receptors. 
The second binding mode is typical of BMP receptors and involves a co-operative, 
interaction between type I and II receptors that bind ligand with high affinity when 
expressed together but low affinity when expressed separately. Upon 
heterotetrameric complex formation, receptor II, which is a constitutively active 
kinase, phosphorylates receptor I on serine and threonine residues within the GS 
domain'. Once activated, receptor I phosphorylates Smad (for Sma and MaJ) 
proteins that cairy the signal to the nucleus.
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A total of nine vertebrate Smads have been identified to date, as well as 
two in Drosophila and five in nematodes (for review see Massagué, 1998; 
Whitman, 1998). Smads are classified into three distinct categories. The first 
category comprises Smads that are directly phosphorylated by type I receptors 
and when overexpressed mimic specific signaling pathways ("receptor-regulated 
Smads", e.g. vertebrate Smadl, Smad2, Smad3, SmadS, and Smad8, Drosophila 
Mad). The second group of Smads appears to be shaied among multiple signaling 
pathways (e.g. vertebrate Smad4 and Drosophila Medea). The third category of 
Smads are those that when overexpressed inhibit TGF-p superfamhy signaling 
["inhibitory Smads", e.g. vertebrate Smad6, Smad7, and Drosophila Daughter 
against Dpp (Dad)]. There remain some Smads that have not been categorized in 
the above framework (e.g. daf-3). Examination of the primary sequence of Smads 
has revealed extensive sequence homology in two distinct regions. The first is an 
amino-terminal domain designated the Mad homology 1 (MHl) domain and the 
second a caiboxy terminal domain designated MH2. The region between the MHl 
and MH2 domains is referred to as the linker region and is poorly conserved 
among Smads.
In the basal state, Smads exist as homotrimers that reside in the cytoplasm. 
Upon ligand activation of the receptor complex, the type I receptor kinase 
phosphorylates the receptor regulated Smads which then form a heterohexameric 
complex with Smad4 and move into the nucleus. Three types of mechanisms by 
which Smads direct specific transcriptional responses have been identified. These 
are: transcriptional transactivation (a function intrinsic to the MH2 domain), 
specific association with a nuclear transcriptional factor and DNA-binding activity 
intrinsic to the MHl domain (for review, see Whitman, 1998; Massagué, 1998).
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Figure 1,5, Schematic diagram of ligand-receptor interactions in the GDNF 
ligand family deduced from multiple experimental paradigms in vitro.
Large arrows indicate preferred ligand-receptor interactions, whereas smaller 
arrows indicate alternative receptor interactions. GFRa-1/Ret is the most 
promiscuous member of the receptor family, with the ability to interact with three 
of the four ligands, whereas GFRa-3/Ret is the least, in that it can only interact 
with artemin.
The GDNF family signal transduction is unique for two reasons. First, they 
are the only TGF-P-like factors that signal through a tyrosine kinase. Second, this 
is the fii'st example of tyrosine kinase receptor that requires a glycolipid-anchored 
component (a-component) to bind ligand. GDNF family ligands signal through a 
common signal transducing component, named Ret (Durbec et al., 1996a; Trupp
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et al., 1996; Vega et al., 1996; Worby et al., 1996) in conjunction with one of a 
family of GPI-linked receptors (GFRa-1 to 4) that confers ligand specificity 
(Baloh et al., 1988a; Buj-Bello et al., 1997; Jing et al., 1996, 1997; Klein et al., 
1997; Naveüham et al., 1998; Thompson et al., 1998; Treanor et al, 1996; Trupp 
et al, 1998; Worby et al, 1998). Studies of ligand binding. Ret phosphorylation, 
and the responses of cells expressing these receptors have indicated that GFRa- 
1/Ret is the preferred receptor for GDNF (Jing et al, 1996; Treanor et al, 1996), 
GFRa-2/Ret is the preferred receptor for neurturin (Baloh et al., 1997; Buj-BeUo 
et al, 1997; Creedon et al, 1997; Jing et al., 1997; Klein et al, 1997; Sanicola et 
al, 1997; Suvanto et al, 1997; Trupp et al, 1998; Widenfalk et al, 1997), GFRa- 
3/Ret is the receptor for artemin (Baloh et al, 1998a) and GFRa-4/Ret is the 
receptor for persephin (Enokido et al, 1998) (see Figure 1.5).
Ret (rearranged during transfection) is a proto-oncogene that was first 
identified by transfection of NIH 3T3 cells with human T-cell lymphoma DNA 
(Takahashi et al, 1985). Full length human ret cDNA was subsequently cloned, 
sequenced and identified as a receptor tyrosine kinase (RTK) protein (Takahashi 
et al, 1988, 1989). The homologous mouse, chicken and zebrafish Ret proto­
oncogenes have also been cloned (Iwamoto et al, 1993; Schuchardt et al, 1995; 
Marcos-Gutierrez et al, 1997). Two Ret protein isoforms, which differ in then 
carboxy-terminal sequence, have been conserved between mammals and birds. 
The 53 C-terminal amino acids of the long isoform are absent from the short 
isoform, and are replaced by nine different amino acids (Tahira et al, 1990; 
Iwamoto et al, 1993; Schuchardt et al., 1995). In addition to the two isoforms, a 
third with 43 carboxyl terminal amino acids has been identified in mice (Myers et 
al, 1995). The Ret protein contains a large extracellular domain with no similarity 
to any other RTK. This domain includes a cadherin-like region distal to the 
membrane and a closer cysteine-rich region. The extracellular domain is followed
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by a single transmembrane domain, and an intracellular tyrosine kinase domain 
that is separated into two by a small insertion sequence.
Mutations in the human Ret gene aie involved in the pathogenesis of at 
least five diseases (for review see, Pasini et al., 1996; Edery et al., 1997; Kusafuka 
and Puri, 1997; Goodfellow and Wells, 1995; Mak and Ponder, 1996). Somatic 
rearrangements of Ret are responsible for a variable proportion of papillary 
thyroid carcinomas (Grieco et al., 1990; Bongarzone et al., 1994; Santoro et al.,
1994), while germline Ret mutations are associated with the three variants of the 
inherited cancer syndrome known as multiple endocrine neoplasia type 2:
MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC) (Donis- 
Keller et al., 1993; Mulligan et al., 1995; Hofstra et al., 1994; Carlson et al.,
1994a, b). Finally, germline Ret mutations have also been associated with an 
autosomal dominant form of the Hirschsprung disease (HSCR) (aganghonic 
megacolon) (Angrist et al., 1993; Attié et al., 1995; Romeo et al., 1994; Seri et 
al., 1997), a congenital disorder of the enteric nervous system characterized by a 
marked genetic heterogeneity (Chakravarti, 1996; Edery et al., 1996; Hofstra et 
al., 1996; Ivanchuk et al., 1996). Hirschsprung disease is likely the result of loss- 
of-function mutations in Ret and the cancer syndromes seem to be gam-of- 
function mutations. Interestingly, all of these lesions affect neural crest derivatives.
The requirement for Ret in the formation of the enteric nervous system has 
been confirmed by a transgenic mouse mutant in which targeted insertional 
mutagenesis was used to disrupt the Ret kinase domain. Mice homozygous for the 
mutant allele lack myenteric neurons from the small and large intestine, the 
oesophagus and stomach. These mice are also characterized by the absence of the 
superior cervical ganglion and either rudimentaiy kidneys or the absence of 
kidneys. The phenotype of the Ret mutant mouse bears a striking resemblance to jithat of the GDNF knockout (Schuchardt et al., 1994, 1996; Durbec et al, 1996b). |
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It is currently believed that GDNF and like hgands interact with Ret and 
one of a family of GPI-linked receptors (GFRa-1 to 4) to transduce their signal. 
GFRa-1, is a 468 amino acid protein that was initially isolated by virtue of its 
abihty to bind GDNF in a screen of cDNA expression libraries derived from 
enriched populations of GDNF-responsive rat retmal photoreceptors (Jing et al., 
1996) and rat midbrain dopaminergic neurons (Treanor et al., 1996). Both human 
and chicken GFRa-1 have subsequently been cloned and share 93% and 80% 
amino acid identity with their rat homologue, respectively (Jing et al., 1996; Buj- 
BeUo et al., 1997). GFRa-1 is a glycoprotein that contains 31 conserved cysteine 
residues, a putative signal peptide at the amino terminus, and a stretch of 23 
hydrophobic amino acids at the carboxy-termhius which mediate its binding to the 
cell membrane via a GPI-linkage (Treanor et al., 1996).
A BLAST search of the Genbank Expressed Sequence Tag (EST) database for 
sequences similar to rat GFRa-1 resulted in the identification of GFRa-2 and 
GFRa-3 (Trupp et al., 1998; Nomoto et al., 1998; Klein et al., 1997; Baloh et al., 
1997; Jing et al, 1997; Worby et al., 1998). Rat GFRa-2 is a 464 amino acid 
residue polypeptide that has 48% and 33% identity with GFRa-1 and GFRa-3, 
respectively. Both human and chicken GFRa-2 have also been cloned (Sanicola et 
al, 1997; Suvanto et al., 1997; Buj-BeUo et al, 1997).
Rat GFRa-3 is 397 amino acids long and bas 35% identity to GFRa-1 protein. It 
appears to be the most divergent member of the GFRa receptor family (Jing et al, 
1997; Naveühan et al, 1998; Nomoto et al, 1998; Worby et al, 1998).
GFRa-4 was isolated by screening an ElO chicken brain cDNA library with a 
mouse GFRa-1 probe. The nucleotide sequence of chicken GFRa-4 predicts a 
431 amino acid protein that has approximately 40% identity to both mouse and 
chicken GFRa-1 and GFRa-2, but only 27% identity with mouse GFRa-3 
(Thompson et al, 1998). A common feature among all four receptors is the
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conservation of 28 cysteine residues, indicating that they have similar three- 
dimensional structures. Several potential N-glycosylation sites exist in the GFRa 
but are not found at the same position in all receptors.
The physiological relevance of the GPI-linked receptors has been 
examined by the use of knockout mice. GFRa-1 deficient mice demonstrate 
absence of enteric neurons and agenesis of the kidney, characteristics that are 
reminiscent of both GDNF and Ret deficient mice (Cacalano et al., 1998; 
Enomoto et al., 1998). Midbrain dopaminergic and motor neurons are largely 
unaffected in GFRa-1 nuU mice (Cacalano et al., 1998; Enomoto et al., 1998). 
Minimal or no neuronal losses are also observed in a number of peripheral ganglia, 
including the superior cervical and nodose, which aie severely affected in both Ret 
and GDNF deficient mice (Cacalano et al., 1998; Enomoto et al., 1998). These 
observations suggest that whhe stringent physiological pairing exists between 
GFRa-1 and GDNF in renal and enteric nervous system development, significant 
cross-talk between GDNF and GFRa receptors must occur in other neuronal 
populations (Cacalano et al., 1998; Enomoto et al, 1998).
Unlike GFRa-1 knockout mice which die soon after birth, mice lacking 
GFRa-2 are viable and fertile. However, they have dry eyes and grow poorly after 
weaning, presumably due to malnutrition. GFRa-2 deficient mice display deficits 
in the enteric and parasympathetic nervous system that are strikingly similar to 
those of NTN deficient mice. The cholinergic innervation of the lacrimal and 
salivary gland is almost absent and is severely reduced in the small bowel. In 
contrast, sympathetic innervation appeal’s normal (Rossi et al, 1999).
At present, all evidence indicate that the GPI components are required for 
activation of the Ret receptor tyrosine kinase by GDNF-like ligands. However, it 
is still unclear whether GDNF first binds to GPI-linked components and 
subsequently this complex interacts with Ret (Jing et al, 1996; Treanor et al.
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1996), or whether GDNF ligands stabilize existing complexes between Ret and 
GPI anchored receptors at the cell membrane. In fact, both GFRa-1 and GFRa-2 
have been detected in Ret immunoprecipitates from unstimulated cells co- 
expressing both receptors (Klein et al., 1997; Treanor et al., 1996) and soluble Ret 
extracellular domain is able to interact with soluble GFRa-1 in vitro (Sanicola et 
al., 1997). These data suggest that complexes between Ret and GPI-linked 
receptors are present at the cell membrane in the absence of ligand.
Details of the intracellular signaling pathway triggered by activated Ret 
have recently emerged. It has been shown that Ret can bind and phosphorylate the 
SH2 domain of adaptor proteins such as She, She, Grb2, and GrblO (BoreUo et 
al, 1994; Pandey et al, 1995; Arighi et al, 1997; Lorenzo et al, 1997). Further, 
GDNF and NTN have been shown to stimulate PI-3 kinase activity and activate 
the Ras-MAPK-ERK pathway (Creedon et al, 1997; van Weering and Bos, 1997; 
Ohiwa et al, 1997; Worby et al, 1996). Moreover, Ret is able to activate INK, in 
a pathway divergent from that of ERK, mediated by Rho/Rac related smaU 
GTPases and, particularly, by Cdc42 (ChiarieUo et al, 1998).
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1.6. Research objectives
The aims of this project were four-fold.
My first objective was to determine the mRNA distribution of the newly 
discovered GFRa-4 receptor and provide a comparative expression study between 
this receptor and other family members at successive stages of tissue development. 
My second objective was to analyze the distribution of GDNF family receptors in 
very early hindbrain tissues.
My third objective was to examine whether there is a correlation between receptor 
expression and the change in responsiveness of peripheral neurons to GDNF and 
NTN during development.
My last objective was to investigate the regulation of GDNF receptor expression 
in developing PNS neurons.
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Chapter 2
Expression of GFRa-1, GFRa-2, GFRa-4 and ret 
mRNAs during development
2.1. Introduction
GDNF (Lin et al, 1993a) and neurturin (Kotzbauer et al, 1996), together 
with the recently identified persephin (Milbrandt et al, 1998) and artemin (Baloh 
et al., 1998a), comprise a group of closely related, secreted proteins within the 
TGF-(3 superfamily that promote the survival of various kinds of neurons of the 
peripheral and/or central nervous system. This protein family utilizes multi- 
component receptors that consist of a common signaling component, the Ret 
receptor tyrosine kinase, plus one of a family of GPI-linked receptors (GFRa-1 to 
4) that confers specificity.
Northern blotting and in situ hybridization have revealed widespread 
expression of ret and GFRa mRNAs, with both overlapping and complementary 
patterns, in the body and nervous system. In the adult CNS, GFRa-1 mRNA is 
widely distributed and found in almost all areas of the mesenchephalon and pons, 
the lateral and medial habenular, zona incerta, dorsal lateral geniculate and 
subgeniculate nuclei of the thalamus, the dentate gyrus and pyramidal cells of the 
hippocampus, the hypothalamic nuclei, the amygdala, the cerebellum, layers IV-V
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of the cerebral cortex and ventral horn of spinal cord (Trupp et al., 1997, 1998; 
Yu et al., 1998; Glazner et al., 1998; Golden et al., 1998). Outside the CNS, 
GFRa-1 mRNA expression has been detected in the inner ear, olfactory 
epithelium, vomeronasal organ, developing tongue papillae and teeth, liver, uteric 
buds of kidney, heart, in embryonic smooth and striated muscles around the 
enteric nervous system in the oesophagus, gut and stomach. In the PNS, GFRa-1 
mRNA has been detected in trigeminal (TG), superior cervical (SCG) and dorsal 
root (DRG) ganglia (Treanor et al., 1996; Nosrat et al, 1997; Yu et al, 1998; 
Sanicola et al, 1997).
GFRa-2 mRNA is also widely distributed, but not quite to the same extent 
as GFRa-1 mRNA. In the CNS, GFRa-2 mRNA is expressed in the glomerular, 
mitral and granule cell layers of the olfactory bulb, inferior and superior colhculi, 
pineal gland, lateral septum, cortex, striatum, olfactory tubercule, hippocampus, 
amygdala, both reticular and ventral medial thalamus, ventral tegmental area, 
lateral fields of the substantia nigra and ventral horn of the spinal cord (Trupp et 
al, 1998; Yu et al, 1998; Golden et al, 1998; Widenfalk et al, 1997). Outside the 
CNS, GFRa-2 mRNA expression has been detected in lung, spleen, kidney, heart, 
developing teeth, testis, intestine and kidney. Within the PNS, GFRa-2 mRNA 
has been found in dorsal root, trigeminal and superior cervical gangha (Widenfalk 
et al, 1997; Jing et al., 1997; Yu et al., 1998; Suvanto et al, 1997).
Unlike GFRa-1 and GFRa-2 mRNAs, GFRa-3 mRNA could not be found 
in RNA samples extracted from total postnatal or adult rat brain. Low levels of 
GFRa-3 mRNA have, however, been detected in samples of embryonic rat brain
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(Trupp et al, 1998; Nomoto et al., 1998). GFRa-3 distribution in neuronal tissue 
is very limited. By in situ hybridization, GFRa-3 mRNA has been detected in the 
thalamic parafascicular nucleus, medial preoptic nucleus of the hypothalamus and 
amygdalohippocampal anterolateral nucleus (Trupp et al., 1998). High levels of 
GFRa-3 mRNA are expressed in the PNS gangha including the TG, SCG and 
DRG and lower levels are expressed in the spinal cord. GFRa-3 mRNA shows a 
widespread pattern of expression in non-neuronal tissues including embryonic, but 
not adult, pancreas and skeletal muscle; adult spleen, ovary, and heart; late 
postnatal sahvary gland, hver, lung and kidney (Trupp et al., 1998; Nomoto et al, 
1998; Naveüham et al, 1998; Jing et al., 1997).
GFRa-4 mRNA appears to be widely expressed within the chick CNS. 
Northern analysis shows high levels of expression in the spinal cord and lower 
levels of expression in the meduHa oblongata, pons, cerebehum, and midbrain. In 
situ hybridization has revealed GFRa-4 transcripts in both the dorsal and ventral 
gray column of the spinal cord as weU as in Purkinje ceUs and granule cehs and 
neurons of the deep nuclei of the cerebehum (Thompson et al, 1998).
FinaUy, several studies have confirmed the broad distribution of ret 
transcripts in the CNS. In the CNS, ret mRNA can be found in almost ah areas of 
mesencephalon and pons, the reticular thalamic, subthalamic, lateral habenular and 
medial habenular nuclei of the thalamus, the glomerular layer of the olfactory bulb, 
the Purkinje layer, molecular layer and deep cerebehar nuclei of the cerebehum 
and the ventral horn of the spinal cord (Trupp et al, 1998; Yu et al, 1998; 
Glazner et al., 1998; Golden et al, 1998). Outside the CNS, ret mRNA has been
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detected in kidney, intestine, lung, salivary gland, thymus, spleen and lymp node. 
Within the PNS, ret mRNA can be found in dorsal root, trigeminal and superior 
cervical ganglia (Yu et al., 1998; Tsuzuki et al., 1995).
The diverse actions of GDNF and NTN in the nervous system, the severity 
of GDNF, GFRa-1, and ret knockouts and the widespread distribution of both 
ligands and receptors in developing and adult tissues indicate very important roles 
for the GDNF family of neurotrophic factors in the development and maintenance 
of body and brain (Moore et al., 1996; Pichel et al., 1996a, b; Cacalano et al., 
1998;. Schuchardt et al., 1994, 1996;. Suter-Crazzolara and Unsicker, 1994; 
Choi-Lundberg and Bohn, 1995; Widenfalk et al., 1997; Kotzbauer et al., 1996; 
Mübrandt et al, 1998; Baloh et al, 1998a; Trupp et al, 1997, 1998; Jing et al, 
1997; Nomoto et al, 1998; Thompson et al, 1998).
I have sought to further characterize these roles in thiee ways. Fust, I 
analyzed the mRNA expression of the GFRa and ret receptors in very early 
embryos especially in the hindbrain region. Second, I determined the distribution 
of the mRNA for the recently discovered receptor GFRa-4 in the body and 
undertook a comparative study of GFRa-1, GFRa-2, GFRa-4 and ret mRNA 
expression (GFRa-3 remains to be found in the chicken) at successive stages of 
organ development. Finally, I attempted to link the responsiveness of PNS 
neurons to GDNF and NTN with the levels of receptor mRNAs expressed by the 
neurons.
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The method I employed to assay the levels of receptor mRNAs in early 
hindbrain and PNS neurons was competitive RT-PCR, while for the distribution of 
the receptors in different organs I used a semi-quantitative RT-PCR assay.
2.2. Methods
I. Introduction
RT-PCR is an extremely sensitive method of detecting mRNAs and is the 
method of choice when analyzing the expression of rare mRNA species. RT-PCR 
is at least an order of magnitude more sensitive than Northern blotting and RNase 
protection assays, allowing the detection of fewer target mRNA molecules from 
lower starting amounts of RNA extracted from smaller amounts of tissues. RT- 
PCR has not routinely been used in the past for quantitative or semi-quantitative 
assays because of the difficulty in standardizing the efficiency of individual 
reactions. If two identical RT-PCR reactions were set up side by side, in identical 
tubes with the same amount of starting mRNA template, one would expect both 
tubes to contain the same amount of the specific cDNA product at the end of the 
RT-PCR reaction. However, because of the enormous amplification of reverse 
transcribed mRNAs that occurs in each RT-PCR reaction during multiple rounds 
of thermocycling, very small differences between the efficiency of the two 
reactions, either in the reverse transcription step or in individual PCR cycles 
(due, for example, to variations in microfuge tube thickness, pipetting or 
thermocycler block temperature), can result in large differences in the amount of 
the final DNA product. When RT-PCR is being used to measure large differences 
in the initial amounts of target mRNAs between two samples, for example when 
measuring viral loads in serum samples, such small differences in reaction 
efficiencies are insignificant and meaningful data can be obtained, as long as the 
PCR reaction is stopped whilst it is in the log phase, either without any form of
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calibration or with an external calibration curve. However, when RT-PCR is 
being used to measure small differences in the levels of rare mRNAs between 
different RNA samples some form of internal control or calibration is required 
within each RT-PCR reaction to ensure accurate results. One way to calibrate 
individual reactions is to include known amounts of a so-called competitor DNA 
species in each RT-PCR reaction. The competitor is amplified with the same 
primers as the target cDNA and so theoretically the ratio between competitor 
PCR products from individual PCR reactions can be used as a measure of the 
relative efficiency of amplification of the target cDNA species in each reaction. 
This information can be used to adjust quantitative data obtained from the RT- 
PCR assay to allow for differences in the efficiency of the PCR between different 
reactions. The most commonly used competitor species are synthetic DNAs that 
bear little resemblance to the cDNA being assayed apart from the primer binding 
sequences. Because the size and sequence of such competitors are often very 
different to the target cDNA species being assayed, they have very different 
amplification kinetics from the tar get cDNA and therefore the relative efficiency 
of competitor amplification between individual reactions does not accurately 
reflect the differences in the efficiency of amplification of the target cDNA 
between these reactions. In addition, the use of cDNA competitors does not allow 
differences in the efficiency of reverse transcription between individual RT-PCR 
reactions to be assessed. In short, the use of such competitor cDNA species does 
not allow accurate calibration of RT-PCR reactions and therefore does not allow 
accurate quantification of the levels of specific mRNAs within individual RNA 
samples.
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The quantitative RT-PCR assay used to obtain the majority of the 
expression data presented in this thesis used a different specific cRNA competitor 
species to calibrate the RT-PCR assay for each mRNA under investigation. Since 
the competitor was added as cRNA to the initial RT reaction, differences in the 
efficiency of reverse transcription between individual reactions were taken into 
account. The cRNA competitor was transcribed in vitro from a cDNA competitor 
construct that was made from a cDNA clone of each of the mRNAs being 
assayed. The cDNA competitor construct was identical to the cDNA of the 
mRNA under assay except that it was 3-4% longer than the native cDNA 
between the PGR assay primer binding sites. The extra nucleotide base pairs 
were simply added to the cDNA clone by cutting it with a restriction enzyme that 
produces cohesive ends with a 5' overhang, filling the cohesive ends with 
Klenow polymerase to make blunt ends and religating the blunt ends. Because 
the competitor cRNA contains the same primer bindings sites and is almost 
identical in sequence to the taiget mRNA, it is reverse transcribed and amplified 
with virtually identical kinetics to the taiget mRNA. Therefore, if the initial 
amount of competitor cRNA added to each reaction is known, the ratio between 
the RT-PCR products of the competitor cRNA and the taiget mRNA can be used 
to calculate an accurate value for the amount of target mRNA initially present.
The products of the RT-PCR assay were small, in the region of 100 base 
pairs, which greatly increased the efficiency of the reverse transcription and PCR 
steps. The small size of the products, however, has two drawbacks. First, because 
of the rapid annealing of short DNA strands, it encourages the formation of 
heteroduplexes between competitor and target DNA strands as the concentrations
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of PCR products build up (observed as higher molecular weight bands on 
autoradiographs). Heteroduplex formation reduces the accuracy of the RT-PCR 
assay and so must be avoided by limiting the number of PCR cycles performed. 
Second, the small size of the RT-PCR products means that they cannot be 
visualized by ethidium bromide staining when the PCR reaction is still in the log 
phase. To solve this problem, and also to increase the sensitivity of the assay, the
PCR reaction was performed with ^^P end-labelled primers and the products 
were visualized by autoradiography. The use of end-labelled primers, as opposed 
to incorporation of radiolabelled nucleotides, greatly increases the percent 
labelling of PCR products when the PCR products are small. In addition, it 
prevents the high background, resulting from mispriming by short cDNA 
fragments that is often seen on autoradiographs following radioactive 
incorporation. The RT-PCR products of the target mRNA and competitor cRNA 
were separated by electrophoresis on 8% polyacrylamide gels and, following 
autoradiography, the amount of each product was quantified by densitometry.
The response of X-ray film to ^^P is only linear over a narrow range. 
Therefore, to obtain accurate results from the assay it was important that the 
intensity of the RT-PCR products of the taiget mRNA and competitor cRNA did 
not differ by more than three-fold. Initial RNA/competitor titrations were 
performed to establish the correct level of competitor for each RNA sample. In 
most cases reverse transcription reactions were performed containing the 
appropriate amount of competitor cRNAs for several different mRNA species, 
including the mRNA for the housekeeping protein L27. Small aliquots of the 
cDNA products from each reaction were subsequently amplified in separate
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reactions with primers specific to each cDNA being assayed. This approach not 
only saved time, but also reduced the amount of valuable total RNA samples 
needed for analysis of the expression of several mRNAs and increased the 
accuracy of data when the level of receptor mRNA expression was calculated 
relative to L27 mRNA.
The competitive RT-PCR technique is extremely accurate, but is 
relatively time consuming to perform. When analyzing the expression of GDNF 
family receptors in a range of organs and tissues throughout development (this 
chapter), I was not interested in the fine details of developmental expression of 
each mRNA, in each organ, at each time point. Rather, I was looking for broad 
trends in expression patterns, both between different tissues and organs and also 
in a developmental context. For this reason, mRNA levels were not assayed using 
competitive RT-PCR, but by using a semi-quantitative RT-PCR assay that did 
not attempt to calibrate individual RT-PCR reactions. In short, RNA samples 
were appropriately diluted so that they contained the same approximate 
concentration of total RNA (following pilot RT-PCR reactions with L27 primers 
to assess approximate RNA concentrations). An equal amount of each total RNA 
sample was reverse transcribed in a separate reaction. Aliquots of cDNA from
each completed RT-reaction were then amplified in separate reactions with ^2p 
end-labelled primers specific for each receptor cDNA, in addition to L27 cDNA. 
RT-PCR products were then analyzed by electrophoresis on polyacrylamide gels, 
followed by autoradiography. In order to obtain as accurate data as possible on 
the relative expression of each receptor mRNA, in each tissue, at each
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developmental stage, it was necessary to ensure that: (i) the PCR reaction 
remained in the mid-log phase (determined by analyzing RT-PCR products from 
individual reactions after different numbers of cycles), (ii) the volumes of RNA 
and cDNAs pipetted at each stage were accurate, (iii) exactly the same volume of 
RT-PCR products from each reaction were analyzed by electrophoresis.
An account of the techniques used to study the expression of the GDNF 
family receptors is given below. First, tissues from chicken embryos were isolated. 
Then, RNA isolation was performed, and finally RT-PCR was carried out. The 
detailed methodology that led to the construction of the competitor RNAs is also 
provided.
II. Protocols 
Dissection of Embryonic Tissue
White Leghorn chicken eggs were incubated at 38°C in a forced-draft 
incubator. The various organs, rhombomeres, and PNS ganglia were dissected 
h'om chicken embryos at the required age (More details are given in the methods 
section of chapter 3). For the studies using purified neurons, dissected ganglia 
were incubated in 0.1% trypsin/calcium-and magnesium-free Hank's balanced salt 
solution (HBSS) for 10, 15, 20, 22, and 25 minutes at 37°C for E8, ElO, E12, 
E14, and E16 ganglia, respectively. The trypsinized tissue was washed twice in
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Hank's F14 medium containing 10% heat inactivated horse serum (HIHS) and 
once in HBSS before being mechanically dissociated by gentle trituration, in ~ 1ml 
of HBSS, using a fined-polished Pasteur pipette.
Non-neuronal cells were removed by differential sedimentation (Davies, 1988c). 
Dissected tissues and >95% pure neurons were stored at -80°C until required. The 
dissections were performed under standard sterile conditions in a laminar flow 
hood under a stereomicroscope. All dissections were done in L I5 media.
RNA isolation and purification
The acidic guanidinium thiocyanate RNA extraction method described by 
Chomczynski and Sacchi, (1987) provides a pure preparation of undegraded RNA 
in high yields. Cells were lysed in 500pl of solution D {50ml of stock solution 
(250g guanidinium thiocyanate; 293ml DEPC-treated H2 O; 17.6ml 0.75M sodium 
citrate pH7; 24.6ml 10% N-laryl sarcosyl) plus 360pl 2-mercaptoethanol} by 
passing the neuronal suspension through a 25 gauge needle fitted to a 1ml syringe. 
The following solutions were added sequentially: 2pl of 5mg/ml E. coli tRNA 
(SIGMA); 50pl of 2M sodium acetate pH4.4; 500pl of water-saturated acidic 
phenol (SIGMA); 150pl of 25:1 chloroform: isoamyl alcohol (SIGMA). The 
mixture was shaken vigorously, incubated on ice for 5-15 minutes and centrifuged 
at 13,000rpm for 5-30 minutes. The upper aqueous phase was transferred to a 
fresh microfuge tube and RNA was precipitated by the addition of two volumes of 
ethanol, followed by incubation at -20°C overnight. RNA was recovered fi'om the
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ethanolic mixture by centrifuging at 13,000rpm for 30 minutes. The resulting 
RNA pellet was washed thoroughly with 70% ethanol before being allowed to ah 
dry.
After resuspending the RNA pellet in SOpl of lOmM Tris pH7.5, 6mM MgCl2 
(Promega), 20mM VRC (vanadyl-ribonucleoside complex, RNAase inhibitor, 
SIGMA), 5pl of 7,500units/ml RNAase-free DNAase I (Pharmacia), the RNA 
was incubated at 37°C for 90-120 minutes. The RNA was further purified using 
the RNaid kit fiom BIO 101. In brief, 180pl (~3 volumes) of 3M NaClOg were 
added to the RNA followed by 10-30pl of RNA binding (RNAID) matrix (the 
exact volume was dependent on the amount of RNA as judged from the starting 
tissue). After thorough mixing, the slurry was incubated at room temperature for 
15-30 minutes with periodic mixing to allow the RNA to adsorb to the matrix. 
The matrix was sedimented by brief centrifugation and was washed with 700pl of 
the RNaid wash solution. This wash procedure was repeated one more time, 
followed by a final sedimentation of the matrix and complete removal of the wash 
solution. RNA was eluted from the matrix material by resuspending in 40-100pl of 
water (preferably DEPC-treated water), followed by incubating at 60°C for 2-3 
minutes. Following centrifugation for 1-2 minutes, the supernatant containing the 
RNA was transferred to a fresh tube and stored at -80°C until required.
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Construction of RNA competitor species 
General plan
The fii'st step in the construction of the competitor RNA was the isolation 
of a fragment of the required cDNA by RT-PCR. For this purpose, primers 600- 
800bp apart were used to amplify first strand cDNA from chicken brain. The PCR 
products were then run out next to a DNA ladder on an agarose gel and the band 
of interest excised and purified. The cDNA was then ligated into a transcription 
plasmid vector and the resulting construct was used to transform competent ceUs. 
The transformed cells were plated out onto agar and left to grow until visible 
colonies appeared. To determine which of the transformed colonies bore the 
desired recombinant plasmid, DNA was purified from several colonies using a 
mini-prep kit. Aliquots of plasmid DNA were digested with different restriction 
enzymes, and constructs containing the correct insert were identified by 
elctrophoresis of digested DNA. Sufficient quantities of the correct plasmid DNA, 
to allow construction of the competitor cDNA, were purified by a miniprep 
plasmid purification kit.
The next step in the construction of the competitor RNA was the 
modification of the insert cDNA so that it would be slightly different in size from 
the native template. To do this, plasmid DNA was digested with a restriction 
enzyme that produces 4bp 5’ overhangs. The overhangs were filled-in with 
Klenow polymerase and the blunt ends were re-ligated. The result was a control 
template 4bp longer than the native template. Before transformation into 
competent bacteria, the recombinant plasmid was digested with the same
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restriction enzyme used to cut it before the fill-in reaction. Plasmid containing a 
filled-in site will not cut, whereas unfilled plasmid will. Since transformation 
efficiency of linear DNA is a lot smaller than that of a cii'culai* DNA, very few 
plasmid DNA molecules which were not filled-in with the Klenow polymerase find 
theii* way into competent cells. Following transformation, the cells were grown on 
agar plates until colonies appeal”. To confirm that the fill-in reaction had worked 
and find the orientation of the receptor cDNA fragment in the vector, several 
colonies were picked, grown in LB broth and the plasmid DNA was purified using 
a kit. Aliquots of plasmid DNA were digested with different enzymes and the 
digested DNA was resolved by electrophoresis. The digests were compared to a 
DNA ladder and recombinant plasmids containing the proper insert were 
determined. Since it was possible that 1,2 or 3 rather than 4bp were filled-in, PCR 
was performed against an unfilled plasmid DNA and products were resolved by 
acrylamide gel electrophoresis. To further confirm the quality of the control 
cDNA, an aliquot was sent to an in-house sequencing service for sequencing.
The last step in the construction of the competitor RNA was the 
transcription of the filled cDNA clone. In order to produce run-off transcripts of 
defined length, the plasmid DNA was linearized with an appropriate restriction 
enzyme that cuts at the 3’ end of the insert. Special care was taken to avoid the 
use of an enzyme, which produced 3’ protruding ends. Extraneous transcripts 
have been reported to appear in addition to the expected transcript when such 
template is transcribed (Schenborn and Mierendorf, 1985). The extraneous 
transcripts can contain sequences complementary to the expected transcript as 
well as sequences corresponding to the vector DNA. Moreover, the restriction
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enzyme chosen to cut the competitor, had its cleavage site as far as possible from 
the fiU-in site. In this way, multiple points along the 3’ end of the RNA transcript 
could serve as templates for random hexamers to prime, improving the efficiency 
of the reverse transcription reaction. Following digestion, the plasmid was run out 
on an agarose gel and the band corresponding to the linearized plasmid was 
excised. Linearized DNA was then purified and in vitro transcribed. Plasmid DNA 
was removed from the RNA by DNAase treatment. An aliquot of purified RNA 
was checked for integrity and size on an agarose gel and its concentration was 
spectrophotometrically determined. The remaining RNA was diluted, ethanol 
precipitated and stored until required.
A, Cloning the cDNA competitor templates by RT-PCR
Total RNA from E13 chick brain (known to express high levels of the 
GDNF family receptors) was extracted by the Chomczynski and Sacchi (1987) 
method. 5pl of RNA was reverse transcribed in 50pl reaction mixture containing 
lOfil of 5xRT Superscript buffer (GIBCO BRL), 5pl of 5mM dNTPs (MBI 
Fermentas), 5pl of lOOpM random hexanucleotides (Pharmacia) and 5pl of O.IM 
DTT (GIBCO BRL). The sample was heated for 3 minutes at 90°C to denature 
any secondary structure within the RNAs. Following this, l-2pl of Superscript 
reverse transcriptase was added to the mixture, which was then incubated at 37°C 
for 1 hour. The reaction was stopped, and the RNA template degraded, by heating 
the sample for 6 minutes at 95°C.
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PCR primers for isolating GDNF family receptor cDNAs were designed based on 
published sequence information. Care was taken to choose primers that lay in 
regions of the receptor sequences that contained little homology with other GDNF 
receptor family members (see Table 2.1, 2.2 and 2.3). For each receptor, a region 
of about 600-800bp was amplified. The PCR reaction mixture consisted of;
32.75pl H2 O
5 pi RT product
5pl lOx buffer (Promega)
3pl 25mM MgCl2 (Promega)
2pl 5mM dNTPs 
1+1 pi SOpmoles primers
0.25pl of 3u/pl Taq DNA polymerase (Promega) 
After mixing, the reaction was overlaid with ~40pl of mineral oil 
(SIGMA). The tube was transferred to the heating block of a PCR machine and 
amplification was cairied out for 42 cycles using the foUowing parameters: 
dénaturation at 95°C for 60 seconds, annealing at 50-65°C (exact annealing 
temperature was dependent on primer sequence) for 60 seconds and DNA 
synthesis at 72°C for 90 seconds. The PCR reaction was completed with a 10 
minute extension at 72°C. The PCR products were run out on a 1% agarose gel 
(GIBCO BRL) and the band of interest was excised with a scalpel. The DNA was 
purified from agarose with the Geneclean®II kit. Purified DNA was recovered in 
20pl of water. The purified DNA was ligated into the pGEM-T vector (Promega) 
according to manufacturer's recommendations. The ligation mixture was used 
directly to transform highly competent Exoli XLl cells (Maniatis, 1989).
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Table 2.1. Forward isolation primer sequences for the GDNF family receptors.
Receptor Forward isolation primers
GFRoc-l 5-GCCACATATCCTCGGAGAATTC-3'
GFRa-2 5-CCAGAAGACCTTTGTGGATCAG-3'
GFRoc-4 5-TCATGCAGTGTATCGCAG-3'
Ret 5-GAGAACGTCTACATTGACC-3'
Table 2.2. Reverse isolation primer sequences for the GDNF family receptors.
Receptor Reverse isolation primers
GFRa-1 5’-TAGAATGGCTTCTCAGCAGG-3'
GFRa-2 5-GACAGCCTCACACCGTTTGAAT-3'
GFRa-4 5-GCATAACGCGACCTACAGACG-3'
Ret 5-GCATCATACACAGTTAGCG-3'
Table 2.3. Sizes of the GDNF family receptor cDNAs cloned by RT-PCR.
Receptor Size of receptor 
cDNA cloned bp
GFRa-1 687
GFRa-2 627
GFRa-4 622
Ret 785
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B, Transformation of competent cells
Competent cells {E, coli XLl Blue MRF') were stored at -80°C. They 
were removed from the freezer prior to transformation and defrosted on ice. 5- 
lOpl (<1/10 of competent cell volume) of the ligation mixture was added to lOOpl 
of competent cells and mixed by gently flicking the tube. Following incubation on 
ice for 40-60 minutes, the cells were transferred to a water bath at 42°C for 90 
seconds (heat shock). The cells were returned to ice for 5 minutes after which 
800pl of LB-broth was added and the whole suspension was transferred to a 7ml 
bijou. The cells were incubated at 37‘^ C, for 40-60 minutes, before being plated 
onto LB agai” (GIBCO BRL) containing lOOmg/ml ampiciUin (SIGMA).
C, Analysis of transformants to verify the presence of insert cDNA
After 16-20 hours at 37°C, ampiciUin resistant colonies were picked and 
used to inoculate 3ml of LB medium containing ampiciUin (100 mg/ml). FoUowing 
10-16 hours incubation at 37°C, plasmid DNA was extracted from the resulting 
bacterial suspension using a QIAprep Spin Miniprep kit. The DNA was recovered 
in 60pl of H2 O. To confinn the presence of the insert cDNA, I performed a 
restriction analysis of the plasmid DNA. lOpl aUquots of plasmid DNA were 
digested with different enzymes in reaction volumes of 20pl. The mixtures were 
incubated at the required temperature for at least an hour. DNA fragments
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resulting from the restriction enzyme digest were analyzed by electrophoresis in a 
1% agarose gel (NA-grade agarose, GIBCO BRL).
D, Modification of cloned DNA to make competitor cDNA 
I. Purification of plasmid DNA
50ml LB media containing lOOmg/ml ampiciUin were inoculated with 5pl 
of a bacterial suspension that contained vector DNA with an appropriately sized 
insert. FoUowing overnight incubation at 37°C, the QIAprep Spin Miniprep kit 
was used to purify plasmid DNA from 3ml of the bacterial suspension. Plasmid 
DNA was recovered in 60pl of H2 O.
II. Restriction digestion to produce 5’ protruding ends
40pl of each plasmid DNA (~10pg) was digested overnight with an 
appropriate restriction enzyme in the manufacturers recommended buffer at the 
required temperature. The restriction enzyme chosen cut the cloned cDNA at a 
single internal site to leave 4bp 5’ overhangs (see Table 2.4).
I l l
Table 2.4. Restriction sites in the GDNF receptor family fiUed to make the 
competitors.
Receptor Restriction 
site filled-in
GFRa-1 Bst98 I
GFRa-2 BamHI
GFRa-4 Kas I
Ret X hol
III. Fill-in of DNA ends with Klenow polymerase
Following digestion with restriction enzymes, plasmid DNA was purified 
using the Geneclean®!! kit. Klenow DNA polymerase was used to fill-in the 
recessed 3' ends (to produce blunt ends) in the following way. A microfuge tube 
containing 11 pi H2O, 3pl of lOx reaction buffer (NEB), 5pl of 5mM dNTPs 
(MBI Fermentas), lOpl (0.2-4pg) plasmid was heated for 5 minutes at 68°C 
before being placed on ice for 1 minute (this step denatures double-stranded 
structures that may have formed fiom protruding single-stranded termini). 1-5 
units of Klenow polymerase (NEB or Promega) per microgram of DNA were then 
added and the reaction was allowed to proceed for 15 minutes at 25°C. After this 
period, the reaction was stopped by heating at 75°C for 10 minutes.
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IV. Purification of filled cDNA
Following the fill-in reaction, DNA was purified away from dNTPs and 
Klenow enzyme using the Geneclean®!! kit. The DNA was recovered in 17pl 
H2O.
V. Ligation of newly generated blunt-ends
The following reagents were added to a microfuge tube and mixed thoroughly:
2pl lOx T4 hgase buffer (NEB, containing ATP)
16pl plasmid DNA
2pl of 400u/pl T4 DNA ligase (NEB)
The ligation reaction was performed overnight at a temperature gradient staiting 
at 12°C and finishing at 4°C.
VI. Purification
Following ligation DNA ligase and ATP were removed from plasmid DNA with 
the Geneclean®II kit.
VII. Restriction enzyme digestion to reduce false positive clones
In order to reduce the number of false positive colonies (i.e. colonies 
which contain plasmid DNA in which the 5' overhangs have not been filled with 
Klenow), plasmid DNA was digested prior to transformation with the same 
restriction enzyme that was used to generate the 5' overhangs for the fiU-in (for 2 
hours, followed by heat inactivation).
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VIII. Transformation of filled, ligated cDNAs
7pl of digested plasmid were used for the transformation of lOOpl of competent 
ceUs as detailed above.
IX. Restriction enzyme analysis of transformants
After 16-20 hours at 37°C, ampiciUin resistant colonies were picked and 
used to inoculate 3ml of LB medium containing ampiciUin (100 mg/ml). These 
cultures were incubated for 10-16 hours at 37°C to produce enough bacteria for 
miniprep plasmid DNA extraction. A QIAprep Spin Miniprep kit was then used to 
purify the plasmid DNA. The DNA peUet was recovered in 60pl of H2 O. To 
confiim that the fiU-in reaction had worked, and to determine the orientation of 
the receptor cDNA fragment in the vector, a series of restriction enzyme digests 
were performed on the miniprep DNA. lOpl aUquots of plasmid DNA were 
digested with different enzymes in reaction volumes of 20pl. The mixtures were 
incubated at the appropriate temperature for at least an hour. DNA fragments 
resulting from the restriction digest were analyzed by electrophoresis on 1.5-2% 
agarose gels (NA-grade agarose, GIBCO BRL).
X. PCR analysis of transformants
Since restriction digestion could not determine whether aU 4 bases were 
fiUed-in by Klenow, PCR was used to compare the different plasmids with an 
unfUled plasmid. PCR reactions were carried out in a volume of 50pl. For each 
PCR reaction, 45pl of master mix solution was added to the 5pl of O.lpg/ml 
plasmid DNA. The composition of the master mix was (n:= number of tubes); n x
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36.33|il of H2 O, n x 5\xl of lOxPCR buffer supplemented with MgCl2 (Helena 
Biosciences), n x Ipl of 5mM dNTP (MBI Fermentas), n x 0.17pl of 5u/pl Taq 
DNA polymerase (Helena Biosciences) and n x 2.5pl labelled primers. After 
mixing, the reaction was overlaid with 40pl of mineral oU. The tubes were 
transferred to the heating block of a PCR machine and amplification was cairied 
out for 22 cycles using the following parameters: dénaturation at 95°C for 60 
seconds, annealing at 50-65°C (exact annealing temperature was dependent on 
primer sequence) for 60 seconds and DNA synthesis at 68°C for 60 seconds. The 
PCR reaction was completed with a 10 minute extension at 68°C. The PCR 
products were run out on a 8% non-denaturing polyacrylamide gel and the 
preferred plasmid detected. To further confirm the sequence quality of the control 
cDNA, a sample was sent out for sequencing.
XI. Restriction enzyme digestion to produce cDNA of defined length
In order to produce run-off RNA transcripts of a defined length from the 
cloned cDNA, plasmid DNA (~10pg) was linearized at the 3' end of the receptor 
cDNA insert by overnight digestion with an appropriate restriction enzyme. 
Special care was taken to choose an enzyme that produces blunt-end and cuts as 
far away as possible from the fill-in site.
XII. Purification of linearized plasmid
Lineai'ized plasmid was purified away from any tracers of uncut plasmid in 
the following manner. The digested plasmid was run on a 1% low melting agaiose
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gel and the band corresponding to linearized plasmid DNA was cut out with a 
razor blade. DNA was recovered from the gel slice with the Geneclean®II kit.
E, In vitro transcription 
Synthesis of competitor RNA
Competitor RNA transcripts were transcribed in 2x 50|l i 1 reaction mixtures 
containing the following:
3plH20
lOpl 5x transcription buffer (Promega)
4pl lOOmM dTT (Promega)
4pl lOmM ATP (Promega)
4pl lOmM GTP (Promega)
4pl lOmM UTP (Promega)
5pl 32u/pl RNA guai'd (Pharmacia) 
lOpl plasmid (l-5pgl
Ipl of 30-50u T7/SP6 RNA polvmerase (Promega)
It is important that all materials are at room temperature and are added in the 
sequence shown above. The reaction components were thoroughly mixed before 
and after the addition of the RNA polymerase. Following incubation at 37°C for 1 
hour, a further Ipl of Sp6/T7 RNA polymerase was added to each reaction, and 
the reactions were allowed to proceed at 37°C for another 60 minutes. At the end
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of this period, the two reactions were pooled in one tube. At this point, 5pl VRC, 
20pl of 25mM MgCl2 and 5pl of 7,500u/ml DNAase I were added and the 
plasmid DNA was degraded by incubation at 37°C for 90-120 minutes. The RNA 
transcripts were purified with the RNAid kit as described above with the 
exception that the washing step was repeated thiee rather than two times, so that 
traces of VRC would be totally removed. (VRC are a potent inhibitor of reverse 
transcriptase and can also interfere with the measurement of RNA concentration). 
Purified RNA was recovered in 70pl of DEPC-treated H2 O. A lOpl aliquot of the 
RNA was used to determine the RNA concentration spectrophotometrically. 
Another lOpl was run out on a 1% DEPC-treated agarose gel to check the size 
and integrity of the RNA product. The remaining RNA was diluted and 
precipitated by the addition of 0.1 volumes of 3M sodium acetate, 3 volumes of 
ethanol and E. coli tRNA, such that the final ethanolic mixture contained Ing of 
transcript RNA and 20ng of E.coli tRNA per microHtre. The ethanol precipitated 
transcripts were stored at -20°C until required.
Labeling primers
Primers were labelled with ^^P on then 5' ends in a 30jal reaction 
containing the following: 6pl H2 O, 3pl of lOx T4 PNK forward buffer A (MBI
Fermentas), 3pl of Ipg/pl primer, 15pl T^^P ATP (Amersham) and 3pl of lOu/pl 
T4 polynucleotide kinase (MBI Fermentas). Following thorough mixing, the
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labelling reaction was carried out at 37°C for 60-120 minutes. Primers were 
purified using the Mermaid oligonucleotide purification kit (BIO 101). Labelled 
oligos were eluted from the mermaid matrix in 400pl of H2 O by incubating at 
65°C for 2-5 minutes. FoUowing brief (2 minutes) centrifugation at 13,000 rpm, 
the primers were transferred into fresh microfuge tubes and stored at -20°C untU 
requned.
RT-PCR assay 
A, Reverse transcription
Reverse transcription reactions were cairied out m a volume of 30pl. Each 
reaction mixture contained the foUowing components: 6pl of 5x reverse 
transcription buffer, 3pl of 5mM dNTPs, 3pl of lOOpM random hexanucleotides, 
3pl of O.IM DTT, Ipl of each of the receptor competitor RNAs at an appropriate 
concentration (to compaie the relative levels of the receptors in different samples, 
the cRNA competitor template for ubiquitous, constitutively expressed L27 
ribosomal protein was also included in the reverse transcription reaction), 0.1- 
lOpl of total RNA, water up to a volume of 29pl. The reverse transcription mix 
was made as a master mix for each batch of RT reactions being carried out. The 
master mix contained aU components except total RNA and Superscript Reverse 
Transcriptase. The use of a master mix ensured uniformity of conditions in aU 
reactions carried out using that mix. A negative control, where aU different RNAs
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were added together but no reverse transcriptase, was used to determine the 
purity of the RNA samples (i.e. no DNA contamination). The tubes were 
transferred to a PCR block and heated for 2-3 minutes at 90°C, followed by 45-90 
minutes at 37°C and concluding with 6 minutes at 95 °C. Reverse transcriptase 
was added to each reaction, except the no RT control at the beginning of the 
second step.
B, Polymerase chain reaction (PCR) assay
PCR reactions were carried out in a volume of 50pl. For each PCR 
reaction 45pl of master mix solution was added to the 5pl of cDNAs. The 
composition of the master mix was (n:= number of tubes): n x 36.33pl of H2 O, n 
X 5pl of lOxPCR buffer supplemented with MgCl2 (Helena Biosciences), n x Ipl 
of 5mM dNTP (MBI Fermentas), n x 0.17pl of 5u/pl Taq DNA polymerase 
(Helena Biosciences) and n x 2.5pl labelled primers (see Tables 2.5, 2.6, and 2.7). 
After mixing, each reaction was overlaid with ~40pl of mineral oil. The 
dénaturation, annealing and elongation conditions for each template are shown in 
Table 2.8. Each step of the cycle lasted 1 minute. The number of cycles were 
dependent on the nature and concentration of the cDNA template to be amplified 
and largely had to be determined empirically.
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Table 2.5. Forward assay primer sequences for the GDNF family receptors.
Receptor Forward assay primers
GFRa-1 5-ACCTGAGAAGGAGGATGG-3'
GFRa-2 5’-CCTTTGTGGATCAGAAGGC-3'
GFRa-4 5-CGTGGACGAGATGTGCCAACG-3'
Ret 5-CACTTTCATCTGTGCCAG-3'
L27 5-GGCTGTCATCGTGAAGAACATC-3'
Table 2.6. Reverse assay primer sequences for the GDNF family receptors.
Receptor Reverse assay primers
GFRa-1 5'-TGACATCCTTGATAATCT-3'
GFRa-2 5-AGCTTCAGCAGCACAATGG-3'
GFRa-4 5-GCACGCGGTCGAAGAACTTGC-3'
Ret 5'-AGTCTTCTCTATCTAGGC-3'
L27 5'-CTTCGCTATCTTCTTCTTGCCC-3’
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Table 2.7. Size of RT-PCR products.
Receptor Native PCR 
product bp
PCR product of 
control template bp
GFRa-1 99 103
GFRa-2 82 86
GFRa-4 129 133
Ret 122 126
L27 127 131
Table 2.8. PCR cycling conditions.
Receptor Dénaturation (°C) Annealing (°C) Elongation (°C)
GFRa-1 95 50 68
GFRa-2 95 50 68
GFRa-4 95 50 68
Ret 95 50 68
L27 95 50 68
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c , Electrophoresis of PCR products
The PCR products of the control and native cDNA templates were 
resolved on 8% non-denaturing polyacrylamide gels. The gels were run at 
constant 430V. Following electrophoresis, the gel was transferred to Whatman 
3MM paper and dried for -15 minutes at 80°C on a slab gel dryer. After the gel 
was thoroughly dried, it was autoradiographed. The autoradiographs were 
scanned with a densitometer and the intensity of the respective signals ascertained 
using ImageQuant software.
D, Semi-quantitative RT-PCR assay
Semi-quantitative RT-PCR was used to determine the expression pattern 
of GFRa-1, GFRa-2, GFRa-4 and ret mRNAs in various embryonic tissues. The 
method employed is very similar to the one reported earlier for the competitive 
PCR. However, it differs in two points. Fiist, the RT reaction did not include 
competitor RNAs. Second, to ascertain the reproducibility of the results, each 
PCR was repeated twice for two different numbers of cycles. In general, these 
where 22-24 cycles for GFRa-1, 21-23 cycles for GFRa-2, 25-27 cycles for 
GFRa-4, 25-27 cycles for ret, and 19 cycles for L27. The cycling conditions were 
optimal for the amplification of each transcript so that the rate of reaction did not 
plateau.
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2.3. Results
I. Early expression of GDNF family receptors in chicken rhombomeres
Using the very sensitive, quantitative method of competitive RT-PCR, I 
performed an analysis on hindbrains fiom E2, E3, and E4 chicken embryos. At E2, 
all four receptors could be detected in total hindbrain (see Figure 2.1). Moderate 
GFRa-1, low GFRa-2 and weak ret and GFRa-4 mRNA expression levels were 
observed.
24 hours later (day 3), when the rhombomeres have increased in size and their 
dissection is possible, receptor expression is widespread. All rhombomeres 
examined appear to express receptor components with approximately the same 
intensity (see Figures 2.2A, B, C, D). Interestingly, in a similai' study by Pachnis 
and colleagues, ret expression could only be localized in rhombomere 4 of the 
mouse embryo at this stage of development (Pachnis et al., 1993). Figure 2.2D 
shows that rhombomere 4 is actually the one with the lowest ret expression. 
Nevertheless, the trend changes at day 4, with r4 being the rhombomere with the 
highest expression (Figure 2.3D).
In addition to the widespread, uniform expression of the receptors, there was a 
6.5-fold increase in the levels of GFRa-1 mRNA between days 2 and 3, and a 
more moderate 2.5-fold increase in the levels of GFRa-4 and ret mRNAs. GFRa- 
2 mRNA expression remained at the same low level as day 2.
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Between day 3 and 4 there was a small increase in GFRa-1 and ret mRNA levels 
in the hindbrain whereas, GFRa-2 and GFRa-4 mRNA levels remained the same 
(see Figures 2.3A, B, C, D). Again, there was no dramatic difference in the 
expression of each receptor between individual rhombomeres, although there was 
some minor variation, namely in r2 which had a 2-fold increase in GFRa-4 levels 
ffom the previous day, and r3 which had a small decrease in ret expression (Figure 
2.3C, D). At day 4 rhombomere 7 cannot be clearly delineated and therefore only 
data for rhombomeres 2 to 6 are shown.
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2 days old hindbrain
GFRa-1 GFRa-2 GFRa-4 ret
Figure 2.1. Bar chart of the levels of GFRa-1, GFRa-2, GFRa-4 and ret 
mRNAs relative to L27 mRNA in total RNA extracted from E2 chicken 
hindbrains. The mean ± standard error of 2 separate assays are represented by 
each bar.
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Figure 2.2. Bar charts of the levels of GFRa-1 (A), GFRa-2 (B), GFRa-4 (C) 
and ret (D) mRNAs relative to L27 mRNA in total RNA extracted from 
rhombomeres 2 to 7 of E3 chicken hindbrains. The mean ± standard error of 2 
separate assays are represented by each bar.
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Figure 2.3. Bar charts of the levels of GFRa-1 (A), GFRa-2 (B), GFRa-4 (C) 
and ret (D) mRNAs relative to L27 mRNA in total RNA extracted ffom 
rhombomeres 2 to 6 of E4 chicken hindbrains. The mean ± standard error of 2 
separate assays are represented by each bar.
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II. Expression of GDNF family receptor components during development
To understand if and how GDNF family members are involved in the 
formation of any particular tissue or organ of the body, it is essential to study the 
expression of the receptors at successive stages of development. Previous studies 
have indicated that all organs express one or more of the GDNF family receptor 
components to some extent. Therefore, I decided to map the developmental 
expression of all receptor components in the major tissues of the chicken embryo 
at four day intervals. Figure 2.4 shows that the developmental pattern of 
expression of receptor mRNAs varies widely across different tissues. In some 
tissues, there are similar developmental changes in the expression of GFRa-1, 
GFRa-2, GFRa-4, and ret mRNAs. For example, between E6 and E l8 the levels 
of these mRNAs increase in brain and decrease in muscle and intestine. In some 
tissues, the relative levels of some of these mRNAs, such as GFRa-1 and GFRa-4 
in the case of kidney, and GFRa-1 and GFRa-2 in the case of Hver, remain fairly 
constant during development. In other tissues, these mRNAs display different 
temporal patterns of expression. For example, whereas the level of GFRa-1 
mRNA in heart gradually decrease between E6 and E14, GFRa-2, GFRa-4 and 
ret mRNAs exhibit a clear increase over the same period.
Figure 2.4 indicates that with the exception of lung, muscle, intestine and 
kidney, GFRa-4 mRNA is expressed highest at later ages. I have, therefore, 
dhectly compared the relative levels of GFRa-1, GFRa-2, GFRa-4 and ret 
mRNAs in a variety of tissues and organs at E18 by the same method (semi-
130
quantitative RT/PCR). Figure 2.5 reveals that GFRa-4 is expressed in high levels 
in the kidney and brain, lower levels in the skin, and very low levels in liver, heart, 
muscle, stomach and intestine. For the same age and tissues, GFRa-1 mRNA is 
expressed at similar levels in most organs except the heart and muscle where the 
levels are much lower; GFRa-2 mRNA levels are high in the liver, lower in the 
brain and skin, and very low elsewhere. Ret mRNA is expressed at higher levels in 
the brain, liver and intestine than in other tissues.
Taken together, the above study demonstrates that GFRa-1, GFRa-2, 
GFRa-4 and ret mRNAs have overlapping, though distinct, patterns of expression 
in the chicken embryo during development, indicating different physiological roles 
in organ- and tissue- genesis.
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Figure 2.4. Autoradiograms showing the RT/PCR products for GFRa-1, GFRa- 
2, GFRa-4 and ret at E6, ElO, E14, and E18 in heart, lung, and skeletal muscle 
(A), skin, brain, and stomach (B), and liver, kidney and intestine (C). The same 
mRNA preparations were used for aU reactions with each set of primers and were 
diluted appropriately to contain very similar levels of L27 mRNA, as shown by the 
similar levels of the RT/PCR products for L27 mRNA in the bottom 
autoradiograms in the age set for each tissue. Control reactions from which the 
reverse transcriptase step was omitted (not shown) were carried out for each 
reaction and were negative in all cases, demonstrating that there was no detectable 
contamination by genomic DNA in any of the preparations. The autoradiograms 
were developed for different lengths of time so that very weak bands could be 
observed. Very similar results were obtained from a separate set of tissues.
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Figure 2.5. Autoradiograms showing the RT/PCR products for GFRa-1, GFRa- 
2, GFRa-4 and ret in a variety of tissues at E18 and in lung, skeletal muscle, and 
intestine at E14, E6, and ElO, respectively, the ages at which GFRa-4 mRNA 
expression was highest in these tissues. The same mRNA preparations were used 
for all reactions with each set of primers and were diluted appropriately to contain 
very similar levels of L27 mRNA, as shown by the similar levels of the RT/PCR 
products for L27 mRNA in the bottom autoradiogram. Control reactions from 
which the reverse transcriptase step was omitted (controls 1 and 2 which contain 
extracted RNA ffom 6 of the 12 tissues) show that there was no detectable 
contamination by genomic DNA.
Very similar results were obtained ffom a separate set of tissues.
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III. Expression of GFRa-1, GFRa-2 and ret mRNAs in the PNS neurons
Several studies have indicated that GDNF and NTN are trophic factors for 
PNS neurons and that their receptors are expressed in various ganglia at some 
developmental stages. Hov/ever, no detailed developmental studies of receptor 
expression in different ganglia have been reported and there has been no 
systematic comparison of receptor expression with the responsiveness of neurons 
to GDNF and NTN.
Here, I describe the expression of the receptors in representative 
populations of avian parasympathetic, sympathetic and sensory neurons 
throughout embryonic development.
Parasympathetic neurons: ciliary ganglion
The ciUaiy ganglion is comprised of parasympathetic neurons that 
innervate the iiis, ciliary body and choroid and are supported by CNTF, GDNF 
and NTN in culture but not by neurotrophins (Barbin et al., 1984; Buj-Bello et al., 
1995; AUsopp et al. 1993, Forgie et al., 1999). A colleague, Alison Forgie, has 
shown that ciliary neurons are equally responsive to GDNF and NTN early in 
development but later on (E8 onwards) they rapidly loose responsiveness to 
GDNF whilst retaining sensitivity to NTN (Figure 2.6A). Figures 2.7A and B 
show the developmental expression of GFRa-1, GFRa-2 and ret mRNAs in intact 
ciliary ganglia with embryonic age. In agreement with the survival data, GFRa-2 
mRNA is expressed at higher levels than GFRa-1 mRNA. However, the dramatic 
loss of responsiveness to GDNF between E8 and E12 is not accompanied by a
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decrease in the level of GFRa-1 mRNA. Rather, the level of GFRa-1 mRNA 
remains the same fi'om E8 onwards.
As mentioned eai'lier, GFRa and Ret distribution is wide, therefore I have 
examined the extent to which non-neuronal cells in peripheral ganglia express 
GDNF family receptors. Using the method of differential sedimentation (Davies, 
1988c), I prepared purified neurons and non-neuronal cells. To my surprise, 
GFRa-1 and GFRa-2 mRNAs were expressed at approximately the same levels in 
both neurons and non-neuronal cells in all ganglia examined. Interestingly, the 
expression of ret mRNA was maiginal in the case of non-neuronal cells (data for 
ciliary non-neuronal cells are shown in Figure 2.6B).
Since expression of GFRa mRNA by non-neuronal cells may explain the 
lack of correlation between GFRa expression and cüiaiy neuron survival, I re­
examined receptor expression in purified neurons at E8 and E l2. Again, as in the 
case of the intact ganglia, GFRa-2 mRNA levels were higher than those of GFRa- 
1 mRNA and the switch in responsiveness to GDNF was not accompanied by a 
decrease in the GFRa-1 mRNA levels (Figure2.6B).
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Figure 2.6. (A) Graph of the EC50 values of E6, E8, ElO and E12 ciliary 
ganglion neurons grown with GDNF or NTN over a range of concentrations 
(Adapted from Forgie et al., 1999). (B) Bar chart of the levels of GFRa-1, 
GFRa-2, GFRa-4 and ret mRNAs relative to L27 mRNA in total RNA extracted 
from purified ciliary ganglion neuronal and non-neuronal cells of E8 and E12 
chicken embryos. The mean ± standard error of 3 separate assays are represented 
by each bar.
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Figure 2.7. Graph of the levels of GFRa-1 (A), GFRa-2 (B) and ret (C) mRNAs 
relative to L27 mRNA in total RNA extracted from intact ciliary ganglia of E6, 
E8, ElO and E12 chicken embryos. The mean ± standard error of 2 separate 
assays are represented by each bar.
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Sympathetic neurons: lumbar sympathetic chain
The sympathetic neurons of the embryonic paravertebral sympathetic chain 
are supported by NGF, CNTF, GDNF and NTN in culture (Chun and Patterson, 
1977; Bai'bin et al, 1984; Buj-BeUo et al, 1995; Forgie et al, 1999; personal data 
not shown). Alison Forgie has shown that sympathetic neurons are far more 
responsive to NTN early in development and equally responsive to GDNF and 
NTN later on (Figure 2.8A). Figures 2.9A and B show the expression of GFRa-1, 
GFRa-2 and ret mRNAs in the intact ganglia. As in the case of the ciHaiy ganglia, 
changes in responsiveness to GDNF and NTN are not reflected by changes in the 
expression of receptor mRNAs in intact ganglia; GFRa-1 mRNA levels remain 
more or less constant throughout development, while GFRa-2 and ret mRNA 
levels appear to slightly increase with age. In purified neurons (Figure 2.8B), 
GFRa-1 mRNA levels do go up with time as might be expected firom the increase 
in responsiveness of the neurons to GDNF from ElO to E l6. However, GFRa-2 
mRNA expression also increases markedly between ElO and E l6, although 
responsiveness to NTN does not significantly change.
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Figure 2.8. (A) Graph of the EC50 values of ElO, E l2, E 14 and E16 sympathetic 
chain neurons grown with GDNF or NTN over a range of concentrations (Adapted 
from Forgie et al., 1999). (B) Bar chart of the levels of GFRa-1, GFRa-2, GFRa- 
4 and ret mRNAs relative to L27 mRNA in total RNA extracted from purified 
ciliary ganghon neuronal and non-neuronal cells of ElO and E16 chicken embryos. 
The mean ± standard error of 3 separate assays are represented by each bar.
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Figure 2.9. Graph of the levels of GFRa-1 (A), GFRa-2 (B) and ret (C) mRNAs 
relative to L27 mRNA in total RNA extracted from intact paravertebral 
sympathetic ganglia of ElO, E l2, E14 and E16 chicken embryos. The mean ± 
standard error of 2 separate assays are represented by each bar.
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Sensory neurons: nodose ganglia
The sensory neurons of the nodose ganglion innervate the thoracic and 
abdominal viscera and consist of neurons that respond to BDNF, GDNF and NTN 
(Lindsay et al., 1985; Davies et al., 1986; Buj-Bello et al., 1995; Forgie et al, 
1999). Alison Forgie has shown that nodose neurons are more sensitive to GDNF 
than NTN and become increasingly responsive to GDNF from E8 to E12 (Figure 
2.10A). Figures 2.11A and B shows the developmental expression of the 
receptors in the intact ganglia. In agreement with the survival data, GFRa-1 
mRNA levels are higher than GFRa-2 mRNA levels throughout development. 
GFRa-1 mRNA expression in intact ganglia does not appear' to reflect the 
increasing responsiveness of nodose neurons to GDNF between E8 and E l2. 
However, in the case of purified neurons (Figure 2.10B) GFRa-1 mRNA 
expression is higher than GFRa-2 mRNA and increases with age. In contrast, 
GFRa-2 mRNA expression in purified neurons remains constant throughout 
development.
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Figure 2.10. (A) Graph of the EC50 values of E8, ElO and E12 nodose neurons 
grown with GDNF or NTN over a range of concentrations (Adapted from Forgie 
et al., 1999). (B) Bar chart of the levels of GFRa-1, GFRa-2, GFRa-4 and ret 
mRNAs relative to L27 mRNA in total RNA extracted from purified nodose 
ganghon neuronal and non-neuronal ceUs of E8 and E12 chicken embryos. The 
mean ± standard error of 4 separate assays are represented by each bar.
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Figure 2.11. Graph of the levels of GFRa-1 (A), GFRa-2 (B) and ret (C) 
mRNAs relative to L27 mRNA in total RNA extracted from intact nodose ganglia 
of E8, ElO and E12 chicken embryos. The mean ± standard error of 2 separate 
assays are represented by each bar.
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IV. Expression of GFRa-4 mRNA in PNS neurons
Several studies have indicated that PSP is not a trophic factor for PNS 
neurons (Milbrandt et al., 1998; Forgie, unpublished observations, personal data 
not shown). To find out whether this is due to lack of GFRa-4 expression, I 
examined the mRNA levels of the receptor in these neurons. All neurons examined 
were found to express, albeit in low levels, GFRa-4 mRNA (results fiom ciliary, 
paravertebral sympathetic and nodose neurons are shown in Figure 2.12). In all 
cases, with the exception of paravertebral sympathetic neurons, the levels of 
GFRa-4 mRNA increased with age. The highest expression of GFRa-4 mRNA 
was detected in early paravertebral sympathetic neurons.
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Figure 2.12. Bar charts of the levels of GFRa-4 mRNA relative to L27 mRNA in 
total RNA extracted ffom purified ciliary (A), paravertebral sympathetic (B) and 
nodose (C) ganglion neurons of chicken embryos at the ages indicated. The mean 
± standard error of 3 separate assays are represented by each bar.
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2.4. Discussion
In this chapter, I have examined the distribution of the GDNF-like 
receptors during embryo genesis, with paiticular emphasis on the PNS.
Hindbrain
At E2, a developmental stage that coincides with the migration of neural 
crest all GFRa and ret receptor mRNAs are detectable in the hindbrain (a brief 
review of the development of the hindbrain is provided in appendix I). GFRa-1 
mRNA shows the highest expression, followed by GFRa-2, ret and GFRa-4 
mRNAs. Between E2 and E3, where dissection of the individual rhombomeres is 
feasible, there is a considerable increase in GFRa-1 expression, a moderate 
increase in GFRa-4 and ret expression and no change in GFRa-2 expression. 
Interestingly, aU different rhombomeres express the various receptor components 
at similar levels. This is in contrast with the observation that ret mRNA expression 
is restricted to r4 in mouse at this stage of development (Pachnis et al., 1993). It is 
worth noting, that some other differences in the pattern of ret mRNA expression 
have also been observed between mouse and chicken. These differences include 
the trigeminal ganglion (where ret mRNA is expressed eai'lier in chicken 
development than in mouse development), the ventral roots of the spinal cord, the 
mesonephric tubules and the mesenchymal cells of the branchial arches (expression 
only in chicken) and testes (strong expression in chick versus a barely detectable 
signal in mouse) (Pachnis et al., 1993; Schuchardt et al., 1995; Iwamoto et al., 
1993). These evolutionary differences come as a surprise taking into account the
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importance of Ret as a transducing receptor for at least four neurotropliic factors. 
Several alternative explanations may be proposed. One is that after the divergence 
of birds and mammals, the function of Ret was taken over in some mammalian cell 
types by a different receptor. Alternatively Ret may have taken on an additional 
function in the avian lineage. Another possibility is that the sites where Ret is 
expressed in chick but not mouse may represent sites where the Ret gene is 
expressed but Ret protein is not functional or expressed, eliminating the 
evolutionary pressure to either maintain or silence expression. This issue may be 
addressed by further analyses of mouse embryos homozygous for the ret mutation, 
or through studies of ret function during avian embryogenesis.
It has been suggested that the patterning information for neuronal 
components of each branchial arch is contained within the neural crest that 
populates that arch and that this information has been imprinted on the neural 
crest according to where it originated along the anteroposterior axis of the brain 
neuroepithelium (Noden, 1983; 1988). Although the results we present here do 
not describe the expression pattern of the receptors in individual rhombomeres at 
day 2, when most migration takes place, the very low levels of all receptors at this 
age and the uniform expression of the receptors in aU rhombomeres at days 3 and 
4 suggest that the GDNF family receptors are not involved in specifying the 
migration pathway of neural crest cells, and the initial patterning of neural crest 
derivatives. Further studies will be required to establish whether the switch-on in 
the expression of the GDNF receptor in neural crest-derived ganglia later in 
development is due to intrinsic information acquired by their rhombomeric origin 
and/or local cues. At present, several studies suggest, that for at least the
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patterning of neural crest migration, both inherited information from rhombomers 
and pathway- or target- derived cues (e.g. from tissues such as the otic vesicle) 
are required (Noden, 1983; Hunt et al., 1991; Kurati and Eichele, 1993; Sechrist 
et al., 1994).
It is also worth noting the significant upregulation of GFRa-1 mRNA from 
day 2 to days 3 and 4. This very high GFRa-1 mRNA expression implies 
potentially important role for this receptor in the development of the hindbrain. 
Interestingly, ret mRNA in the hindbrain remains very low at all thiee ages studied 
when compai'ed to its expression in neural crest derivatives later in development. 
These findings suggest that ret is not functional m hindbrain at this stage and that 
GFRa-1 may either use another signal transducing receptor to exert its role or 
alternatively may merely serve to regulate the availability of GDNF to other cell 
types. One caveat to this interpretation is that the relationship between mRNA and 
protein levels is not known for the GFRa and Ret receptors in developing 
chickens.
Organogenesis
GDNF family ligands and receptors have a wide distribution in the 
periphery both in embryos and adults, suggesting important roles in organ 
development and maintenance. To get a better understanding of these roles in 
organogenesis, the expression of the receptors was analyzed at successive stages 
of development.
The results show a complex and varied pattern of receptor mRNAs 
expression. In some tissues, the developmental changes in the expression of
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GFRa-1, GFRa-2, GFRa-4, and ret mRNA aie similai* (e.g. brain, intestine, 
muscle). In others, some of the receptors show a decrease in expression while the 
remaining receptors show an increase in expression over the same period (e.g. 
heart). In some tissues, some receptors display constant expression throughout 
development, while the rest display a distinct temporal pattern (e.g. kidney).
To address the role of specific signaling by the a-components it is 
necessary to compaie their expression to that of ret. In general, it appears as if ret 
mRNA expression follows the major changes in the expression of GFRa mRNAs. 
For example, in hver between E6 and E14 the levels of GFRa mRNAs remain 
constant while between E14 and E18 GFRa-1 and GFRa-2 are maintained but 
there is a massive upregulation of GFRa-4 mRNA (Figure 2.4). Accordingly, ret 
mRNA is expressed at very low levels between E6 and E14 but is upregulated 
between E14 and E l8. Similarly, in intestine and brain all GFRa mRNAs have a 
common expression pattern and ret mRNA appears to miiTor this pattern. 
Furthermore, in heart all three GFRa mRNAs and ret mRNA are highly expressed 
between E14 and E l8. In muscle, GFRa mRNA expression decrease with age, ret 
mRNA follows this decrease.
There are, however, some patterns that do not fit to the above assumption. For 
example, ret mRNA shows high level expression in E6 lung, compared to ElO and 
E14, but GFRa mRNAs are expressed at very low levels (Figure 2.4). In addition, 
ret mRNA expression is very low in E l8 kidney compared to other tissues while 
both GFRa-4 and GFRa-1 mRNAs display among their highest expression in the
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body at this age (Figure 2.5). Further, ret mRNA is expressed at high levels in E l8 
intestine, but GFRa mRNA expression is not significant (Figure 2.5).
These observations indicate a very complex mode of interactions, which at 
present is difficult to interpret. However, several possible explanations could 
account for the expression patterns we see. The presence of high levels of some of 
these GFRa mRNAs in tissues such as E18 kidney and stomach (Figure 2.5), 
which have no appreciable amounts of ret mRNA, suggest that the a-components 
may associate with additional, still unknown, Ret-like signal transducing 
molecules. Alternatively, membrane bound or possibly truncated soluble forms of 
GFRa may act to regulate the availability of ligands in the extracellular space in 
the absence of ret signaling.
It appears as if ret mRNA can be expressed at high levels in some tissues 
whilst GFRa mRNAs are only maiginally expressed (e.g. intestine) (Figure 2.5). 
This could be explained in various ways. Ret has been shown to be constitutively 
active in the absence of ligands and GFRas (Trupp et al., 1998). Ret therefore 
may function in a ligand-independent signal transduction pathway when expressed 
alone. Another possibility is that Ret expression may be regulated at the protein, 
and not the mRNA level. Finally, it is possible that other, still unknown, GFRas 
may also signal through Ret. These GFRas could have complementary patterns 
with the ones we already know.
Taken together, this study has demonstrated that GFRa-1, GFRa-2, 
GFRa-4 and ret mRNAs have both complementary and overlapping, though 
distinctive, patterns of expression in the avian embryo during development.
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Peripheral nervous system
Neurons of the peripheral nervous system have been invaluable for 
understanding fundamental aspects of neurotrophic factor biology and for 
clarifying the functions of neurotrophic factor receptors (Davies, 1994b;
Henderson, 1996; Davies, 1997a,b). I have, therefore, studied the relationship 
between responsiveness of PNS neurons to GDNF and NTN and the expression of 
mRNAs encoding receptors for these factors. Whereas all of the populations of 
neurons express relative high levels of ret mRNA, which appears to be essential 
for both GDNF and NTN signaling, there aie differences in the relative levels of 
GFRa-1 and GFRa-2 mRNAs. Generally, neurons that are more responsive to 
GDNF express relatively higher levels of GFRa-1 mRNA, and neurons that are 
more responsive to NTN express relatively higher levels of GFRa-2 mRNA. This 
is consistent with data supporting the idea that GFRa-1 is the preferred receptor 
for GDNF and GFRa-2 is the preferred receptor for NTN and suggests that 
differences in responsiveness of neurons to GDNF and NTN is governed in pait 
by the relative levels of expression of members of the GFRa family receptors.
However, developmental changes in responsiveness to these factors are not 
consistently paralleled by changes in the relative levels of GFRa transcripts. In 
particular, the marked decrease in the response of ciliaiy neurons to GDNF 
between E8 and E12 is not associated with a corresponding decrease in the level 
of GFRa-1 mRNA, indeed the ratio between GFRa-1 and GFRa-2 transcripts in 
ciliary neurons are very similar in both ages (Figure 2.6B). Although it is possible 
that there are changes in the relative levels of GFRa-1 and GFRa-2 proteins in I
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PNS neurons during development that are not reflected in the steady state levels 
of GFRa transcripts, these data raise the possibility that in addition to differences 
in the relative levels of GFRa receptors, other factors such as expression of 
components of the signal transducing machinery could affect the sensitivity of 
neurons to GDNF and NTN.
An interesting chai acteristic of the PNS ganglia is that non-neuronal cells 
contained within them express similar levels of GFRa mRNAs to neurons, but do 
not express appreciable levels of ret mRNA (data for cihaiy non-neuronal cells are 
shown in Figure 2.6B). In general, GFRa-1 is expressed at either similar or higher 
levels in non-neuronal cells than in neurons. GFRa-2 is expressed at similar or 
lower levels in non-neuronal cells compared to neurons. Whilst ret mRNA 
expression is only marginal in non-neuronal cells it is possible that even this low 
ret mRNA expression is the result of contamination (~ 5%) of the non-neuronal 
fraction with small neurons during the differential sedimentation procedure. The 
finding that non-neuronal cells express the GFRa mRNAs but not ret mRNA is 
similar to the situation where p75, but not Trks, are expressed by Schwann cells in 
developing or lesioned peripheral nerves. In this case it is assumed that the 
Schwann cells make neurotrophins and present them on the cell surface bound to 
p75. It is possible that Schwann cells, or other glial cells or fibroblasts, within 
peripheral ganglia synthesize GDNF-like ligands which they then present on their 
surface bound to GFRa. Alternatively, GFRa could function as reservoiis to 
capture ligands diffusing through the extracellular milieu. In both cases, neurons 
expressing ret could then be trans-activated by the ligand-GFRa complex.
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Persephin is a recently isolated member of the GDNF family. 
Unlike the other members, PSP does not support the survival of PNS neurons, 
either alone or in combination with other growth factors (GDNF, TGFp-1, and 
TGFp-2) or depolarization (Mübrandt et al., 1998; personal data). One possible 
explanation is that GFRa-4, the receptor for PSP, is absent from the ganglia. 
Therefore, I examined whether GFRa-4 mRNA is expressed in purified PNS 
neurons. AU neurons from SCG, VLTG, vestibular, paravertebral sympathetic, 
nodose, DMTG, and cUiary gangUa were found to express, albeit in low levels, 
GFRa-4 mRNA (data for ciliary, paravertebral sympathetic and nodose are shown 
in Figure 2.12). In aU cases, with the exception of paravertebral sympathetic 
neurons, the levels of GFRa-4 mRNA increase with age. This developmental 
trend is similar to the one observed for organs and tissues, indicating that GFRa-4 
acts late in embryogenesis.
The observation that PNS neurons do not respond to PSP but 
express GFRa-4 mRNA can be explained in various ways. One possibility is that 
PSP requires a stiU unknown cofactor in order to exert its neurotrophic potential 
as was observed for GDNF (Kiieglstein et al., 1998a). Another possibility is that 
PSP is not a survival factor for peripheral neurons but a modulator of neural 
phenotype. Furthermore, it is possible that GFRa-4 expression may be regulated 
at the protein, and not the mRNA, level. FinaUy, GFRa-4 mRNA is dramaticaUy 
(>5-fold) down-regulated (see Figure 3.55) when neurons are put in culture which 
could account for the lack of responsiveness of neurons to PSP.
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Taken together, these results illustrate the growing complexity of trophic 
interactions governing the development of organs and ganglia at different stages 
of development. Further studies will be required to address the physiological 
importance of these interactions.
155
Chapter 3
Regulation of GFRa-1, GFRa-2, GFRa-4 and ret mRNA 
expression in the peripheral nervous system
3.1. Introduction
Neurotrophic factors are a heterogeneous group of signaling molecules 
that orchestrate multiple aspects of the development and maintenance of the 
central and peripheral nervous systems. The GDNF family of ligands, consisting of 
glial cell line-derived neurotrophic factor (GDNF; Lin et al., 1993a), neurturin 
(NTN; Kotzbauer et al., 1996), persephin (PSP; Milbrandt et al., 1998), and 
artemin (ART; Baloh et al., 1998a) comprise a subfamily of ligands within the 
TGF-P superfamily of signaling molecules that have neurotrophic properties. 
Interest in the GDNF family was initially fuelled largely by the ability of all known 
members to support the survival of dopaminergic midbrain neurons and spinal and 
facial motor neurons in both in vitro survival and in vivo injury paradigms, 
identifying them as potential therapeutic agents in the treatment of 
neurodegenerative diseases (Lin et al., 1993a; Henderson et al., 1994; Oppenheim 
et al., 1995; Horger et al., 1998; Milbrandt et al., 1998; Baloh et al., 1998a; 
reviewed by Grondin and Gash, 1998).
However, the GDNF ligands also influence a broad spectrum of other 
neuronal populations in both the CNS and PNS. GDNF, NTN and ART support 
the survival of many peripheral neurons in culture, including sympathetic, 
parasympathetic, sensory and enteric neurons (Buj-Bello et al., 1995; Ebendal et 
al., 1995; Trupp et al., 1995; Kotzbauer et al, 1996; Heuckeroth et al, 1998; 
Baloh et al, 1998a). In contrast, PSP does not share any of these peripheral
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activities but does support the survival of dopaminergic midbrain neurons and 
motor neurons (Mübrandt et al., 1998).
Although members of the TGF-P superfamüy, the GDNF ligands utilize a 
receptor system that is more simüai* to that observed for many cytokines, in that a 
common signaling component, namely the Ret tyrosine kinase (Durbec et al., 
1996a; Tmpp et al., 1996; Vega et al, 1996; Worby et al, 1996) plus one of a 
famüy of GPI-linked receptors (GFRa-1 to 4) that confers specificity (Baloh et 
al, 1998a; Buj-Bello et al., 1997; Jmg et al, 1996; 1997; Klein et al, 1997; 
Naveilhan et al, 1998; Thompson et al, 1998; Treanor et al, 1996; Trupp et 
al, 1998; Worby et al, 1998).
Results from ligand binding and Ret phosphorylation indicate that GFRa- 
1/Ret is the preferred receptor for GDNF (Jing et al, 1996; Treanor et al, 1996), 
GFRa-2/Ret is the preferred receptor for NTN (Baloh et al, 1997; Buj-Bello et 
al, 1997; Creedon et al, 1997; Jing et al, 1997; Klein et al, 1997; Sanicola et al., 
1997; Suvanto et al, 1997; Trupp et al., 1998; Widenfalk et al, 1997), GFRa- 
3/Ret is the receptor for ART (Baloh et al, 1998a) and GFRa-4/Ret is the 
receptor for PSP (Enokido et al, 1998). These in vitro studies together with the 
finding that more neurons are lost in GDNF-/- mice than in GFRa-1-/- mice 
(Cacalano et al, 1998; Enomoto et al, 1998; Moore et al, 1996; Pichel et al, 
1996a, b; Sanchez et al., 1996) have revealed that some degree of cross-talk can 
occur between receptors.
Ret and the GFRa receptors have distinctive patterns of expression that in 
general accord with the known responses of neurons and other ceUs to their 
ligands (Baloh et al, 1997, 1998b; Buj-BeUo et al, 1997; Creedon et al, 1997; 
Jing et al, 1996, 1997; Klein et al., 1997; MoUiver et al, 1997; Naveilhan et al, 
1998; Pachnis et al, 1993; Sanicola et al, 1997; Schuchardt et al, 1995; Suvanto 
et al, 1997; Treanor et al, 1996; Trupp et al, 1996; Tsuzuki et al, 1995; Vega et
157
al., 1996; Widenfalk et al, 1997; Worby et al., 1996, 1998). However, nothing is 
known about what regulates the regional and dynamic changes in the expression 
of these receptors in the developing nervous system.
To begin to address this issue, I have used an in vitro approach involving 
neuronal cultures and competitive RT-PCR to study the steady-state levels of 
mRNAs encoding ret, GFRa-1, GFRa-2 and GFRa-4 in several populations of 
PNS neurons grown under different experimental conditions.
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3.2. Methods
Neuronal cultures
White Leghorn chicken eggs were incubated at 38°C in a forced-draft 
incubator. The sympathetic chain was dissected from E8, ElO, E12, E14, and E16 
embryos (Figure 3.1) and the nodose ciliary, and dorsomedial (DMTG) ganglia 
from E8 embryos (Figures 3.2 and 3.3) (Davies, 1995). The dissections were 
performed with electrolytically shaipened needles under sterile conditions, in a 
laminar flow hood, using under a stereo microscope. All dissections were done in 
L I5 medium.
The dissected ganglia were incubated at 37°C in 0.1% trypsin/calcium-and 
magnesium-free Hank's balanced salt solution (HESS) for 10, 15, 20, 22, and 25 
minutes for E8, ElO, E12, E14, and E16 ganglia, respectively. The trypsinized 
tissue was washed twice in Hank's F14 medium containing 10% heat inactivated 
horse serum (HIHS) and once in HBSS, after which it was mechanically 
dissociated by gentle trituration, in -1ml of HBSS, using a fined-polished Pasteur 
pipette.
Non-neuronal cells were removed by differential sedimentation (Davies, 
1988c) and the neurons (>95% pure) were plated in 35mm plastic tissue culture 
dishes (Nunclon) that had been pre-coated with poly-DL-ornithine (0.5mg/ml, in 
0.15M borate buffer, overnight at RT) and laminin (20p,g/ml, in F-14 medium for 
4-12 hours in a humidified CO2  incubator at 37°C). Neurons were plated at a
density of 500-2,000 neurons per dish. The neurons were cultured in 2ml of Ham's 
F14 medium plus 10% HIHS, either with or without neurotrophic factors or 
different levels of KCl, in a humidified 4% CO2  incubator at 37°C.
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Three to six hours after plating, the number of attached neurons within a 
12x12mm square in the centre of each dish was counted using an inverted phase- 
contrast microscope. The number of surviving cells in this same area was counted 
24 and 48 hours after plating and survival was expressed as a percentage of the 
number of attached neurons at 3 to 6 hours.
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Figure 3.1. Camera lucida drawing of the ventral aspect of the lumbosacral 
region of an ElO chick embryo after evisceration showing the location of the 
sympathetic ganglia. DRG: dorsal root ganglia; SC: sympathetic chain; SP: spinal 
cord. (Adapted from Davies, 1988c)
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TMN
Figure 3.2. Schematic illustration of an ElO chick embryo showing the locations 
of populations of cranial sensory neurons. TMN: trigeminal mesencephalic 
nucleus; T: trigeminal ganglion; J: jugular ganglion; N: nodose ganglion; VA: 
vestibular acoustic ganglion; G: geniculate ganglion; P: petrosal ganghon, 
(Adapted from Davies and Lindsay, 1985).
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Figure 3.3. Dorsal aspect of the cranial base after removal of the brain showing 
the lines for subdissecting the tissue into blocks that contain the trigeminal 
ganglion (T) (block A), the vestibulo-acoustic ganglion (V) and geniculate 
ganglion (block B), and the Jugular (J) and petrosal ganglia (block C). 
Subdissection of the trigeminal ganglion is achieved by separating the opthalmic 
lobe (OL) from the maxillomandibular lobe (MML) along the interrupted line (A). 
The dorsomedial portion (DM) can be separated from the ventrolateral as shown 
(B). (Modified from Davies, 1988c).
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Measurement of GFRa-1, GFRa-2, GFRa-4 and ret mRNA levels
A competitive reverse transcription/polymerase chain reaction (RT/PCR) 
technique was used to measure the levels of mRNAs encoding GFRa-1, GFRa-2, 
GFRa-4 and ret in total RNA extracted from freshly purified neurons and neurons 
that had been cultured under different experimental conditions. To compare the 
relative levels of the receptors in different samples, the cRNA competitor template 
for the ubiquitous, constitutively expressed L27 ribosomal protein was also 
included in the reverse transcription reactions. RNA extraction, RT and 
amplification were carried out as described in chapter 2. The PCR products were 
resolved on 8% polyacrylamide gels, autoradiographed and quantified as described 
previously (chapter 2).
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Results
I. GFRa-1, GFRa-2 and ret mRNA expression is not regulated by GDNF
and NTN in PNS neurons
Because numerous previous studies have shown that neurotrophins 
increase the expression of mRNAs encoding their receptors in neurons, I studied 
the effects of GDNF and NTN on GFRa-1, GFRa-2 and ret mRNA expression in 
E12 sympathetic and E8 nodose, ciliary, SCG, and DMTG neurons.
Like NGF, GDNF and NTN promote the in vitro survival of the great majority of 
E12 sympathetic neurons (Figure 3.4E). The levels of GFRa-1, GFRa-2 and ret 
mRNAs expressed by sympathetic neurons cultured for 24 hours with GDNF or 
NTN were very similar to those cultures supplemented with NGF (Figure 3.4). 
Similar results were obtained in cultures supplemented with GDNF and NTN at 
concentrations ranging from 5 to 500ng/ml (data not shown).
The parasympathetic neurons of the ciliary ganglion are supported by 
CNTF, GDNF and NTN in culture. These each factors promote the survival of the 
majority of neurons. Although the neurons cultured with CNTF had distinct 
expression patterns from those cultured with GDNF and NTN, GDNF and/or 
NTN at concentrations ranging from 10 to 300ng/ml, either with or without 
CNTF, yielded very similar data for the expression of all three receptors, 
indicating the lack of regulation under these conditions (data not shown).
E8 DMTG neurons are well supported by NGF but hardly at all (around 
10%) by GDNF or NTN. In NGF containing cultures supplemented with GDNF 
and/or NTN at concentrations of 30 and 300 ng/ml, the levels of GFRa-1,
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Figure 3.4. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E12 sympathetic neurons 
incubated for 24 hours in basal medium (control) and medium containing 10 ng/ml 
NGF (NGF), GDNF (GDNF) and NTN (NTN) or 40 mM KCl plus 10 ng/ml NGF 
(NGF + KCl), GDNF (GDNF+KCl) and NTN (NTN+KCl). The mean ± standard 
error of 2 separate assays are represented by each bar.
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GFRa-2 and ret mRNAs are similai' to those cultures supplemented with NGF 
alone (data not shown).
Similar results were obtained from the study of E8 SCG and E8 nodose 
neurons. These data suggest that neither GDNF nor NTN significantly affect the 
expression of mRNAs encoding their ligands in developing sympathetic neurons. 
Preliminary experiments also indicate that PSP and ART do not regulate the 
expression of GFRa and ret mRNAs in E12 sympathetic neurons (data not 
shown).
I
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II. Regulation of GFRa and ret mRNA expression by depolarization
To determine if depolarization affects GFRa and ret mRNA expression, I 
exposed cultures of E12 sympathetic neurons to depolarizing levels of potassium 
ions (40mM KCl) for a period of 24 hours. Figure 3.5 shows that a depolarizing 
level of KCl (40mM) caused a marked increase in the level of GFRa-1 and GFRa- 
4 mRNAs, a marked decrease in the level of GFRa-2 mRNA and a slight decrease 
in ret mRNA. Neurons grown for the same length of time in medium containing 
basal KCl (5mM) and supplemented with NGF expressed similar levels of GFRa- 
1, GFRa-2 and ret mRNAs to those measured in freshly isolated neurons prior to 
plating, whereas GFRa-4 mRNA expression decreased with time in culture 
(Figures 3.5 and 3.6). The marked effects of 40mM KCl on GFRa-1, GFRa-2 and 
GFRa-4 mRNAs were observed in both the presence and absence of NGF but 
were more pronounced in its absence. Compared with the levels in control 
cultures, cultures supplemented with 40mM KCl alone exhibited a 6-fold increase 
in the level of GFRa-1 mRNA, a 6-fold decrease in the level of GFRa-2 mRNA, a 
3-fold increase in the level of GFRa-4 mRNA and a slight decrease in the level of 
ret mRNA. Although the levels of GFRa and ret mRNAs in Figure 3.5 are shown 
relative to L27 mRNA to facilitate direct comparison of the relative levels of 
GFRa-1 and GFRa-2 mRNAs in purified neurons freshly isolated from the 
sedimenting column and neurons that had been maintained in culture, very similar 
results were observed when the levels of GFRa and ret mRNAs were expressed 
relative to neuron number (data not shown). The levels of GFRa and ret mRNAs 
in neurons grown with NGF plus 40mM KCl were also very similar to the levels
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Figure 3.5. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E12 sympathetic neurons 
incubated for 24 hours in basal medium (control) and medium containing 10 ng/ml 
NGF (NGF), 40 mM KCl (KCl) or 40 mM KCl plus 10 ng/ml NGF (NGF + KCl). 
For comparison, the levels of GFRa-1 and ret mRNAs relative to L27 mRNA in 
purified E12 sympathetic neurons freshly isolated from the sedimenting column 
(column) are also shown. The mean ± standard error of 6 separate assays are 
represented by each bar.
173
of these mRNAs in neurons grown with GDNF or NTN plus 40mM KCl (Figure 
3.4).
To determine how rapidly depolarization affects the expression of GFRa 
mRNAs, I measured the levels of these mRNAs at time intervals in E12 
sympathetic neuron cultures grown in NGF-supplemented medium containing KCl 
at either 5 mM or 40 mM. Figure 3.6 shows that within 6 hours of exposure to 40 
mM KCl there were marked changes in the level of GFRa-1 and GFRa-2 
mRNAs, with less pronounced changes in the levels of GFRa-4 and ret mRNAs. 
These changes in the expression of GFRa-1 and GFRa-2 mRNAs became more 
dramatic after 12 hours exposure to 40 mM KCl, and there were no further 
changes after 24 hours exposure. The changes in the expression of GFRa-4 and 
ret mRNAs were most pronounced after 48hi's exposure, the last time-point 
examined. The finding that all neurons were surviving 12 hours after plating in 
cultures containing NGF alone and NGF plus 40 mM KCl (Figure 3.6), 
demonstrates that 40 mM KCl has a direct effect on GFRa-1, GFRa-2 and 
GFRa-4 mRNA expression rather than selectively supporting the survival of a 
subset of neurons that has high levels of GFRa-1 and GFRa-4 mRNAs, and low 
levels of GFRa-2 mRNA.
To determine if depolarization exerts a similar effect on GFRa and ret 
mRNA expression throughout sympathetic neuron development, I grew 
sympathetic neurons at intervals from E8 to E16 in medium containing 40 mM 
KCl, with or without NGF, or m medium containing 5 mM KCl plus NGF to 
sustain neuronal survival for a 24 hour period. Figure 3.7 shows that at all ages 
studied the level of GFRa-1 mRNA was much higher and the level of GFRa-2 
mRNA much lower in cultures containing 40 mM KCl compared with cultures 
containing 5 mM KCl.
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Figure 3.6. Bar charts of the percent survival and graphs of the levels of GFRa 
and ret mRNAs relative to L27 mRNA in cultures of purified E12 sympathetic 
neurons incubated for different times in medium containing 10 ng/ml NGF (NGF) 
or 40 mM KCl plus 10 ng/ml NGF (KCl + NGF). The zero time point shows the 
levels of GFRa and ret mRNAs relative to L27 mRNA in purified E l2 
sympathetic neurons freshly isolated from the sedimenting column. The mean ± 
standard error of 2 separate assays are represented by each data point.
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With the exception of E8 cultures, the level of GFRa-4 mRNA expression was 
higher in cultures supplemented with 40mM KCL In contrast to the marked effects 
of 40 mM KCl on GFRa mRNA expression in sympathetic neurons cultured at 
stages throughout their embryonic development, 40 mM KCl did not have a 
consistent effect on ret mRNA expression in these cultures (Figure 3.7). The 
levels of ret mRNA in cultures containing 40 mM KCl were very similar to those 
containing 5 mM KCl at ElO, E14 and E16, and were slightly higher at E8 and 
slightly lower at E12. These results suggest that depolarization does not have a 
marked effect on ret mRNA expression in developing sympathetic neurons.
At all ages studied, the majority of neurons survived under each 
experimental condition (Figure 3.7). The increase in the total number of neurons 
in E8 cultures between 6 and 24 hours incubation was due to the proliferation of 
sympathetic neuroblasts present in these early cultures (Ernsberger et al., 1989b).
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Figure 3.7. Graphs of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E8, ElO, E12, E14 and E16 
sympathetic neurons incubated for 24 hours in medium containing 10 ng/ml NGF 
(NGF), 40 mM KCl (KCl) or 40 mM KCl plus 10 ng/ml NGF (NGF + KCl). The 
mean ± standard error of 2 separate assays are represented by each data point.
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III. The effects of elevated KCl on GFRa mRNA expression depends on 
influx through voltage-sensitive L-type Ca^ "^  channels
To determine if the marked changes in GFRa mRNA expression caused by 
depolarizing levels of KCl were due to Ca^ "*" influx thiough voltage-sensitive 
Ca^"  ^ channels, I investigated if these changes could be prevented by the L-type
Ca^ "*' channel antagonists nifedipine and verapamil. E12 sympathetic neurons were 
grown for 24 hours in NGF-supplemented medium containing either basal KCl 
(5mM) or a depolarizing level of KCl (40mM) with and without these drugs. 
Figure 3.8 shows that nifedipine and verapamil completely inhibited the 40mM 
KCl induced increase in GFRa-1 and GFRa-4 mRNAs, the slight decrease in ret 
mRNA and partially inhibited the 40mM KCl induced decrease in GFRa-2 
mRNA. Neither of these drugs affected the levels of GFRa and ret mRNAs in 
medium containing basal levels of KCl. These results suggest that the effects of 
depolarizing levels of KCl on GFRa and ret mRNA expression are mediated by
Ca^"  ^ influx through voltage-sensitive L-type Ca^"  ^ channels. Neither nifedipine 
nor verapamil affected the survival of neurons incubated with NGF, but did inhibit 
the slightly enhanced survival of neurons grown with NGF plus 40mM KCl. This 
shows that these drugs are not neurotoxic at the concentrations used and that the
survival-promoting effects of 40mM KCl aie also due to Ca^"  ^ influx thiough
voltage-sensitive Ca^’*' channels, as shown previously (CoUms and Lüe, 1989; 
Koike et al., 1989; Koike and Tanaka, 1991; Larmet et al., 1992).
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Figure 3.8. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E12 sympathetic neurons 
incubated for 24 hours in medium containing 10 ng/ml NGF (NGF) or 40 mM 
KCl plus 10 ng/ml NGF (NGF + KCl) with and without nifedipine or verapamil (at 
1 or 10 mM). The mean ± standard error of 2 separate assays are represented by 
each bar.
185
We also investigated if Ca^ "*" influx through N-type Ca '^*’ channels plays a role in 
mediating the effects of depolarization on GFRa and ret mRNA expression. The
N-type Ca^"  ^ channel antagonist co-conotoxin G VIA at concentrations known to
effectively block N-type Ca^"  ^channels (0.1 to 1 mM) did not influence the effect 
of 40mM KCl on the levels of GFRa-1 and GFRa-2 mRNAs and did not affect 
neuronal survival with or without KCl (Figure 3.9). These results indicate that the 
changes in GFRa and ret mRNA expression induced by elevated extracellular K+ 
do not depend on Ca^"  ^influx through N-type Ca^ "*" channels.
Tetrodotoxin, a Na+ channel antagonist, had also no effect on GFRa and 
ret mRNA expression in sympathetic neurons grown with either 5 mM or 40 mM 
KCl in the culture medium (data not shown). This indicates that the changes in
GFRa-1 and GFRa-2 mRNA expression induced by elevated extracellular K+ do 
not depend on Na+ influx through voltage-gated Na+ channels.
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Figure 3.9. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E12 sympathetic neurons 
incubated for 24 hours in medium containing 10 ng/ml NGF (NGF) or 40 mM 
KCl plus 10 ng/ml NGF (NGF + KCl) with and without w-conotoxin GVIA at 
concentrations of 0.1 or 1 mM. The mean ± standard error of 2 separate assays 
are represented by each bar.
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IV. The effects of depolarization on regulation of GFRa and ret mRNA 
expression in parasympathetic and sensory neurons
To determine if depolarization has similar effects on the expression of 
GFRa and ret mRNAs in other kinds of neurons, I studied the effect of 40mM 
KCl on the levels of these mRNAs in cultures of pai'asympathetic neurons from 
the ciliary ganglion and sensory neurons from the nodose ganglion. These 
experiments were carried out by incubating purified neurons for 24 hours in 
medium containing basal (5mM) or depolarizing (40mM) levels of KCl together 
with a neurotrophic factor that very effectively promoted their survival (GDNF or 
NTN in the case of ciliary neurons and BDNF in the case of nodose neurons). The 
neurons were also grown in medium containing 40mM KCl alone, which 
promoted the survival of the majority of ciliary neurons and promoted the survival 
of a subset of nodose neurons (Figures 3.10 and 3.11).
In cultures of E8 ciliary ganghon neurons, 40mM KCl caused a substantial 
increase in the levels of GFRa-1 and ret mRNAs and a substantial decrease in the 
level of GFRa-2 and GFRa-4 mRNAs (Figure 3.10). Compared with the levels in 
cultures containing GDNF or NTN alone, cultures supplemented with 40mM KCl 
alone exhibited a 23-fold increase in the level of GFRa-1 mRNA, a 17-fold 
decrease m the level of GFRa-2 mRNA, an average of 13-fold decrease in GFRa- 
4 mRNA and a 1.7-fold increase in ret mRNA. These results indicate that 
depolarization has a simhai" effect on the expression of GFRa-1 and GFRa-2, but 
not GFRa-4 and ret mRNAs in sympathetic and parasympathetic neurons. They 
also show that the changes in GFRa and ret mRNA expression are more 
pronounced in parasympathetic neurons.
In cultures of E8 nodose ganglion neurons, 40mM KCl increased the level 
of GFRa-1 and ret mRNA, decreased the level of GFRa-2 mRNA and had no
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Figure 3.10. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E8 ciliary neurons incubated 
for 24 hours in medium containing 10 ng/ml GDNF (GDNF), 10 ng/ml NTN 
(NTN), GDNF plus 40 mM KCl (GDNF+KCl), NTN plus 40 mM KCl 
(NTN+KCl) or 40 mM KCl (KCl). The mean ± standard error of 2 separate 
assays are represented by each bar.
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effect on GFRa-4 mRNA expression (Figure 3.11). Compaied with the levels in 
cultures containing BDNF, cultures supplemented with 40mM KCl alone exhibited 
only a 1.7-fold increase in the level of GFRa-1 mRNA, a 1.4-fold decrease in the 
level of GFRa-2 mRNA and had no effect on GFRa-4 and ret mRNAs. These 
results suggest that depolarization does influence GFRa (with the exception of 
GFRa-4) and ret mRNA expression in sensory neurons, although not as markedly 
as in autonomic neurons.
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Figure 3.11. Bar charts of the percent survival and the levels of GFRa and ret 
mRNAs relative to L27 mRNA in cultures of purified E8 nodose neurons 
incubated for 24 hours in medium containing 10 ng/ml BDNF (BDNF), BDNF 
plus 40 mM KCl (BDNF+KCl) or 40 mM KCl (KCl). The mean + standard error 
of 2 separate assays are represented by each bar.
197
V. Depolarization shifts the response of neurons to GDNF and NTN
To investigate if the changes in the levels of GFRa-1 and GFRa-2 mRNAs 
caused by depolarizing levels of KCl are translated into changes in the response of 
the neurons to GDNF and NTN, I incubated E12 sympathetic neurons with and 
without depolarizing levels of KCl for 12 hours and then switched to medium 
containing a range of concentrations of either GDNF or NTN for 24 hours to see 
if an initial period of depolarization would shift the dose responses of these 
neurons to these neurotrophic factors. To ensure maximal survival during the 
initial incubation period, both 5 mM and 40 mM KCl cultures were supplemented 
with saturating levels of either GDNF or NTN. The dose response of neurons to 
GDNF that were initially incubated with depolarizing levels of KCl was shifted to 
lower concentrations than neurons that were not exposed to depolaiizing levels of 
KCl (Figure 3,12). In contrast, the dose response of neurons to NTN that were 
initially incubated with depolarizing levels of KCl was shifted to high 
concentrations than neurons that were not exposed to depolarizing levels of KCl 
(Figure 3.12). Thus, whereas depolarization increases expression of GFRa-1 
mRNA and makes neurons more sensitive to its preferred ligand GDNF, it 
decreases expression of GFRa-2 mRNA and makes neurons less sensitive to its 
preferred ligand NTN.
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Figure 3.12. Graphs of the percent survival after 24 hours incubation of E12 
sympathetic neurons that were initially incubated for 12 hours in medium 
containing 20 ng/ml GDNF (A) or 20 ng/ml NTN (B) with either 5 mM KCl 
(basal KCl) or 40 mM KCl and then washed and switched to medium containing 5 
mM KCl with different concentrations GDNF (A) or NTN (B). The percent 
survival in control cultures was subtracted. The mean ± standard error of 2 
separate assays are represented by each bar.
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2.3. Discussion
I have used an in vitro approach to study the regulation of GFRa-1, 
GFRa-2, GFRa-4 and ret mRNA expression in the neurons of the embryonic 
chicken peripheral nervous system. Because preliminar y experiments revealed that 
the non-neuronal cells of peripheral ganglia express low levels of these mRNAs, I 
used differential sedimentation (Davies, 1988c) to remove most of the non­
neuronal cells before plating the neurons at low density in laminin-coated petri 
dishes (>95% neurons). The most extensive analysis was carried out on 
sympathetic neurons because the majority of these neurons can be sustained in 
culture with several different neurotrophic factors (NGF, CNTF, GDNF and 
NTN) and with depolarizing levels of KCl, thereby enabling me to study receptor 
expression under different experimental conditions. Also, at early developmental 
stages, many of these neurons are able to survive for up to 24 hours in vitro 
without neurotrophic factors in the culture medium, thereby providing a valuable 
control for these studies.
I have shown that depolarizing levels of KCl induce rapid, substantial and 
opposite changes in the expression of GFRa in developing PNS neurons. In 
sympathetic neurons, elevated KCl markedly increases the levels of GFRa-1 and 
GFRa-4 mRNAs, substantially decreases the level of GFRa-2 mRNA and slightly 
decreases the levels of ret mRNA (Figure 3.5). Similar results were observed with
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intact ganglia cultured as expiants. However, the effects of depolarization were 
less pronounced (data not shown).
In parasympathetic neurons, KCl causes a substantial increase in the levels 
of GFRa-1 and ret mRNAs and substantial decrease in the level of GFRa-2 and 
GFRa-4 mRNAs (Figure 3.10). In sensory neurons, KCl increases the level of 
GFRa-1 and ret mRNAs, decreases the level of GFRa-2 mRNA, and has no 
effect on GFRa-4 mRNA expression (Figure 3.11). However the marginal effect 
of KCl on GFRa and ret mRNA expression in nodose neurons together with the 
low survival in KCl and the additive survival of BDNF with KCl make it possible 
that the data could reflect the different expression of GFRa and ret by different 
neuronal subtypes.
I have shown that changes in the levels of GFRa-1 and GFRa-2 mRNAs 
are translated into corresponding changes in the survival responses of the neurons 
to GDNF and NTN. Whereas sympathetic neurons exposed to depolarizing levels 
of KCl become more responsive to GDNF, the preferred GFRa-1 ligand, they 
become less responsive to NTN, the preferred GFRa-2 ligand (Figure 3.12).
The demonstration that these effects of elevated KCl are blocked by L-
type Ca^"  ^ channel antagonists suggests that they are due to Ca^+ influx and
elevation of the intracellular free Ca^+ concentration (Figure 3.8). These results 
imply that neural activity plays a role in selectively regulating the expression of the 
GPI-linked receptors for GDNF and NTN and in modulating the response of 
neurons to these factors.
201
The observation that elevated levels of KCl induce expression of 
transcripts encoding the NGF receptor tyrosine kinase trkA in a retrovirally 
immortalized sympathoadrenal precursor cell line led to the proposal that 
depolarization induces trkA expression and NGF responsiveness in sympathetic 
neuroblasts (Birren et al., 1992). However, in primary cultures of sympathetic 
neuroblasts and post-mitotic sympathetic neurons, depolarizing levels of KCl do 
not increase trkA mRNA expression before, during or after the onset of NGF 
dependence, suggesting that depolarization does not regulate trkA expression in 
normal sympathetic neuroblasts and neurons during development (Wyatt and 
Davies, 1995). Elevated levels of the BDNF/NT-4 receptor tyr osine kinase trkB 
are found in the hippocampus and striatum after generalized seizures produced by 
electrical stimulation or pharmacological methods (Bengzon et al., 1993; Dugich- 
Djordjevic et al., 1995b; Salin et al., 1995). Although these observations have 
raised the possibility that neural activity increases trkB expression in the central 
nervous system, the functional significance of these changes is unclear, especially 
as they are observed in both neurons and glia and involve transcripts encoding 
both catalytic and non-catalytic trkB isoforms. Although my studies have clearly 
shown that depolarization promotes marked changes in the mRNA expression of 
the GPI-linked receptors for the GDNF family, depolarization does not have a 
dramatic effect on the expression of ret mRNA, the common receptor tyrosine 
kinase receptor for members of the GDNF family of neurotrophic factors.
A large number of in vitro and in vivo studies have shown that 
neurotrophins up-regulate the expression of transcripts encoding their receptors. 
The level of the common neurotrophin receptor p75 mRNA is increased by NGF
2 0 2
in sympathetic (Miller et al., 1991, 1994; Verdi and Anderson, 1994; Wyatt et al., 
1995), sensory (Lindsay et al., 1990; Verge et al., 1992; Wyatt and Davies, 1993) 
and basal forebrain cholinergic neurons (Cavicchioli et al., 1989; Fusco et al, 
1991; Higgins et al, 1989; Kojima et al, 1992), and by BDNF in sensory neurons 
(Wyatt et al, 1993). Exogenous NGF increases the level of trkA mRNA in 
forebrain cholinergic neurons (Holtzman et al, 1992; Kojima et al, 1994; Venero 
et al, 1994) and in combination with oestrogen increases trkA mRNA expression 
in PC12 cells (Sohi*abji et al, 1994). BDNF increases the expression of trkB 
transcripts in cultured sensory neurons (Ninkina et al., 1996) and NT-3 increases 
expression of its receptor tyrosine kinase trkC in sensory neurons both in vitro 
and in vivo (Wyatt et al, 1999). In contrast to these studies, I find that expression 
of GFRa-1, GFRa-2, GFRa-4 and ret mRNAs are not significantly affected by 
either GDNF or NTN.
Although I have focused on the consequences that depolarization-induced 
changes in GFRa-1 and GFRa-2 expression have on the survival response of 
developing neurons to GDNF and NTN, it is possible that the effects of 
depolarization on the expression of GFRa-1 and GFRa-2 may have a wider 
significance in modulating the actions of GDNF and NTN. In addition to 
promoting neuronal survival, GDNF has been shown to have a variety of other 
effects on neuronal morphology and physiology. Overexpression of GDNF in 
muscle increases the number of motor axons innervating neuromuscular junctions 
in neonatal mice (Nguyen et al, 1998) and GDNF treatment of cultured Purkinje 
increases dendritic thickening and the development of spines and filopodial
203
extensions (Mount et al., 1995). GDNF increases dopamine release from midbrain 
dopaminergic neurons (Feng et al., 1999; Hebert et al, 1996; Pothos et al, 1998) 
and increases acetylcholine release at neuromuscular junctions (Liou et al, 1997; 
Ribchester et al, 1998). Furthermore, administration of NTN into the striatum of 
intact adult induces behavioral and biochemical changes associated with functional 
upregulation of nigral dopaminergic neurons (Horger et al, 1998). Thus, 
depolarization induced changes in GFRa-1 and GFRa-2 expression may not only 
play a role in regulating neuronal suiwival by GDNF and NTN during 
development, but may play an important role in modulating the effects of GDNF 
and NTN on the structural and functional plasticity of neurons in the developing 
and mature nervous system.
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Appendix I
The avian nervous system arises from the neural plate, which closes to 
form the neural tube, first in the rostral region and then progressively in more 
caudal regions of the embryo. In the head, the neural tube expands to form the 
brain, which paititions into the forebrain, midbrain and hindbrain. The hindbrain 
(rhombencephalon) is subsequently subdivided into seven or eight distinct 
neuromeres, the rhombomeres. The borders between adjacent rhombomeres 
restrict cell movement (Fraser et al., 1990; Birgbauer and Fraser, 1994), rendering 
each rhombomere as a somewhat separate developmental unit. These 
developmental subdivisions are paralleled by molecular specialization. After neural 
tube closure, neural crest cells emerge from the neuroepithelium and begin their 
migration. In the hindbrain, neural crest cell migration is patterned into three 
broad streams of cells, emanating laterally adjacent to rl/2, r4 and r6. Cells within 
the first stream populate the trigeminal ganglion and maxillomandibular arch; 
those within the second populate the hyoid aich, as well as the geniculate and 
vestibulocochlear ganglia; those following the third stream populate the third and 
fourth branchial arches and the remaining peripheral cranial ganglia (the superior, 
petrosal and nodose; Noden, 1975; D'Amico-Martel and Noden, 1983; Lumsden 
et al., 1991). Neural crest cells from rhombomeres 3 and 5 do not migrate through 
the mesoderm surrounding them, but either die or enter into the streams of crest 
cells on either side of them (Graham et al., 1993; Sechrist et al., 1993).
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Appendix n
Solutions and media for tissue culture
Solutions
HESS
Hanks* balanced salts without calcium or magnesium (GibcoBRL).
This medium (serum-ffee and carbonate-ffee) was used to trypsinize and triturate 
the ganglia, and to load the cell suspension onto the dropping funnel during 
differential sedimentation.
1% Trypsin
500mg of trypsin (Worthington) was added to 5ml of Ca/Mg-free PBS 
(GibcoBRL) and sterilized with a 0.22pm filter (Nalgene).
Aliquots of lOOpl in 1ml microfiige tubes were stored in a -30°C freezer.
Laminin
Stored in 20pl aliquots (-30°C) at 1 mg/ml, then diluted to 20pg/ml in fresh F14. 
Polv-DL-ornithine
0.5mg/ml poly-DL-ornithine (SIGMA) in 0.15M boric buffer [4.6g boric acid 
(BDH) in 500ml ddH20, pH8.4] was sterilized with a 0.22pm filter (PaUGelman
Sc).
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HIHS
Heat inactivated horse serum (GibcoBRL).
Media
L15
A IL unit of L I5 powder (GibcoBRL) was added to IL of ddH20 plus lOOmg 
streptomycin (SIGMA) and 60mg penicillin (SIGMA). After adjusting pH to 7.3 
the L I5 was sterilized with an 0.22pm filter (PaUGelman Sc).
HAM'S F12
A IL unit of F-12 powder (GibcoBRL) was added to IL of ddH20 plus lOOmg 
streptomycin (SIGMA) and 60mg penicUlin (SIGMA), The pH was adjusted to 
7.3 and the F I2 was sterilized with a 0.22pm filter (PaUGelman Sc).
HAM'S F14
lOx concentrated stock solution:
A 5L unit of F14 powder (Imperial) was added to 500ml of ddH20 containing 
500mg streptomycin (SIGMA) and 300mg penicUlin (SIGMA). The lOx stock 
was stored in 50ml aUquots at -30“C.
Ix solution:
A 50ml of lOx aUquot was dUuted into 450ml ddH20. Next, Ig of NaHCOg 
(BDH) was added and the solution was adjusted to pH7.0, with dry ice or 5M 
HCl before being sterUized with a 0.22pm filter (PaUGelman Sc).
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Neurotrophic factors
Neurotrophic factors were kept in F12 plus 10% HIHS, pH5.5, at -80°C until 
required.
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